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Aims To assess the impact of RSV and other viral lower respiratory tract infections 
(LRTIs) on chronic respiratory morbidity in prematurely born infants and to 
investigate whether there were any functional or genetic predisposing factors. 
Methods One hundred and fifty three prematurely born infants were followed until 
one year corrected age with approximately half followed until two years of age.  
Lung function was measured at 36 weeks postmenstrual age (PMA) and one year 
corrected age.  Blood or buccal swabs were taken for single nucleotide 
polymorphism (SNP) analysis.  Following neonatal unit discharge, a nasopharyngeal 
aspirate (NPA) was taken whenever an infant had a LRTI.  NPAs were analysed by 
real time PCR for 13 viruses.  At one and two years corrected age healthcare 
utilisation and costs of care were calculated and parents completed a respiratory 
health related questionnaire and a diary card for one month. 
Results Infants developing RSV or other viral LRTIs requiring hospitalisation had 
reduced premorbid lung function compared to infants not hospitalised.  Infants 
developing rhinovirus LRTIs had increased healthcare utilisation, cost of care and 
wheeze at one year corrected age.  Infants developing RSV LRTIs had reduced lung 
function at one year corrected age.  Prematurity was found to be a risk factor for 
developing RSV or other viral LRTIs but not influenza A (H1N1) LRTIs.  A SNP in 
ADAM33 was associated with an increased risk of developing RSV LRTIs, but not 
with significant differences in 36 week PMA lung function results.   SNPs in several 
genes were associated with increased chronic respiratory morbidity (IL10, NOS2A, 
SFTPC, MMP16 and VDR) and reduced lung function at one year (MMP16, NOS2A, 
SFTPC and VDR) in infants who had had RSV LRTIs. 
Conclusion In prematurely born infants, RSV and other viral LRTIs were associated 
with increased chronic respiratory morbidity at follow up, with some infants being 
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genetically predisposed to this after RSV LRTI.  Premorbid abnormal lung function 
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Viruses frequently cause respiratory tract infections especially in children less 
than five years of age (Pitman et al. 2007).  Respiratory syncytial virus (RSV) 
infects almost all children by two years of age (Glezen et al. 1986).  Up to 
80% of hospital admissions for bronchiolitis are due to RSV, and RSV LRTIs 
have been associated with chronic respiratory morbidity.  Many other viruses, 
however, are also associated with respiratory illnesses in children including 
rhinovirus, influenza, parainfluenza, adenovirus, enterovirus and 
parechovirus, as well as viruses that have only more recently been identified, 
for example human metapneumovirus and human bocavirus.  All these 
viruses can present with either a mild upper respiratory tract infection or a 
lower respiratory tract infection (LRTI).  LRTIs are characterised by coryza, 
cough, wheeze and dyspnoea and can be mild (requiring no medical 
attention) to severe (requiring mechanical ventilation). 
 
1.1 Respiratory viruses 
Viruses are classified by the International Committee of Taxonomy of Viruses 
(ICTV) (ICTV 2009) (Table 1.1).   
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Table 1.1: International Committee on Taxonomy of Viruses classification of viruses 
 
Order Family Subfamily Genus Species Genome 
Mononegavirales Paramyxoviridae Paramyxovirinae Respirovirus Parainfluenza types 1 
and 3 
Non-segmented, positive sense, 
single stranded  RNA 
   Rubulavirus Parainfluenza type 2 Non-segmented, positive sense, 
single stranded  RNA 
   Pneumovirus RSV A and RSV B Non-segmented, negative sense, 
single stranded  RNA 
   Metapneumovirus Human metapneumovirus Non-segmented, positive sense, 
single stranded  RNA 
Picornavirales Picornaviridae No subfamily 
classified 
Enterovirus Enterovirus Non-segmented, positive sense, 
single stranded  RNA 
    Rhinovirus Non-segmented, positive sense, 
single stranded  RNA 
   Parechovirus Parechovirus Non-segmented, positive sense, 
single stranded  RNA 
No order assigned Orthomyxoviridae No subfamily 
classified 
Influenza A and B Influenza types A and B Segmented, negative sense, 
single stranded  RNA 
 Adenoviridae No subfamily 
classified 
Mastadenovirus Adenovirus Non-segmented, double stranded 
DNA 
 Parvoviridae Parvovirinae Bocavirus Human Bocavirus is not 
classified 
Non-segmented, negative sense, 
single stranded DNA 
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1.1.1 Respiratory Syncytial Virus 
 
Respiratory Syncytial Virus (RSV) is classified by the ICTV as of the order 
Mononegavirales, family Paramyxoviridae, subfamily Pneumovirinae, and 
genus Pneumovirus (ICTV 2009) (Table 1.1).  RSV is an enveloped, non-
segmented virus with a negative sense, single-stranded RNA genome, 
containing ten genes encoding various proteins (Figure 1.1).  The ten 
proteins can be divided into eight structural and two non-structural proteins.  
The structural proteins include the nucleoprotein (the major RNA binding 
nucleocapsid protein), the large polymerase complex and phosphoproteins 
(both involved in RNA dependent RNA polymerase activity), the fusion (F) 
protein (which is involved in cell penetration and protection), glycoprotein (G 
protein) (an attachment and protective protein), small hydrophobic (SH) 
protein and two matrix (M, M2) proteins (involved in attachment) (Hall 2001; 
Hacking & Hull 2002).  The two non-structural proteins antagonise  and  
interferon (Hacking & Hull 2002). 
 
Figure 1.1: The structure of Respiratory Syncytial Virus 
Adapted from (Hall 2001). 
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There are two distinct subgroups of RSV, RSV A and RSV B, defined by 
antigenic variation mainly in the G protein (Mufson et al. 1985).  Both strains 
circulate simultaneously with the relative proportions of each strain varying 
year by year and by geographic location, although the majority of studies 
show RSV A is more often the dominant strain.  Two large studies (Taylor et 
al. 1989; Hall et al. 1990) each including over 1000 infants reported similar 
results.  Hall et al looked at the different strains over a 15 year period and 
demonstrated RSV A to be dominant (>80% of all RSV positive samples) in 
nine of the 15 years, RSV B to be dominant in four of the 15 years and 
similar proportions of the two strains in the remaining years (Hall et al. 1990).   
Taylor et al reported RSV A was dominant (>80% of isolates were RSV A) in 
six of the 15 years, whereas RSV B was borderline dominant in only one year 
(68% of isolates were RSV B), in the other years there was similar 
proportions of each subgroup (Taylor et al. 1989).  RSV A dominance has 
been found in two more recently reported studies.  RSV A was dominant 
(>50% of cases) in Belgium in seven of the ten years from 1996-2006 
(Zlateva et al. 2007) and in Germany in seven of the nine years from 1998-




Rhinoviruses (HRV) are very small (approximately 27–30 nm in diameter) 
ribonucleic acid viruses consisting of a simple viral capsid and a single strand 
of RNA. The capsid contains four proteins, VP1–VP4, arranged in 60 
repeating protomeric units in an icosahedron (Fendrick 2003).  Rhinoviruses 
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consist of over 100 serotypes classified into three groups (A, B and C) 
according to sequence variations (Lee et al. 2007).  Due to the large number 
of serotypes the identification of individual strains is rarely undertaken due to 
the time and costs involved.   Rhinoviruses are most commonly detected 
during the autumn and spring, but are associated with infection all year round 
(Monto 2002). 
 
1.1.3 Influenza virus 
 
Influenza virus was one of the first viruses to be detected and results in 
yearly epidemics in temperate climates and occasionally in worldwide 
pandemics.  Data from the general practice surveillance network in England 
and Wales between 1967 and 2006 demonstrated peaks of infection 
occurred over the winter months and depending on the exact strain of 
influenza virus, either adults or children were more commonly affected in 
various years (Fleming & Elliot 2008).  There are three subtypes of influenza 
(A, B and C) with subtypes A (FA) and B (FB) being structurally almost 
identical and subtype C being slightly different (Mahony 2008).  The FA virion 
is studded with glycoprotein spikes of haemagglutinin (HA) and 
neuraminidase (NA), in a ratio of approximately four to one, projecting from a 
host cell-derived lipid membrane. A smaller number of matrix (M2) ion 
channels traverse the lipid envelope. The envelope and its three integral 
membrane proteins HA, NA, and M2 overlay a matrix of M1 protein, which 
encloses the virion core. Internal to the M1 matrix are found the nuclear 
export protein (NEP, also called non-structural protein 2, NS2) and the 
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ribonucleoprotein complex, which consists of the viral RNA segments coated 
with nucleoprotein and the heterotrimeric RNA-dependent RNA polymerase 
(Bouvier & Palese 2008).  FA viruses are further characterized by the 
subtype of HA and NA.  Those proteins mutate naturally over time resulting in 
‘antigenic drift’ and global pandemics.  The organization of the FB virion is 
similar to that of FA with four envelope proteins: HA, NA, and, instead of M2, 
NB and BM2 (Bouvier & Palese 2008).  Influenza C virions are structurally 
very different from those of FA and FB with only one major surface 
glycoprotein, the hemagglutinin–esterase-fusion protein, which is functionally 
similar to the HA, and NA and one minor envelope protein (Bouvier & Palese 
2008). 
 
1.1.4 Parainfluenza virus 
 
Parainfluenza (PF) virus possesses at least one non-structural and six 
structural proteins (fusion protein, haemagglutinin neuraminidase protein 
[HN], matrix protein, nucleoprotein, phosphoprotein and large polymerase 
protein), which, with the exception of the HN protein, are very similar 
structurally and functionally to those present in RSV (Hall 2001).  There are 
four subtypes of parainfluenza (PF1-4), with PF4 being less common than 
the subtypes PF1, PF2 and PF3 (Mahony 2008).  An epidemiological study 
(Laurichesse et al. 1999) of the parainfluenza virus including data from 
England and Wales between 1975-1999 demonstrated PF1 and PF2 had 
peaks of infection in alternate years, whereas PF3 and PF4 had yearly 
infection peaks.  PF1, PF2 and PF4 were most commonly reported in the 
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winter months (October – January) whereas PF3 was most commonly 
reported between April and August.  PF3 and PF4 were more commonly 




Adenoviruses (AdV) are non-enveloped and 65 to 80 nanometres (nm) in 
diameter.  The virion has 20 triangular faces and 12 vertices, with 240 
hexons and 12 pentons. Each penton consists of a base and a fibre with a 
terminal knob. Inside the capsid is a single molecule of double-stranded 
DNA.  Over 50 serotypes of human AdVs have been recognized and grouped 
into six species (A-F) on the basis of their haemagglutinating properties, 
biophysical and biochemical criteria and DNA sequence homology (Nazir & 
Metcalf 2005).  Although all six species can cause all common types of 
illness (e.g. respiratory, gastrointestinal, conjunctivitis) associated with AdV, 
one large study (over 3000 samples) showed that the C species appeared to 
more commonly cause respiratory illness in children less than five years of 
age than the other species (Cooper et al. 2000).  There were also marked 
differences in seasonality within and between the six species with some 
serotypes being more common in the spring and summer and others in the 







Parechoviruses (PEV), like HRV, are from the picornaviridae family (Table 
1.1) thus their structure is very similar to that of HRV (Stanway et al. 2000).  
PEVs have recently been reclassified and there are at least six different 
types (PEV 1-6) (Harvala et al. 2008).  PEV2 is rarely detected in humans, 
but the other five types have been associated with respiratory tract infections 
in young children (with PEV1 and PEV6 being the most common), although 
all PEV types are also commonly found in nasal secretions of children 
without respiratory symptoms (Harvala et al. 2008).  A UK study of 
respiratory samples taken in 2007 demonstrated peaks of PEV infection 
occurred in late summer (July and August) and early winter (November and 
December) (Harvala et al. 2008).  A large study from the Netherlands 
between 2000-2007 (van der Sanden et al. 2008) demonstrated PEV1 was 
most commonly detected in the autumn and winter months, whereas PEV3 
was mainly detected in the spring and summer.  No seasonality could be 
identified for the other PEV types due to small numbers of positive samples.  
A periodicity was also noted; for PEV1 high peaks of infection occurred 
yearly, whereas high peaks of PEV3 infection occurred in alternate years 
(van der Sanden et al. 2008).  It must be noted that this study (van der 
Sanden et al. 2008) included samples from multiple anatomical sites (i.e. 
respiratory secretions, stool samples, cerebrospinal fluid) rather than just 
respiratory samples as in the study from the UK (Harvala et al. 2008), which 





Enteroviruses (EV), as HRV and PEV, are classified in the picornaviridae 
family (Table 1.1) and have a similar structure.  There are over 60 subgroups 
and they commonly cause respiratory illness in infants and young children, 
although they also are found in asymptomatic individuals (Mahony 2008).  EV 
demonstrate a similar seasonality to HRV, causing respiratory infections 
most commonly in the spring and autumn (Jacques et al. 2008). 
 
1.1.8 Human Metapneumovirus 
 
Human metapneumovirus (HMPV) was first detected in 2001 from infants 
and children with respiratory tract symptoms in the Netherlands and is 
classified in the metapneumovirus genus (Table 1.1).  It consists of nine 
proteins (nucleocapsid RNA binding protein, nucleocapsid phosphoprotein, 
non-glycosylated matrix protein, fusion glycoprotein, transcription elongation 
factor, RNA synthesis regulatory factor, small hydrophobic surface protein, 
major attachment protein and a major polymerase subunit) (Biacchesi 2003) 
and consists of two genetically distinct subgroups (A and B) with each 
subgroup divided further into another two groups (A1, A2 and B1 and B2) 
(Mackay et al. 2004).  A 25 year longitudinal study in the USA retrospectively 
tested respiratory samples for HMPV from previously healthy children less 
than five years of age and found peaks of infection occurred in late winter 
coinciding with the second half of the RSV season (Williams et al. 2004). 
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1.1.9 Human Bocavirus 
 
Human Bocavirus (HBOV) was first detected in 2005 from randomly selected 
respiratory samples from children and adults in Sweden (Allander et al. 
2005).  It is from the Parvoviridae family, although has not been formally 
classified (Table 1.1).  HBOV is a small, non-enveloped virus with an 
isometric nucleocapsid that contains a single molecule of linear, single-
stranded DNA; the complete genome length has not been determined.  The 
genome encodes for the non-structural proteins (NS1 and NP1) and two viral 
capsid proteins (VP1 and VP2) although the function of these proteins are 
currently unknown (Schildgen et al. 2008).  Although HBOV is frequently 
detected in respiratory samples, there is some debate as to whether it is 
pathogenic, as it is frequently found in asymptomatic children (Martin et al. 
2009) and respiratory samples positive for HBOV are also often positive for 
another respiratory virus (e.g. RSV) (Choi et al. 2006; Manning et al. 2006).  
The seasonality of HBOV has yet to be fully elucidated, but may be more 




The pathological findings in acute bronchiolitis were initially demonstrated at 
autopsy by Hubble and Osborn (Hubble & Osborn 1941).  RSV infection 
results in acute inflammation mainly involving the medium and small 
bronchioles (less than 150m in diameter) (Johnson et al. 2007).  
Inflammatory infiltrates are symmetrical and circumferential in the small 
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bronchioles and larger airways, but at the level of the terminal bronchioles 
are often asymmetrical and more clearly centred around the pulmonary 
arteriole.  Airway lumens are occluded by epithelial sloughing, macrophages, 
fibrin and mucus and inflammatory cells aggregate around the bronchial 
arteries resulting in dilatation and congestion (Johnson et al. 2007).  
Mechanical obstruction, therefore, of the small airways appears to be 
important in the pathogenesis of RSV disease (Johnson et al. 2007).  The 
infant lung has smaller calibre airways and very poor collateral ventilation 
with little communication between neighbouring alveoli (Aherne et al. 1970).  
In comparison, the adult lung has good collateral ventilation allowing a 
sufficiently high pressure to build up distal to an occluding plug to lead to its 
expulsion, however, this appears not to happen in the infant lung (Aherne et 
al. 1970). 
 
Histological evidence of recovery from bronchiolitis, by studying ciliated 
epithelial cells from nasal epithelial biopsies, becomes apparent within days 
after the onset of symptoms, although complete resolution can take several 
months (Wong et al. 2005).  Symptoms may persist for several weeks after 
the acute infection has cleared (Hall 2001). 
 
Aherne et al and Ferris et al demonstrated similar histopathological findings 
at autopsy in infants with bronchiolitis regardless of the viral aetiology (RSV, 
adenovirus, parainfluenza, influenza or rhinovirus), suggesting all viruses 
lead to a similar pathological process (Aherne et al. 1970; Ferris et al. 1973). 
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1.3 Clinical presentation of RSV 
 
RSV infection affects children in epidemics with marked seasonality.  In 
temperate climates, in both the northern and southern hemispheres, there 
are epidemics of RSV in the winter, whereas in the tropics there are 
epidemics during the hot and rainy seasons (Shek & Lee 2003). At extremes 
of temperature RSV activity is more continuous throughout the year (Welliver 
2007).  Humidity and ultraviolet B (UVB) radiation have been linked with 
susceptibility to symptomatic RSV infection, with higher levels of humidity 
and lower levels of UVB increasing vulnerability (Welliver 2007; Yusuf et al. 
2007). 
 
RSV transmission occurs by two routes; large particle or droplet formation or 
via direct inoculation from fomites, into the eyes or nose, such that close 
contact (proximity of less than six feet) is required for the spread of the virus 
(Hall & Douglas 1981). 
 
Once the virus infects the upper respiratory tract there is an incubation period 
of two to eight days in which RSV replicates in the nasopharyngeal 
epithelium, often causing coryzal symptoms.  It then spreads to the lower 
respiratory tract one to three days later (Hall 2001).  LRTIs are characterised 
by cough, dyspnoea and cyanosis.  Clinical examination may reveal 
prolonged expiration, wheeze, crackles and signs of respiratory distress (Hall 
2001).  Infants may require nasogastric feeding or intravenous fluids.  Infants 
may also present with apnoea, which is more common in prematurely born 
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infants, those with BPD (Meert et al. 1989) and infants less than three 




Mortality from bronchiolitis (any virus) in infants older than 28 days of age 
considerably diminished in England and Wales between 1979 and 2000 
(from 21.5 to 1.8 per 100,000) (Panickar et al. 2005), with RSV being the 
virus that caused the highest rates of mortality.  Fleming et al estimated that 
in the winters in England between 1989 and 2000 there were a total of 185 
(2.9 per 100,000) deaths from RSV bronchiolitis and 129 (2.0 per 100,000) 
deaths from influenza virus in infants between one and 12 months of age 
(Fleming et al. 2005).  Those data are similar to those from the USA between 
1979 and 1997 which highlighted a mortality rate of approximately 1.5 per 
100,000 for bronchiolitis (any virus) in infants less than one year of age and 
between 171 and 510 RSV-associated deaths in children less than five year 
of ages, with 71% occurring in infants less than one year of age (Shay et al. 
2001).  Deaths peaked in January (18%) and most (76%) occurred during the 
typical November to April RSV season.  Another study (Thompson 2003) in 
the USA comparing RSV and influenza infections between 1990 and 1999 
highlighted mortality rates of 5.4 and 2.2 per 100,000 person-years for RSV 






In 2002, in the USA, there were an estimated 149,000 patients hospitalised 
with bronchiolitis (any virus) accounting for approximately 491,700 inpatient 
days per year, with a total annual cost of $US 543 million and a mean cost of 
$US 3799 per patient (Pelletier et al. 2006).  Although any of the common 
respiratory viruses can cause disease severe enough to warrant 
hospitalisation, the majority of hospitalisations are due to RSV.  One study 
estimated approximately 27,900 children aged less than four years of age 
were hospitalised every year in England and Wales due to RSV compared to 
only 4200 due to influenza (Pitman et al. 2007).  A prospective study of 1429 
previously well children less than five years of age followed between 1974 
and 1993 as part of a vaccine evaluation programme, found only two children 
(1.4 per 1000 children) were admitted for a LRTI with an NPA positive for 
Parainfluenza (one PF1 and one PF3) (Reed et al. 1997). 
 
Another study estimated rates of hospitalisation during times of high 
influenza, but low RSV, prevalence in the community and found 
hospitalisation rates for acute respiratory disease of 16-19 per 100,000 
person years in previously well children less than two years of age (Izurieta 
et al. 2000).  This increased to 64-98 per 100,000 person years for children 
less than two years of age with high risk conditions (including prematurity and 
chronic respiratory and cardiac conditions) (Izurieta et al. 2000).  A limitation 
of that study (Izurieta et al. 2000) was the lack of virologically confirmed 
illness in the infants.   
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Amongst infants and young children up to 56 months of age hospitalised for 
viral LRTIs, those with HMPV were compared to those with RSV (Mullins et 
al. 2004).  Infants with HMPV were older (median age of hospitalisation 11.5 
versus 3 months, p<0.001) and had more underlying medical conditions 
(54% versus 29%, p<0.05).  Most children in the HMPV group had asthma as 
an underlying condition (8 out of 14).  There were no significant differences in 
the other clinical characteristics of the two groups (Mullins et al. 2004).  A 
study of children less than three years of age attending an emergency 
department compared the presentations of the children infected with HMPV, 
RSV and HRV (Manoha et al. 2007).  Significantly more infants with RSV 
infection were hospitalised as a result of their infection than those with HMPV 
(67% versus 47%, p<0.02) and of those hospitalised, those with HMPV had 
higher rates of asthma than those with RSV (25% versus 4%, p<0.02).  
Infants with RSV were significantly more likely to present with cough, 
pharyngitis, bronchitis and feeding difficulty than infants with HRV (Manoha 
et al. 2007).  Calvo et al compared children less than 14 years of age 
infected with HBOV to those infected with RSV, AdV and HRV (Calvo et al. 
2008).  Children developing HBOV were older than those with RSV (20.8 
versus 9.8 months, p=0.017) and were less likely to be hospitalised with a 
diagnosis of bronchiolitis (32% versus 65%, p<0.0001).  In addition, children 
with HBOV had a higher leucocyte count and higher serum C reactive protein 
level (Calvo et al. 2008). 
 
Apart from the type of virus affecting an individual there are also multiple risk 
factors for hospitalisation with RSV bronchiolitis (Table 1.2). 
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Table 1.2: Risk factors for hospitalisation with RSV bronchiolitis 
Reference Risk factor for hospitalisation 
(Hall et al. 2009) Prematurity 
(Cilla et al. 2006) Birth weight <2500g 
(Simon et al. 2007) BPD 
(Duppenthaler et al. 2004; 
MacDonald et al., 1982) 
Congenital cardiac disease  
(Hall et al. 1986) Immunodeficiency 
(Wilkesmann et al. 2007) Neurological impairment 
(Simoes, 2003) Male gender 
(Simoes, 2003) Young age (<6 months) 
(Simoes, 2003) Birth in the first half of the RSV season 
(Simoes, 2003) Crowding/siblings 
(Simoes, 2003) Attendance at day-care 
(Bradley et al. 2005) Maternal smoking 






1.6 Long term respiratory morbidity following viral infections in term 
born infants 
 
1.6.1 Follow up of infants hospitalised with viral LRTIs 
 
A study following up infants previously hospitalised for RSV LRTI found that 
at eight years of age they had experienced more episodes of wheeze since 
discharge and had reduced lung function (lower peak expiratory flow rate 
[PEFR] and FEV0.75/VC) compared to an age, sex and social class matched 
group (Sims et al. 1978).  Another study investigating infants ten years after 
hospitalisation for RSV LRTI showed significantly more of the RSV group 
compared to the controls had a history of cough (9% versus 2%) and wheeze 
(42% versus 19%), significantly lower lung function (reduced PEFR, FVC, 
FEV1, FEV1/FVC, MEF50, MEF75 and MEF25-75) and evidence of increased 
bronchial lability after either an exercise or histamine challenge (Pullan & 
Hey, 1982).  A limitation of both of those studies (Sims et al. 1978; Pullan & 
Hey 1982) was that the control groups were not contemporaneously recruited 
and followed. 
 
Two longitudinal studies have recruited subjects and controls simultaneously 
(Sigurs et al. 1995; Korppi et al. 2004).  Sigurs et al (1995) demonstrated that 
at three years of age the RSV group had more asthma (23% versus 1%, 
p<0.001) and atopy as assessed by either skin prick testing or serum IgE to 
various allergens (32% versus 9%, p=0.002) suggesting RSV LRTI was 
involved in the development of asthma and atopy.  At seven years of age, the 
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RSV group had significantly higher rates of asthma diagnosis than the control 
group (30% versus 3%, p<0.001) (Sigurs et al. 2000).  In addition, RSV 
bronchiolitis was a significant risk factor for the development of allergic 
sensitisation (odds ratio of 2.4) (Sigurs et al. 2000). At 13 years of age the 
RSV group had more current asthma or wheeze (43% versus 8%, p<0.001), 
reduced baseline lung function (FEV1, FEV1/FVC, FEF25) and a greater fall in 
FEV1 on challenge testing (6.1% versus 4.6%, p=0.047) than the control 
group (Sigurs et al. 2005).  In another prospectively followed cohort, young 
adults followed for 20 years after RSV LRTI in infancy were found to have 
similar rates of doctor-diagnosed asthma, but increased lung function 
abnormalities, that is reduced FEV% and MEF25, independent of atopy, 
compared to the control group (Korppi et al. 2004). 
 
One study has investigated the risk of chronic respiratory morbidity after 
hospitalisation with HMPV infection (García-García et al. 2007). HMPV 
bronchiolitis in infancy was associated with an increased risk of an asthma 
diagnosis (OR 15.9) at five years of age, and that this risk was greater than 
that for RSV (OR 10.1) (García-García et al. 2007). 
 
Table 1.3 gives the results of previous lung function studies following viral 
LRTIs in previously healthy infants and children.  It demonstrates viral LRTIs 
in infancy, mainly infants requiring hospitalisation for RSV infection, are 
associated with abnormal lung function from immediately after the acute 
infection into early adulthood.  This raises the questions of whether viral 
LRTIs other than RSV are similarly associated with abnormal lung function at 
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follow up and whether infants with underlying conditions (e.g. prematurely 




Table 1.3: Results of previous lung function studies following viral LRTI in previously healthy infants and children (Updated from PhD thesis by S. Broughton, 2009) 
















  Control 
Group (n) 
Lung function tests Results 

















(TGV >40ml/kg) at 1-18 
days, 39% 
hyperinflated by 13 
months. 




88% DFA No Yes 2 weeks, 3 
and 12 
months 
24 69 FRCHe, Crs No significant 
differences 




Yes DFA Yes Yes 4 months 
after 
admission 
14 6 Crs, Rrs,  
Vmax FRC and 
FRCpleth 
Elevated TGV 





No Not done Yes 50% 8 and 14 
months 
18 24 Vmax FRC and PC30 Lower Vmax FRC and 
PC30 at 8 and 14 
months 





60% DFA or viral 
culture 




13 0 Plethysmography, 
Vmax FRC and PD30 
15% hyperinflated 
(TGV>120% predicted), 
40% raised Raw (>140% 
predicted) and 100% 
reduced Vmax FRC at 9 
weeks. 
8% hyperinflated, 24% 
raised Raw at 8 months 




Yes Not stated No Yes 11 months 29 29 FRCpleth, Raw,  
Crs, tPTEF/tE 
Decreased tPTEF/tE 







Not stated No Yes At discharge, 
3 and 12 
months after 
discharge 
93 0 FRCpleth, Raw, sGaw 77% hyperinflated  
(TGV >40 mL/kg) at 
discharge, 43% at 3 
months, 17% at 1 year 
(Young et al. 
1995) 
<1 year 20% Not stated Not stated 20% (both 
RSV) 
1 year 10 236 Vmax FRC, Crs, Rrs, 











‘viral studies’ No Yes 2 years after 
infection 




(Murray et al. 
1992) 
<1 year 68% DFA or viral 
culture 
No Yes 6 years 73 73 Spirometry, PEFR, 
PC20 
Increased PC20 




100% DFA & viral 
culture 
No Yes 6 years 25 0 Spirometry, PD20 Lower FEV1/VC (16%) 
(Poulsen et al. 
2006) 
0.9 years 100% DFA & RSV 
Ab assay 
No Some 6.8 years 78 78 FEV1, PEFR Lower FEV1 and PEFR 
(Hall et al. 1984) <24 
months 
Yes Viral culture No Yes 7 (6-8) years 23 0 Spirometry, PEFR Lower FEF25-75 
 




50% DFA or viral 
culture 
No Yes 7 years 200 200 Spirometry, PEFR, 
forced oscillometry 
 
Lower PEFR, FEV0.75, 
FEV1, FEV1/FVC and 
FEF25-50 
(Cassimos et al. 
2008) 
<1 year 100% DFA No Yes 7.5 (4.0-9.5) 
years 
189 60 Spirometry, PEFR Lower FEV1, FEF50 and 
PEFR 
(Fjaerli et al. 
2005) 
<1year 61% DFA  No Yes 7.7 (7.2-8.5) 
years 
57 64 Spirometry Lower FEV1 and FEF50 
(Juntti et al. 
2003) 
<1 year 100% DFA or latex 
agglutination 
test 
No Yes 8 (6.9-10.3) 
years 





(Sims et al. 1978) “infancy” Yes Viral culture No, but 95% 
had wheeze 
Yes 8 years 35 35 Spirometry, PEFR Lower PEFR and 
FEV0.75/VC 




No Not done Yes Yes 9-12 years 48 0 Spirometry, 
plethysmography, 
PEFR 
Lower VC, FEV1, 
MEF25-75, PEFR, raised 
TLC and RV/TLC 




66% DFA No Yes 10 years 61 47 Spirometry, PEFR, 
plethysmography 
Lower PEFR, FEV0.75, 
FEV1, FEF25-75 and 
higher Raw 
(McConnochie et 
al. 1985)  
24 
months 
No Not done Yes 4% (1 infant) 10 (8-12) 
years 
25 25 Spirometry, PEFR Lower FEF25-75 




Yes Not stated Not stated Yes 10 (8.9-11.5) 
years 
98 104 Spirometry, PEFR, 
single breath 
nitrogen wash-out 
Lower PEFR, FVC, 
FEV1, FEV1/FVC, 
MEF50, MEF75, MEF25-75 
(Turner et al. <2 years Yes Not stated No 2 infants 11 years 16 159 Spirometry Reduced FEF25-75 
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2002) 




No Not done Yes Yes 11 years 23 0 Plethysmography, 
PEFR, Spirometry 
41% elevated RV/TLC.   
(Stein et al. 1999) <36 
months 
Yes Not stated No No 11 years 110 189 FEVI Reduced FEV1 
(Hyvärinen et al. 
2007) 
<2 years 30% DFA, RSV Ab 
assay and 
RT-PCR 
Yes Yes 11.4 (10.3-
12.3) years 
80 0 Spirometry, PD20 33% had an abnormal 
spirometry result, 23% 
abnormal PD20 





100% EIA No Yes 13.4 (13.0-
14.0) years 
47 93 Spirometry  Lower FEV1/FVC and 
FEF75 
(Korppi et al. 
2004) 
<2 years 100% DFA, RSV Ab 
assay 
No Yes 19 (18-20) 
years 
36 45 Spirometry, PD20 Lower FEV1/FVC and 
MEF25 
(Larouche 2000) <18 
months 
No Not done No Yes 21 (17-30) 
years 
42 42 Spirometry, PC20 Lower FEV1/FVC, PC20 
 
Key for Table 1.3: 
Crs: Compliance of the respiratory system 
DFA: Direct fluorescent-antigen test 
EIA: Enzyme immunoassay 
FEF25-50: Forced expiratory flow from 25-50% of vital capacity 
FEF25-75: Forced expiratory flow from 25-75% of vital capacity 
FEF50: Forced expiratory flow at 50% of vital capacity 
FEF75: Forced expiratory flow at 75% of vital capacity 
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FEV0.75: Forced expiratory volume at 0.75 seconds 
FEV1: Forced expiratory volume at one second 
FEV1/FVC: Ratio of forced expiratory volume at one second to forced vital capacity 
FEV0.75/VC: Ratio of forced expiratory volume at 0.75 seconds to vital capacity 
FEV1/VC: Ratio of forced expiratory volume at one second to vital capacity 
FRCHe: Functional residual capacity measured by helium gas dilution 
FRCpleth: Functional residual capacity measured by plethysmography 
MEF25-75: Maximal expiratory flow from 25-50% of vital capacity 
MEF50: Maximal expiratory flow at 50% of vital capacity 
MEF75: Maximal expiratory flow at 75% of vital capacity 
PC20, 30, 40:  Bronchial responsiveness to a provocation challenge 
PD20, 30:  Bronchial responsiveness to a provocation challenge 
PEFR: Peak expiratory flow rate 
Raw: Airways resistance 
Rrs: Resistance of the respiratory system 
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RSV Ab test: RSV antibody test 
RT-PCR: Reverse transcriptase polymerase chain reaction 
RV/TLC: Ratio of residual volume to total lung capacity 
sGaw: Specific airways conductance 
Tme/Te: Ratio of time to maximum expiration to total expiratory time 
TGV: Thoracic gas volume 
TLC: Total lung capacity 
tPTEF/tE: Ratio of time to peak tidal expiratory flow to total expiratory time 
VC: Vital capacity 
Vmax FRC: Maximal flow at functional residual capacity 
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1.6.2 Community based studies 
 
Young et al found no significant differences in lung function results at one 
year of age between those infants who had and had not had viral LRTIs 
(Young et al. 1995). At two years of age, however, the infants who developed 
bronchiolitis had increased rates of asthma and more had had a wheezy 
episode (Young et al. 1995).  The cohort was seen at 11 years (Turner et al. 
2002) and after adjustment for factors known to affect lung function, the 
bronchiolitis group compared to the control group, had reduced FEF25-50 and 
more of them had wheezed at some point since their bronchiolitic episode.  In 
a study of 50 infants, the 25 with viral bronchiolitis (no virology reported) in 
infancy had reduced FEF25-50 at 11 years of age compared to a control group 
of age matched children, but there was no difference in the use of anti 
asthma medication (McConnochie et al. 1985).  Similarly, the Tucson 
Children’s Respiratory Study (Stein et al. 1999) found reduced FEV1 at 11 
years of age in those who had had RSV LRTI in the first three years after 
birth compared to a similarly prospectively followed control group.  The RSV 
group had more wheeze with an odds ratio (OR) of 2.4 for frequent wheeze 
and an OR of 1.7 for infrequent wheeze compared to the no LRTI group.  The 
COAST study (Lemanske et al. 2005) demonstrated, in a high risk cohort, 
that is with at least one atopic parent, that HRV bronchiolitis in infancy was 
associated with an increased risk of subsequent wheezy episodes at three 
years of age (OR 3.6).  Those data (Young et al. 1995; McConnochie et al. 
1985; Stein et al. 1999; Turner et al. 2002; Lemanske et al. 2005) would 
suggest that even viral LRTIs not severe enough to warrant hospitalisation 
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are still associated with chronic respiratory morbidity and that these infants 
may, therefore, have benefitted from prophylaxis.  In addition, those data 
(Young et al. 1995; McConnochie et al. 1985; Stein et al. 1999; Turner et al. 
2002; Lemanske et al. 2005) imply that infants developing milder viral LRTIs 
still use health care resources after the acute episode and therefore cost-
benefit analysis studies should include these infants as well as those with 
more severe disease. 
 
1.6.3 Lung function after other viral LRTIs 
 
Few studies have investigated the effect of viruses other than RSV on 
subsequent lung function in children.  Fjaerli et al found no significant 
differences in FVC, FEV1 or FEF50 between infants hospitalised for RSV LRTI 
or RSV negative LRTI at seven years of age (Fjaerli et al. 2005).  Mok and 
Simpson found no significant differences in PEFR, FEV1, FVC, FEV1/FVC, 
FEF25-50 or Rrs at seven years of age between infants who had been admitted 
for either RSV LRTI or RSV negative LRTI (Mok & Simpson 1982).  
Hyvarinen et al demonstrated that at 11 years of age infants who had been 
hospitalised for RSV negative bronchiolitis (adenovirus, influenza A and B, 
parainfluenza 1-3, rhinovirus, enteroviruses, coronaviruses or no virus 
detected) had significantly better lung function (FVC and FEV1/FVC) than the 
RSV positive group (Hyvärinen et al. 2007). 
 
The Tucson Children’s Respiratory Study (Stein et al. 1999) found no 
association with mild, that is not requiring hospitalisation, parainfluenza or 
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other viral LRTIs (adenovirus, influenza, rhinovirus, cytomegalovirus) in 
infancy and FEV1 at 11 years of age.  They did, however, note that infants 
who developed other LRTIs, but had negative microbiological studies, had 
significantly lower FEV1 than infants who did not develop a LRTI. 
 
In a study of forty four 18-20 year olds prospectively followed from 
hospitalisation for bronchiolitis in infancy, no significant differences were 
found in FEV1, FEV%, MEF50 or MEF25 between infants hospitalised for RSV 
bronchiolitis or non-RSV bronchiolitis (influenza A or B, parainfluenza 1-3, 
adenovirus or negative for all viruses, hospitalised outside the RSV season) 
(Piippo-Savolainen et al. 2007).  Simila et al investigated children who had 
had adenovirus type 7 LRTI between the ages of three months and seven 
years and were followed to 9-12 years of age (Simila et al. 1981). Seventy 
three percent of the children were shown to have abnormal FVC and FEV1 
suggesting adenoviral LRTIs were associated with subsequent reduced lung 
function. 
 
Those data suggest viruses other than RSV may be associated with impaired 
lung function at follow up in term born infants.  Thus, an aim of this thesis 
was to test the hypothesis that other viruses, as well as RSV, adversely 








Infants born prematurely and developing RSV LRTIs are more likely to have 
symptoms of chronic respiratory morbidity (cough and wheeze) at follow up 
than similar infants not developing RSV LRTI (Broughton et al. 2005).  
Broughton et al in a prospectively followed cohort of infants born prior to 32 
weeks of gestation, found infants with RSV LRTI had significantly more and 
longer hospitalisations and more GP attendances in the first year after birth 
than infants who had either no LRTI or a LRTI where no virus was detected 
(‘no virus’ group) (Broughton et al. 2006).  The HMPV group had the highest 
proportion of hospitalisations and longest mean length of hospitalisation.  The 
RSV group had more cough and wheeze than the no virus group, and more 
wheeze than the HRV group.  Multivariate analysis demonstrated HMPV to 
be a risk factor for hospitalisation, GP attendance and wheeze at follow up 
(Broughton et al. 2006). 
 
1.7.2. Lung function 
 
RSV LRTI has been shown to be associated with abnormal lung function at 
follow up in prematurely born infants.  In a cohort of infants born prior to 32 
weeks of gestation those developing RSV LRTI (either in the community or 
requiring hospitalisation) had significantly higher airways resistance (Raw) 
than the infants who did not have a RSV LRTI at one year corrected age 
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(Broughton et al. 2007).  Regression analysis demonstrated HMPV to also be 
associated with increased Raw at follow up (Broughton et al. 2007).  Those 
data suggest other viruses as well as RSV impact on subsequent lung 
function in prematurely born infants and an aim of this thesis was to test that 
hypothesis. 
 
1.8 Viral identification techniques 
 
1.8.1 Conventional techniques 
 
The gold standard for the identification of respiratory viruses has historically 
been viral culture, which involves infecting cells that the virus being tested is 
know to affect and then observing for any cytopathic effects within those 
cells.  One of the major disadvantages of this technique is that it is usually 
too slow for routine clinical practice.  Another conventional technique is the 
direct immunofluorescence assay where a monoclonal antibody joined to a 
fluorophore is directed against an antigen in the virus.  When the antibody 
binds to the antigen the fluorescence produced can be visualised under a 
microscope.  The advantage of this technique is that the turnaround time is 
much faster, meaning it can be used in routine clinical practice (Freymuth et 





1.8.2 Polymerase chain reaction (PCR) 
 
PCR was first described by Saiki et al for the prenatal diagnosis of sickle cell 
anaemia (Saiki et al. 1985) and it has subsequently been used for viral 
identification (Paton et al. 1992). 
 
PCR utilises a pair of primers that hybridise to two strands of a DNA target 
across a defined region that becomes exponentially amplified.  The 
hybridised primers act as a substrate for a DNA polymerase to create two 
complementary strands through the addition of deoxynucleotides.  PCR 
usually involves three steps: 
1. Denaturation: heating the reaction to melt the DNA, producing single-
stranded DNA molecules.  
2. Annealing: Cooling the reaction to allow annealing of the primers to 
hybridise to the single-stranded DNA template. 
3. Extension: DNA polymerase synthesizes a new DNA strand 
complementary to the DNA template strand by adding 
deoxynucleotides complementary to the template in 5' to 3' direction. 
RNA can also be amplified by the addition of a pre-PCR reverse 
transcriptase step.  A complementary DNA (cDNA) strand is initially 
produced, by reverse transcriptase (RT), and the cDNA then undergoes 
PCR.  Therefore, PCR can detect DNA viruses and RT-PCR RNA viruses.  
Traditional detection and analysis of PCR products requires agarose gel 
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electrophoresis in the presence of ethidium bromide with visualisation by 
illumination with short wave UV light (Hibbitts & Fox 2002). 
 
1.8.3 Real-time PCR 
 
Real-time PCR was developed by Higuchi et al enabling the amplification and 
detection of the PCR product to occur in a single reaction tube thus 
eliminating the expensive and time consuming post-PCR steps and also 
increasing the sensitivity and specificity of the test (Higuchi et al. 1992).  In 
real-time PCR a fluorescent reporter dye binds to the PCR product that is 
formed and generates a fluorescent signal that reflects the amount of product 
formed.  One of the main fluorescence-monitoring systems for DNA 
amplification are hydrolysis probes, which include TaqMan probes (Heid et 
al. 1996).  TaqMan probes are dual labeled oligonucleotides containing a 
fluorescent dye on the 5' base, and a quenching dye on the 3' base. When 
irradiated, the excited fluorescent dye transfers its energy by Förster 
resonance energy transfer (FRET) to the nearby quenching dye molecule.  
The close proximity of the reporter and quencher prevents emission of any 
fluorescence while the probe is intact.  When the polymerase replicates a 
template on which a TaqMan probe is bound, its 5' exonuclease activity 
cleaves the 5’ end of the probe which contains the reporter dye. This 
releases the reporter dye from quenching and ends the activity of the 
quencher and the reporter dye starts to emit fluorescence which increases in 
proportion to the rate of probe cleavage and hence product formation. 
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Accumulation of PCR products is detected by monitoring the increase in 
fluorescence of the reporter dye. 
 
Real time PCR also allows several PCR products (usually to a maximum of 
four) to be identified simultaneously (‘real-time multiplex PCR’), providing 
each product gives off a different fluorescent signal (Wittwer et al. 2001); this 
saves time and costs. 
 
PCR has been shown to be more sensitive and specific for viral detection 
than conventional methods (Falsey et al. 2002).  One study in children found 
multiplex PCR resulted in a 34% increase in respiratory virus identification 
over direct fluorescence antibody (DFA) alone and 20% over DFA combined 
with viral culture.  Multiplex PCR identified 14% more RSV cases than DFA, 
10% more RSV cases than DFA and viral culture, and four times as many 
(23 versus 91 infants) HRV cases than DFA (Freymuth et al. 2006).  As a 
consequence in this thesis, respiratory samples will be tested using real-time 
multiplex PCR. 
 
1.9 Treatment of acute bronchiolitis and RSV LRTI 
 
Treatment for acute bronchiolitis (RSV or other viral causes) is mainly 
supportive with oxygen supplementation and ensuring adequate hydration, 
via either nasogastric feeding or intravenous fluids.  No single medication has 





Many studies have investigated the effect of salbutamol or ipratropium 
bromide on the clinical course of bronchiolitis.  A systematic review 
(Gadomski & Bhasale 2006) demonstrated that although bronchodilators 
(including salbutamol and ipratropium bromide) caused significant 
improvements in clinical scores they did not improve oxygen saturations, 
reduce hospital admission after outpatient treatment, shorten the duration of 




Adrenaline has bronchodilator properties, but also decongests the nasal 
mucosa by reducing oedema.  A meta-analysis of 14 randomised controlled 
trials comparing adrenaline with either placebo or another bronchodilator  
demonstrated that adrenaline improved short term clinical scores, but did not 




A systematic review (Patel et al. 2004) demonstrated corticosteroids alone 
did not improve clinical scores, reduce hospital admissions or length of stay 
in hospital.  A small study of 48 term and 13 prematurely born infants 
between three and 12 months of age found nebulised dexamethasone and 
adrenaline resulted in a reduction in length of hospital stay compared to 
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nebulised adrenaline and 0.9% saline (9.1 versus 6.5 days, p=0.018), but 
only in the prematurely born infants (Bentur et al. 2005). 
 
1.9.4 Hypertonic saline 
 
Hypertonic saline may have some benefit in treating infants with acute 
bronchiolitis.  In a meta-analysis, Zhang et al showed hypertonic (3%) saline 
improved clinical scores by between 0.75 (11.2%) and 1.28 (20%) points 
(compared to 0.9% saline) and reduced length of hospital stay by one day 
(25.9%) (Zhang et al. 2008).  In one study (Kuzik et al. 2007) from the above 
meta-analysis there was a 26% reduction in the length of stay in hospitalised 




In a meta-analysis of three clinical trials, chest physiotherapy was not shown 
to reduce length of hospital stay, oxygen requirements or improve the clinical 
scores in infants with acute bronchiolitis (Perrotta et al. 2007). 
 
1.9.6 Recombinant human deoxyribonuclease 
 
Since airway obstruction due to intraluminal mucus plugs is an important 
pathophysiologic feature of RSV bronchiolitis, a mucolytic agent might be 
efficacious.  In a case series (Merkus et al. 2001), improvement in chest 
radiograph findings, oxygenation and blood gas results were reported after 
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recombinant human deoxyribonuclease (rhDNase) administration in five 
infants with severe atelectasis associated with bronchiolitis.  In a randomised 
trial (n=75) (Nasr et al. 2001) an improvement in chest radiograph scores 
was shown in infants receiving rhDNase compared to placebo (the excipient 
of the rhDNase- sodium chloride and calcium chloride), but there was no 
difference in clinical scores or length of hospital stay.  In a larger randomised 
study of infants with moderate RSV bronchiolitis requiring hospital admission 
(n=225), but not intensive care, no difference was demonstrated in length of 
hospitalisation or duration of supplementary oxygen between infants 
receiving rhDNase or placebo (0.9% saline) (Boogaard et al. 2007). 
 
1.9.7 Leukotriene receptor antagonists 
 
Higher levels of cysteinyl leukotriene in bronchoalveolar lavage fluid are 
found in infants with acute RSV infection compared to controls (Kim et al. 
2006).  Nevertheless, in a randomised controlled trial of 55 infants admitted 
to a general paediatric ward, 77% of who were RSV positive, no significant 
differences were detected in length of hospitalisation, clinical score or 
cytokine levels between infants receiving a leukotriene receptor antagonist 
(montelukast) or placebo (Amirav et al. 2008).  The study, however, was 







Infants with severe bronchiolitis, that is those requiring intensive care, have 
been shown to have reduced levels of surfactant (Dargaville et al. 1996); 
therefore replenishing surfactant from an exogenous source would seem a 
plausible treatment.  Tibby et al in a study of 19 ventilated infants, nine 
receiving surfactant and ten controls (receiving air as a placebo), showed two 
doses of bovine surfactant (Survanta) resulted in a reduced deterioration in 
compliance and resistance of the respiratory system, although there were no 
differences in duration of ventilation, intensive care or total hospital stay 
(Tibby et al. 2000). In a randomised trial of 40 infants, the 20 receiving 
exogenous surfactant (Curosurf) had significantly better blood gas results, 
higher static compliance and a shorter duration of mechanical ventilation and 
stay on paediatric intensive care compared to the controls (Luchetti et al. 
2002).  Both studies included only the most severely unwell infants who had 
had either no improvement after 12 hours of mechanical ventilation (Luchetti 
et al. 2002) or were unlikely to remain ventilated for less than 48 hours, 




Ribavirin is a virustatic agent which inhibits RSV transcription, glycoprotein 
expression, syncytium formation and virion release with little cellular toxicity 
in vitro (Zhang et al. 2003).  A systematic review (Ventre & Randolph 2007) 
of 12 studies including 115 infants who received Ribavirin and 112 controls 
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concluded that ribavirin did not statistically significantly reduce the length of 
mechanical ventilation or hospitalisation, but the studies lacked sufficient 




Heliox consists of a mixture of helium and oxygen, which has a lower density 
than air and thus has a reduced resistance to flow in the airways. In addition, 
carbon dioxide diffuses through helium four to five times faster than through 
air, which aids ventilation and carbon dioxide removal.  In a small 
randomised controlled crossover trial, use of heliox in non-ventilated infants 
with mild-moderately severe RSV bronchiolitis was associated with an 
improved clinical score (Hollman et al. 1998).  A more recent prospective, 
interventional crossover study compared infants with bronchiolitis receiving 
continuous positive airway pressure (CPAP) ventilation with either air/oxygen 
or heliox (Martinón-Torres et al. 2008).  Those infants receiving CPAP with 
heliox had a statistically significant improvement in clinical scores and arterial 
blood gas carbon dioxide results compared to those on CPAP driven with 
air/oxygen (Martinón-Torres et al. 2008).  Two other studies (Gross et al. 
2000; Liet et al. 2005), however, found heliox did not result in any improved 
outcomes.  Gross et al (Gross et al. 2000), in ten mechanically ventilated 
infants, did not demonstrate any statistically significant reductions in 
ventilation requirements or oxygenation in infants receiving 15 minute periods 
of varying heliox mixtures (helium proportion varying between 50-70%) 
compared to those receiving oxygen/nitrogen (50:50) mix.  Liet et al in a 
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small (n=39) multi-centre, randomised, double-blind, placebo controlled trial 
found no statistically significant differences in clinical score, need for 
mechanical ventilation or length of stay on paediatric intensive care between 




There are currently no safe and effective vaccinations against the viruses 
that commonly cause bronchiolitis appropriate for use in infants.  In the 
1960s, a formalin inactivated vaccine against RSV was produced (Kapikian 
et al. 1969; Kim et al. 1969).  In children between two and five years of age 
the vaccine was not protective as similar numbers of children developed 
pneumonia in the vaccinated and unvaccinated groups (18% versus 26%).  
In children aged between 6-23 months, however, the vaccine induced an 
exaggerated clinical response to naturally occurring RSV infections; 69% of 
the vaccinated group but only 9% of the control group developed pneumonia 
(p<0.0001) (Kapikian et al. 1969) and 80% of the vaccinated group required 
hospitalisation at the time of RSV infection, compared to 5% of the control 
group (Kim et al. 1969). 
 
Passive immunoprophylaxis has been available either as pooled and 
enriched human immune globulin (RSV-IGIV; Respigam, Medimmune, 
Gaithersburg, USA) or as a monoclonal antibody (Palivizumab; Medimmune, 
Gaithersburg, USA).  Two randomised controlled trials carried out by the 
same study group have investigated the use of RSV-IGIV. The first included 
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101 previously healthy infants born at 33 weeks of gestational age and 
found no difference in length of hospital stay, but a trend towards a reduction 
in intensive care stay (p=0.06), in the infants receiving RSV-IGIV compared 
to those receiving the placebo (Rodriguez et al. 1997).  The second, the 
PREVENT trial, included only high risk infants, that is those born less than 35 
weeks GA with or without BPD, n=510 (1997). RSV-IGIV reduced 
hospitalizations by 41% and reduced length of stay by 53%. In addition, 
infants who received RSV-IGIV required fewer days of supplemental oxygen 
during their hospital admission.  RSV-IGIV was, however, associated with 
side effects.  One percent of all the infants and 13% of those with BPD 
required diuretics at the time of treatment (1997).  RSV-IGIV is administered 
as an intravenous infusion and could have resulted in fluid overload.  In 
addition, it needed to be given once a month over the RSV season and, as it 
is human-derived, there is a potential risk of blood-borne infections. 
 
Palivizumab is a humanized monoclonal antibody (IgG) directed against an 
epitope in the A antigenic site of the F protein of RSV and is about 50-fold 
more potent than RSV-IGIV (Johnson et al. 1997).  It is administered by 
intramuscular injection and is given monthly over the RSV season.  The 
IMpact RSV study (1998) was a randomised, double-blind, placebo-
controlled trial including 1502 prematurely born infants (<36 weeks GA) and 
demonstrated palivizumab administration resulted in a significant reduction in 
hospitalisation (4.8% vs. 10.6%, p<0.001), fewer total days of hospitalisation, 
fewer days of increased oxygen supplementation and fewer intensive care 
 62 
admissions, although no statistically significant reduction in the need for 
mechanical ventilation (1998).   
 
Sub group analysis demonstrated infants with BPD had a 39% reduction 
(p=0.038) in hospitalisations compared to the control group (1998).  In 
addition, infants without BPD had a 78% reduction (p<0.001), infants born 
<32 weeks GA a 47% reduction (p=0.003) and infants born between 32-35 
weeks GA an 80% reduction (p=0.002) in hospitalisation compared to the 
control group (1998). 
 
As palivizumab is a relatively expensive medication (£360 per 50 mg vial) 
(Royal College of Paediatrics and Child Health 2008) cost benefit analysis 
studies have been undertaken and not shown palivizumab to be cost 
effective except in very high risk infants.  A systematic review and economic 
evaluation by the Health Technology Assessment Programme (UK) 
demonstrated palivizumab may only be cost-effective for children with 
chronic lung disease when the children had two or more additional risk 
factors (e.g. age at start of RSV season, siblings at school) (Wang et al. 
2008).  As a consequence palivizumab is not routinely given to all 
prematurely born infants.  It is, therefore, important to try to identify more 
accurately which infants will go on to develop RSV and subsequent morbidity 




There is limited evidence that palivizumab may reduce chronic respiratory 
morbidity.  A non-randomised study followed up 427 infants born at less than 
36 weeks GA without BPD. Infants had either received palivizumab or not 
(the reasons why infants did or did not receive palivizumab were not explored 
in the study) and were followed for two years with telephone calls or visits to 
the study centre.  Palivizumab was associated with a 49% relative reduction 
in the proportion of children with parental reported recurrent wheezing (three 
or more episodes of wheeze over one year) and a 51% relative reduction in 
physician diagnosed recurrent wheeze compared to the infants who had not 
received palivizumab (which included infants who had and had not been 
hospitalised for RSV infection) by two years (Simoes et al. 2007).  When 
comparing the palivizumab treated group with the subgroup of those not 
receiving palivizumab who had not been hospitalised for RSV infection, the 
palivizumab group still had a 43% relative reduction in the proportion of 
children with parental reported recurrent wheezing and a 19% relative 
reduction in the proportion of children with physician diagnosed recurrent 
wheezing.  It must be noted, however, that infants who had received 
palivizumab and had been hospitalised for RSV infection in the first year after 
birth were excluded from the study, therefore potentially biasing the results 






1.10 Assessment of respiratory morbidity 
 
1.10.1 Diary cards 
 
Determining the frequency of respiratory symptoms such as cough and 
wheeze at follow-up can give an assessment of chronic respiratory morbidity. 
These symptoms can be documented by parent completed diary cards, 
which have been used to show prematurely born infants who develop RSV 
LRTI are more likely to cough and wheeze (Broughton et al. 2005) than those 
with no LRTI or RSV negative LRTIs and to assess infants’ responses to 
medications for post-bronchiolitis wheeze (Fox et al. 1999; Bisgaard 2003). 
 
1.10.2 Healthcare utilisation and costs of care 
 
Respiratory morbidity can be assessed by healthcare utilisation and the 
associated healthcare related costs.  This can be documented by calculating 
the number of GP attendances, hospital attendances (Accident and 
Emergency and out-patient), medication prescriptions and the number, 
duration and level of care (general ward, HDU or PICU) of hospital 
admissions.  The associated costs can then be calculated from reference 
costing schemes (NHS reference costing scheme).  Prematurely born infants 
with BPD who had been hospitalised for RSV infection (confirmed RSV by 
direct immunofluorescence) were shown to have had significantly more and 
longer hospital admissions to general paediatric wards, more admissions to 
PICU and more in-patient costs of care between their index hospital 
 65 
admission (at a median age of seven months) and the end of the follow up 
period (two years of age) than the controls (Greenough et al. 2001).  A 
further follow-up of those infants between the ages of two and four years 
showed the infants who had been hospitalised for RSV infection had more 
out-patient attendances and more medication prescriptions for both all 
medications and for respiratory medications (Greenough et al. 2004).  They 
had greater healthcare costs for out-patient attendances, for all medication 
prescriptions and total cost of care over the follow-up period (Greenough et 
al. 2004).  In addition, Sampalis demonstrated significant differences in 
infants born between 32 and 35 weeks of GA without BPD who had or had 
not had RSV infection (identified from hospital discharge codes, therefore 
included infants with ‘probable’ RSV infection) (Sampalis 2003).  The RSV 
group had more and longer hospitalisations, more out-patient attendances 
and also a five-fold increase in mortality (8.1% versus 1.6%, p=0.001).  All 
those studies included infants who had initially been hospitalised for RSV 
infection and as most infants who develop RSV are not hospitalised those 
studies may underestimate the healthcare burden.  To address this 
Broughton et al prospectively followed infants born less than 32 weeks GA 
and documented RSV LRTIs both in hospital and in the community 
(Broughton et al. 2005).  RSV was identified by either viral culture or direct 
immunofluorescence.  The infants who developed RSV LRTIs had more and 
longer hospitalisations and more GP attendances than the infants who did 
not develop a LRTI, and longer hospitalisations, more PICU admissions and 
more GP attendances than the RSV negative LRTI group.  Infants who 
developed RSV LRTIs not requiring hospitalisation required more GP 
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attendances than the no LRTI group (1.3 versus 0.4, p=0.049) and had 
significantly more wheeze in one month than both the no LRTI group (3.7 
versus 0.6 days, p=0.005) and the RSV negative LRTI group (3.7 versus 0.7 
days, p=0.004).  It was also noted that the RSV negative group had more 
hospital admissions than the no LRTI group suggesting other viruses may 
cause chronic respiratory morbidity (Broughton et al. 2005).  An aim of this 
thesis, therefore, was to investigate whether other viral LRTIs, as well as 
RSV LRTIs, regardless of whether hospitalisation was required, lead to 
increased healthcare utilisation and costs of care in prematurely born infants. 
 
1.11 Assessment of lung function 
 
1.11.1 Measurement of functional residual capacity 
 
Functional residual capacity (FRC) can be measured by inert gas dilution 
techniques or by total body plethysmography.  However, it is not possible to 
perform plethysmography as a bedside test on a NICU.  Different 
methodological approaches have been described for the assessment of FRC 
by gas dilution, including the helium gas dilution technique (FRCHe) and the 
open-circuit, multiple-breath, inert-gas wash-in/out (FRCMBW) technique 
(Hülskamp et al. 2006).  Both approaches measure the volume of lung 
regions that communicate readily with the central airways during tidal 
breathing and therefore can be inaccurate when parts of the lung have long 
time constants.  These techniques can be used prior to NICU discharge and 
at follow up and hence allows lung function to be tracked according to viral 
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status and to determine the impact of viral LRTIs on lung function.  In this 
thesis both inert gas dilution techniques will be used to measure FRC in 
infants prior to NICU discharge and at follow up to allow lung function to be 
tracked.  Total body plethysmography will be used to assess FRC at follow 
up (see section 1.11.4). 
 
1.11.2 Ventilation Inhomogeneity 
 
The multiple breath wash-in/out technique gives an assessment of ventilation 
inhomogeneity (VI), often measured as lung clearance index (LCI), a marker 
of small airway function.  Infants with diseases including cystic fibrosis 
(Aurora et al. 2005) and congenital diaphragmatic hernia (Dotta et al. 2007) 
have been shown to have abnormally raised LCI.  Viral LRTIs affect the small 
airways (Mok & Simpson 1982; Fjaerli et al. 2005) and thus an assessment 
of small airway function by LCI may demonstrate abnormalities not found by 
other lung function techniques and will be assessed in this thesis. 
 
1.11.3 Compliance and resistance of the respiratory system by the 
single breath occlusion technique 
 
Compliance (Crs) and resistance (Rrs) of the respiratory system can be 
measured by the single breath occlusion technique.  A brief airway occlusion 
at end inspiration induces a brief apnoea by the Hering-Breuer inflation 
reflex.  The elastic recoil of the respiratory system can be measured by the 
pressure within a facemask.  Relief of the obstruction results in passive 
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expiration, both flow and volume decrease exponentially once the flow has 
reached a peak, providing the mechanical characteristics of the lung remain 
unchanged.  This allows the assessment of Crs and the time constant (Trs).  
Rrs can then be calculated from the formula Trs=Crs x Rrs (Milner & Rafferty 
2003).  This technique can be used prior to NICU discharge and at follow up 
and hence allows lung function to be tracked according to viral status and to 
determine the impact of viral LRTIs on lung function. 
 
1.11.4 Plethysmographic measurement of FRC 
 
During assessment by whole-body plethysmography, the subject is enclosed 
within a rigid, closed container and changes in alveolar pressure and volume 
are measured (Dubois et al. 1956a; Dubois et al. 1956b). FRC measured by 
plethysmography (FRCpleth) allows the measurement of all gas within the 
thorax, which can then be compared to gas dilutional methods of measuring 
FRC to give an estimation of gas trapping within the thorax (e.g. the 
FRCHe:FRCpleth ratio).  Broughton et al in a study of infants born less than 32 
weeks of gestation measured at one year corrected age, found a mean 
FRCpleth of 30 ml/kg and a mean FRCHe:FRCpleth ratio of 0.82 (Broughton et 
al. 2007).  
 
1.11.5 Plethysmographic measurement of airway resistance 
 
Whole-body plethysmography also allows measurement of airway resistance 
(Raw). Plethysmographic resistance measurements are performed at 
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standard BTPS conditions, using a heated rebreathing bag, so that any 
changes in the flow or pressure recordings reflect changes in Raw rather than 
changes in humidity and temperature of the respired gas throughout the 
respiratory cycle (Gappa et al. 2006). New methods of whole-body 
plethysmography do not measure under standard BTPS conditions and use 
electronic or mathematical algorithms to compensate for thermal artefacts. 
Unfortunately, the current algorithms are not sophisticated enough to achieve 
reliable measurements in infants and very young children and thus may not 
be appropriate for use in this population (Broughton et al. 2007).  For the 
follow up measurements in this study whole-body plethysmography 
measured under standard BTPS conditions was used. 
 
1.11.6 The rapid thoracoabdominal compression technique 
 
The rapid thoracoabdominal compression technique (RTC) generates flow-
volume curves in infants.  It can be carried out using the tidal RTC method or 
the raised volume RTC method (Lum et al. 2006).  Both involve wrapping an 
inflatable jacket around a sedated infant’s chest and abdomen and allowing 
the infant to breathe through a facemask and pneumotachograph. In the tidal 
RTC technique at least five regular tidal breaths are obtained and then an 
initial jacket pressure of 20–30 cm H2O is applied usually at end-inspiration, 
which applies a pressure around the chest and abdomen to force expiration 
(Lum et al. 2006). The manoeuvre is repeated with increasing jacket 
pressure until further increases do not elicit further increases in flow at 
functional residual capacity (FRC) (Lum et al. 2006).  From this, maximal flow 
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at FRC (VmaxFRC) is reported.  With the raised volume RTC technique the 
infant’s lungs are initially inflated to a preset pressure prior to RTC, to force 
expiration from a volume beyond tidal range and then the same methodology 
as for the tidal RTC technique is applied. Results reported from the raised 
volume RTC technique include forced vital capacity (FVC), forced expired 
volume in 0.5 sec (FEV0.5), forced expiratory flow when 50% of FVC has 
been expired (FEF50), forced expiratory flow when 75% of FVC has been 
expired (FEF75) and FEF when 25–75% of FVC has been expired (FEF25–75) 
(Lum et al. 2006).  This, however, is an invasive technique and potential 
problems include gastrointestinal problems or pneumothorax, particularly in 
infants with inhomogeneous lung disease such as prematurely born infants 
with BPD or infants with respiratory insufficiency. 
 
1.12 Premorbid lung function and morbidity associated with viral LRTI 
 
Infants who become symptomatic with RSV infection may do so because of a 
functional predisposition.  
 
1.12.1 Previously healthy, term born infants 
 
The Tucson Children’s Respiratory Study (Martinez et al. 1988) assessed 
lung function, VmaxFRC, FRC, conductance and tidal breathing parameters, 
at eight weeks of age and then prospectively followed the infants until one 
year of age.  Although there were no significant differences in lung function 
between infants who did and did not develop LRTIs, it was demonstrated that 
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infants who developed a wheezy LRTI had a reduced conductance of the 
respiratory system compared to those infants who did not develop a LRTI 
(0.028 versus 0.035 L/sec/cmH2O, p<0.05) (Martinez et al. 1988).  No 
virological results, however, were reported.  Those results could be 
interpreted as indicating that diminished lung function predicts those who 
wheeze with a LRTI rather than those predisposed per se to a viral LRTI.  
Another prospective study measuring lung function before and after 
bronchiolitis at one year of age found that infants with evidence of reduced 
pre-existing respiratory function (lower VmaxFRC) and lower respiratory tract 
symptoms prior to infection, had a non significant (p<0.06) trend to develop 
bronchiolitis (Young et al. 1995).  Virology results, however, were only 
available for the two infants who were admitted to hospital, both of whom 
were RSV positive; the other infants who were not admitted had a doctor 
diagnosis of bronchiolitis.  A follow-up study (Turner et al. 2002) of that 
cohort (Young et al. 1995) highlighted that the infants with bronchiolitis had 
reduced lung function (%FEF25-75) and at a similar level to premorbid levels, 
as assessed by z-scores, at 11 years of age. That study (Turner et al. 2002) 
suggests viral LRTIs affect infants predisposed to poor lung function rather 
than resulting in it and thus preventing viral LRTIs may not result in reduced 
chronic respiratory morbidity in those infants. 
  
1.12.2 Prematurely born infants 
 
In a prospectively followed cohort, infants born prior to 32 weeks of gestation 
and developing RSV LRTI, 40% of whom required hospitalisation, in infancy 
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had an increased Rrs before discharge from the neonatal unit when 
compared with infants not developing a RSV LRTI (Broughton et al. 2006).  
The control group consisted of infants who did not develop a LRTI and 
infants who developed a LRTI caused by another virus.  Thus an aim of this 
thesis was to assess the impact of premorbid lung function on the 
development of RSV and other viral LRTIs in prematurely born infants. 
 
Prematurely born infants have lung function abnormalities as a result of 
antenatal and postnatal insults (Chess et al. 2006).  Therefore, in this thesis 
lung function was assessed prior to NICU discharge and was related to the 
development of subsequent viral LRTIs to help to predict which infants will go 
on to develop RSV or other viral LRTIs. 
 
1.13 Genetic predisposition to RSV LRTI 
 
1.13.1 Single nucleotide polymorphisms associated with RSV LRTI 
 
Single nucleotide polymorphisms (SNPs) in several genes coding for 
cytokines associated with RSV infection have been associated with an 
increased risk of developing RSV bronchiolitis requiring hospitalisation (Table 
1.4).  Most of these studies have investigated very homogenous ethnic 
populations, have been retrospective in nature and have involved only term 
born infants or small numbers of prematurely born infants grouped together 
with term born infants.  In addition, most did not have a similar control group 
(i.e. results of the index patients were compared to healthy adults or blood 
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donors) and did not use the sensitive method of PCR to identify cases.  One 
prospective study has compared infants with RSV infection requiring 
hospitalisation to those with RSV infection not requiring hospitalisation and a 
control group (healthy adults) (Tal et al. 2004).  Two SNPs in TLR-4 were 
compared and it was reported that infants hospitalised for RSV LRTI had a 
common TLR-4 mutation whereas those with RSV infection not requiring 
hospitalisation and the control group did not, suggesting this SNP is 
associated with severe RSV LRTI rather than RSV infection per se . 
 
SNPs were chosen for investigation in this study as they had previously been 
associated with an increased risk of severe RSV infection in infants born at 
term (Hoebee et al. 2004; Wilson et al. 2005; Janssen et al. 2007; Helminen 
et al. 2008) or born prematurely (Siezen et al. 2009), an increased risk of 
developing RDS (Lahti et al. 2004), a decreased risk of developing BPD 
(Hadchouel et al. 2008), an increased risk of recurrent wheeze at one year of 
age after RSV LRTI (Ermers et al. 2011) or reduced preschool lung function 
(Simpson et al. 2005). 
 
An aim of this thesis was to assess whether prematurely born infants had a 
genetic predisposition to developing a RSV LRTI. 
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Table 1.4: Studies investigating SNPs associated with severe RSV infection requiring hospitalisation, in previously 
healthy, term-born infants 




SNPs associated with RSV 
(Hull, 2000)  117 (10 preterm) Cord blood donors 180 1 IL-8 
(Löfgren et al. 2002) 86 Healthy neonates 95 12 SP-A1, SP-A2 
(Lahti et al. 2002) 84 Healthy aged matched infants 93 9 SP-D 
(Choi et al. 2002) 105 Healthy blood donors 315 10 IL-4 
(Hoebee et al. 2003) 200 Healthy adults 447 3 IL-4, IL-4Ra 
(Hull et al. 2003) 580 (116 preterm) Healthy neonates 580 5 CCR5 
(Gentile 2003) 77 None 0 5 IFN gamma, IL-6, IL-10, 
TGFB1 
(Hoebee et al. 2004) 204 Healthy adults 447 3 IL-10 
(Hull et al. 2004) 580 (116 preterm) Healthy neonates 580 63 IL-8, RASSF6 
(Wilson et al. 2005) 580 (116 preterm) Healthy neonates 580 8 IL-10 
(Krueger et al. 2006) 154 Healthy adults 270 5 Nil 
(Puthothu et al. 2006) 131 Adults (either healthy or with 
asthma) 
323 asthma,  
270 healthy 
5 IL-8 (compared to asthma 
group, not healthy group) 
(Puthothu et al. 2006) 131 Healthy adults 270 4 IL-13 
(Puthothu et al. 2007) 154 Healthy adults 270 6 IL-18 
(Janssen et al. 2007) 470 (113 preterm) Healthy adults 447 384 VDR, JUN, IFNA5, NOS2 
(Fjaerli et al. 2007) 18 Infants with RSV not requiring 
hospitalisation 
5 15 FAM102A, TNFRSF25, 
STMN3 
(Amanatidou et al. 2008) 106 Healthy adults 120 7 RANTES 
(Mailaparambil et al. 2008) 156 Healthy adults 270 19 TLR-9,10 
(Hashimoto et al. 2008) 81 Healthy adults 98 9 PGIS 
(Mailaparambil et al. 2008) 156 Healthy children 296 14 Nil 
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1.13.2 SNPs associated with wheezing post-RSV LRTI 
 
A SNP in the gene coding for IL-8 (Goetghebuer et al. 2004) and another in 
the gene coding for IL-13 (Ermers et al. 2007) have been shown to be 
associated with post-RSV bronchiolitis wheeze at six years of age.  In the 
study by Ermers et al, the IL-13 SNP was not associated with wheezing in 
the first three years post-RSV bronchiolitis, but was associated with 
wheezing at six years (Ermers et al. 2007).  Those results suggest that early 
and late wheezing after RSV bronchiolitis may result from a different genetic 
background. 
 
A further aim of this thesis was to assess whether prematurely born infants 
have a genetic predisposition to develop subsequent wheeze and chronic 
respiratory morbidity after developing a RSV LRTI. 
 
1.13.3 SNPs associated with other viral LRTIs in infancy 
 
One study has investigated the genetic predisposition to respiratory viruses 
other than RSV.  Previously healthy term-born infants less than six months of 
age, who had been hospitalised for non-RSV bronchiolitis, and especially 
HRV bronchiolitis, were found to have a polymorphism in the gene coding for 
IL-10 (homozygosity for A at -1082) (Helminen et al. 2008).  The same SNP 
had been associated with RSV bronchiolitis requiring mechanical ventilation 
(Wilson et al. 2005), although no association with RSV was found in that 
study (Helminen et al. 2008). 





RSV LRTI has been associated with chronic respiratory morbidity including 
cough, wheeze, a diagnosis of asthma, lung function abnormalities and 
increased healthcare utilisation and cost of care in both term and prematurely 
born infants.  Other respiratory viruses may cause an acute clinical picture 
similar to that of RSV infection.  Few data exist, however, on their affect on 
subsequent respiratory morbidity, especially in prematurely born infants. 
 
Term born and prematurely born infants may be predisposed to develop RSV 
LRTI by reduced premorbid lung function.  Whether, however, reduced 
premorbid lung function predisposes prematurely born infants to other viral 
LRTIs has rarely been investigated.   In addition, term born infants may be 
genetically predisposed to develop RSV LRTI, but whether prematurely born 















 RSV and other viral LRTIs in prematurely born infants will result in 
increased healthcare utilisation and cost of care. 
 RSV and other viral LRTIs in prematurely born infants will result in 
reduced lung function and increased respiratory symptoms at follow-up. 
 Reduced premorbid lung function will predispose prematurely born infants 
to RSV and other viral LRTIs. 
 Host genotype may influence the likelihood of developing a symptomatic 




 To prospectively follow a cohort of prematurely born infants until two 
years corrected age, documenting all of their LRTIs, both in hospital 
and in the community, and to assess chronic respiratory morbidity 
(respiratory symptoms, lung function, healthcare utilisation and cost of 
care) compared to controls. 
 To determine whether RSV and other viral LRTIs result in a similar 
outcome compared to infants without viral LRTIs. 
 To assess whether diminished lung function prior to neonatal 
discharge predisposes prematurely born infants to symptomatic RSV 
and other viral LRTIs. 
 To determine whether prematurely born infants have a genetic 
predisposition to RSV LRTI and chronic respiratory morbidity. 
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Infants born prior to 36 weeks of gestation were eligible for entry into the 
study when they reached 36 weeks postmenstrual age (PMA) in the six 
months prior to the RSV season (October 1st to March 31st) (Clark, 2000) in 
2008 or 2009. After discharge, infants were prospectively followed; those 
born in 2008 were followed until two years corrected age (2008 cohort), those 
born in 2009 until one year corrected age (2009 cohort).  All recruited infants 
were exposed to at least one RSV season on neonatal/maternity unit 
discharge.  Parents of infants were approached on either the postnatal ward 
or the neonatal unit.  Infants with congenital or chromosomal abnormalities 
were excluded from the study, as were infants who lived too far from the 
hospital to make home visits feasible. 
 
At 36 weeks PMA and prior to neonatal/maternity unit discharge, infants had 
lung function measured: lung volume using a helium gas dilution technique, 
Crs and Rrs using the single breath occlusion technique and lung volume and 
ventilation inhomogeneity (lung clearance index) by the multiple breath wash-
in/out technique. In addition, blood or buccal swabs were obtained from 
infants for DNA extraction and SNP analysis. 
 
All LRTIs were documented from discharge until one (both cohorts) or two 
(2008 cohort only) years corrected age.   
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Following neonatal unit discharge, parents were asked to contact the 
research team whenever their infant had a LRTI and were telephoned every 
two weeks by a researcher. A researcher visited the home or hospital on 
every occasion an infant had a LRTI and obtained a NPA.  NPAs were 
analysed by real time PCR for 13 respiratory viruses. 
 
An infant was considered to have a viral LRTI if they had coryzal symptoms 
with or without fever and either a raised respiratory rate for their age (>60 for 
infants), crackles or wheeze on chest auscultation or respiratory distress (e.g. 
subcostal recession).  This included infants with diagnoses including 
bronchiolitis, pneumonia and viral induced wheeze. The severity of the LRTI 
was assessed by the need for hospitalisation- either ‘severe’ warranting 
hospitalisation or ‘non-severe’ not requiring hospitalisation. 
 
When the infant was 11 (both cohorts) and 23 (2008 cohort only) months 
corrected age, parents were asked to complete a diary card (Appendix 1) for 
one month.  Parents recorded on a daily basis if their infant coughed, 
wheezed, visited a medical practitioner and/or required respiratory related 
medication.  In addition, parents completed a respiratory health-related 
questionnaire (Appendix 2) at one (both cohorts) or two (2008 cohort only) 
years corrected age. 
 
Lung function was measured at one year corrected age.  Measurements 
included those carried out at 36 weeks PMA and in addition whole body 
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plethysmography was performed to measure lung volume and airways 
resistance. 
 
Healthcare utilisation and cost of care were calculated at one (both cohorts) 
and two (2008 cohort only) years corrected age. 
 
The study was approved by the Research Ethics Committee of King’s 
College Hospital NHS Trust.   
 




Weight was measured at 36 weeks PMA and at one year corrected age using 
a digital scale (Marsden digital baby/toddler scale, Marsden weighing group, 
Oxfordshire, UK).  Before weighing the infant, the scale was zeroed, the 
infant was then placed naked on the scale and the weight in kilograms 
recorded. The accuracy of the weighing scales was determined using 
weights of one, two, three and four kg (i.e. the expected weights of infants at 
36 weeks PMA) and weights of 6, 10 and 14 kg (i.e. those expected at one 
year corrected age).  The assessment was performed in triplicate. For the 1-4 
kg weights the mean (range) difference between the actual and measured 
weights was 2 (0-3) g and for the 6-14 kg weights the mean (range) 
difference was 19 (10-35) g. 
 





Length was measured at one year corrected age using an infant stadiometer 
(Holtain Ltd, Crymych, UK). The accuracy of the stadiometer was checked 
using 60 cm and 90 cm metal calibration rods.  The assessment was 
performed in triplicate. The mean difference between rod length and 
measured length was 0.07 cm (0.1 %) at 60 cm and 0.03 cm (0.04 %) at 90 
cm. 
 
2.3 Measurement of lung function at 36 weeks PMA 
 




Lung volume was assessed using a commercially available helium gas 
dilution system (EBS 2615, Equilibrated Bio Systems, New York, USA). The 
FRC system contained a 500 mL re-breathing bag, the system reservoir, 
enclosed in an airtight perspex box.  The re-breathing bag, containing a 
mixture of helium (approximately 10%) and oxygen, was connected to a 
three-way valve to which a facemask could be attached.  The helium 
analyser was calibrated using a certified calibration gas prior to each test.  
Release of the valve from its standby position open to atmosphere resulted in 
connection of the patient port to the re-breathing bag.  The helium analyser 
was contained in a separate unit and connected to the re-breathing bag via 
flexible tubing.  The gas in the re-breathing bag was circulated continuously 
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through the analyser during the measurement and helium concentration in 
the circuit was displayed in real time on a LCD monitor.  Helium equilibration 
was deemed to have occurred if there was no change in helium 
concentration over a 15 second period. The initial and equilibration helium 
concentrations were used to calculate FRC. 
 
2.3.1.2 In vitro assessment  
 
The accuracy of the measurement of volume by the helium gas dilution 
technique was assessed using a lung model which consisted of a 100 mL 
certified calibration syringe (5510, Hans-Rudolph Inc, Montana, USA), with a 
stroke volume of 20-100 mL delivered at a rate of 30 strokes per minute, 
attached to identical spacers to vary the volume of the model (Figure 2.1).   
 
Figure 2.1:  A schematic diagram showing the lung model 
Adapted from PhD thesis by S. Broughton, King’s College London, 2009. 
 
 
This was then attached to the patient port of the three way valve of the 
helium gas analyser using a connector.  The volumes of the lung models 
were determined by water displacement.  During the measurement, 
equilibration was deemed to have occurred when there had been no change 
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in the helium concentration over a 15 second period.  FRC was measured 
three times at each volume tested. 
 
The volumes used in the model were chosen to encompass those likely to be 
measured. To represent neonates, assuming bodyweights of 2.0–3.5 kg with 
predicted FRC in the range of 40-90 mL, volumes of 43, 63, and 83 mL were 
used and to represent infants at one year corrected age with likely 
bodyweights of 8-12 kg, and predicted FRC ranging from 160-300 mL, 
volumes of 139, 222 and 298 mL were used.  The mean (SD) difference in 
the expected and measured volumes was 1.0 (3.4) mL, which is a smaller 
volume than would be clinically meaningful, demonstrating the helium gas 
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Figure 2.2: Bland and Altman plot of expected and measured volumes 
(mL) using the helium gas dilution technique 
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2.3.1.3 In vivo assessment 
 
The sleeping infant lay supine, with their head in the neutral position.  A 
facemask (Rendell Baker, Laerdal, Norway) was held snugly over the mouth 
and nose; silicone putty (Promedics, Port Glasgow, UK) was placed around 
the mask to achieve an airtight seal. The facemask was connected to the re-
breathing bag via a three-way valve. The three-way valve was switched at 
the end of expiration, so that the infant subsequently breathed from the re-
breathing bag.  The initial and equilibration helium concentrations were used 
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to calculate FRC and this was corrected for oxygen consumption assumed to 
be 7 mL/kg/min (Hey, 1969) and body temperature and pressure, saturated 
(BTPS) conditions.  FRC was measured at least twice in each infant, results 
of two measurements were considered acceptable if they were within ten per 
cent of each other.  The reproducibility of FRC was tested on nine infants 
with two sets of tests carried out on the same day.  These results 
demonstrated good short term reproducibility with a co-efficient of variation 
percentage (standard deviation) of 1.9% (1.7) and a mean difference of 0.9 
mL. 
 




The open circuit multiple breath wash-in/out system (MBW) (Exhalyzer D, 
Ecomedics, Duernten, Switzerland) included an ultrasonic flowmeter (USFM) 
with a deadspace reducer (reducing the internal dead space of the flowmeter 
to 1.2 mL) and disposable bacterial filter (Spirette, EcoMedics AG, Duernten, 
Switzerland) inserted into it, connected to a bias flow (8-12 L/min).  The 
USFM and bias flow were both connected to the control unit and switch box 
which controlled the switching between air and the tracer gas mix.  The 
control unit and switch box were also connected to a laptop computer (Dell, 
UK) running WBreath software (WBreath version 3.19.8.0, ndd 
Medizintechnik AG, Zurich, Switzerland).  The USFM measured the inert 
tracer gas (approximately 5% sulphur hexafluoride [SF6] mixed with 21% 
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oxygen, and balance Nitrogen) continuously near the airway opening 
together with the associated flow of respired gas mixture. The USFM allows 
measurement of molar mass (MM) in the range of 20-45 g/mol with a 
precision of 0.01 g/mol.  Inspiratory and expiratory flows were integrated to 
calculate inspired and expired gas volumes (Schibler & Henning 2001; 
Schibler et al. 2002; Pillow et al. 2004).  As MM influences the transit time of 
the ultrasonic signal, inert gases with a MM sufficiently different from normal 
respired gas can be detected and used as a tracer gas for the MBW 
technique. 
 
Calibration was performed before each test.  Room temperature and humidity 
were measured with a humidity and temperature meter (RS 1360, RS 
Components Ltd, Northants, UK) and were entered into the computer 
programme.  Volume was then calibrated using a 100 mL certified calibration 
syringe (5510, Hans-Rudolph Inc, Montana, USA). 
 
After a period of baseline tidal volume measurements in air, the “wash-in” 
phase commenced and the bias flow was automatically switched to the tracer 
gas by the computer software.  “Wash-in” was maintained until the change in 
end expiratory molar mass varied by less than 0.01 g/mol over three 
consecutive breaths.  The “wash-out” phase was then automatically 
commenced by the computer software, and the bias flow was switched to air 
again.  “Wash-out” continued until the change in MM visibly returned to 
baseline (Figure 2.3).  Data was saved in the “raw” format and analysis of the 
                                                                                                                                                                   
 88 
 
data was carried out offline. The MBW technique is also able to measure 
ventilation inhomogeneity (VI), measured as lung clearance index (LCI). 
 
Figure 2.3: The MBW technique output 
The white line is the flow trace, the red line is the volume trace, and the 
yellow line is the molar mass trace. 
 
2.3.2.2 In vitro assessment  
 
The accuracy of the measurement of volume by the MBW technique was 
assessed using the same lung model and the same volumes as for the 
helium gas dilution technique (section 2.3.1.2).  The USFM was attached to 
the lung model and the data from each test were saved in the “raw” format, 
i.e. prior to correction for any factors such as temperature or side chamber 
reservoir effect (see below).  “Wash-in” measures from a baseline of no 
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tracer gas in the lung to the point of tracer gas equilibration within the lung 
(three consecutive breathes with a change in MM of less than 0.01 g/mol, 
automatically calculated by the computer software) (Figure 2.3).  Conversely, 
“wash-out” measures from the point of tracer gas equilibration in the lung to 
the point of equilibration of removal of all tracer gas from the lung, as 
determined by the operator viewing the trace and seeing the MM trace revert 
back to baseline (Figure 2.3). 
 
The MM of the gas in the main stream of the flowmeter was computed from 
the transit time which was directly proportional to the density of the medium, 
which itself was dependent on the precise temperature along the sound 
transmission path.  Because minor changes in temperature along the sound 
transmission path are present during tidal breathing, the changes in 
temperature along the sound transmission path must be simulated using a 
temperature model. The temperature model uses the measured flow, USFM 
dead space and the preset temperature of the inspiratory and expiratory gas 
to calculate the temperature changes along the sound transmission path 
(Hülskamp et al. 2009). The effects of changes in temperature on MM were 
accounted for using the temperature model suggested by Latzin et al (2007). 
 
In the lung model, the analysis also included correction for a side chamber 
reservoir effect (“step response”), but not body temperature and pressure, 
saturated (BTPS) conditions.  FRC was determined by calculating the sum of 
the product of tidal volume and the end expiratory molar mass change for 
each breath of the “wash-in”.  The volume of inhaled or exhaled tracer gas 
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was automatically corrected for re-inspired gas between the bias flow and the 
sensor “mid-point” and for the deadspace between the sensor “mid-point” 
and the mask (Hülskamp et al. 2009).  LCI was calculated as the number of 
volume turnovers (cumulative inspired or expired volume divided by FRC) 
required to reduce the end-tidal tracer gas concentration to 1/40th of the 
concentration at the start of “wash-out” (Schibler et al. 2002) (or if using the 
“wash-in”; increase to 39/40th).  
 
Three technically acceptable “wash-in” and “wash-out” traces were obtained 
for each lung model.  Analysis demonstrated measurement of the “wash-in” 
phase to be more accurate than the “wash-out” phase which always 
underestimated the volume (Table 2.1 and Figures 2.4 and 2.5), thus for this 
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Table 2.1: In vitro results of FRC measured by the MBW technique 




43 51.7 35.4 
43 49.9 33.8 
43 51.8 36.1 
63 60.5 47.4 
63 68.5 51.4 
63 76.7 49.3 
83 78.9 67.3 
83 77.7 65.5 
83 84.7 66.9 
139 143.1 130.4 
139 144.0 131.7 
139 130.1 132.9 
222 195.9 219.1 
222 199.0 219.4 
222 195.7 220.0 
298 275.5 288.9 
298 251.3 264.8 
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Figure 2.4 Bland and Altman plot of expected and measured volumes 
(mL) analysing the “wash-in” phase of the MBW technique 
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Figure 2.5: Bland and Altman plot of expected and measured volumes 
(mL) analysing the “wash-out” phase of the MBW technique 
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2.3.2.3 In vivo assessment  
 
The infant lay supine, with their head in the neutral position and a facemask 
(Rendell Baker, Laerdal Norway) held snugly over their mouth and nose; 
silicone putty (Promedics, Port Glasgow, UK) was placed around the mask to 
achieve an airtight seal. After a period of baseline tidal breathing, breathing in 
air, the “wash-in” phase commenced and the tracer gas was inspired.  
“Wash-in” was maintained until the change in end expiratory molar mass 
varied by less than 0.01 g/mol over three consecutive breaths.  The “wash-
out” phase was then automatically commenced and the infant began 
breathing air again.  “Wash-out” continued until the change in MM returned to 
baseline (Figure 2.3).  FRC and LCI were determined as for the lung model 
(section 2.3.2.2) but analysis also corrected for BTPS and the “effective” 
dead space of the mask used (4 mL at 36 weeks PMA and 13 mL at one year 
corrected age), which was subtracted from the USFM “mid-sensor” FRC 
value to obtain the infant’s FRC. 
 
Data were accepted for analysis if obtained during regular breathing, there 
was no evidence of leak, i.e. no sudden change in MM or flow and there were 
no sighs in the five breaths immediately prior to or the ten breaths 
immediately following commencement of the wash-in or wash-out (Hülskamp 
et al. 2009). 
 
The reproducibility of FRCMBW and LCI was tested on ten infants with two 
sets of tests carried out on the same day.  These results demonstrated good 
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short term reproducibility with a co-efficient of variation percentage (standard 
deviation) of 4.8% (3.8) and 4.6% (4.5) respectively and a mean difference of 
8.3 mL and 0.1 respectively. 
 
2.3.3 Compliance and resistance of the respiratory system  
 
The single breath occlusion technique was used to non-invasively determine 
total respiratory system compliance (Crs) and resistance (Rrs) (LeSoeuf et al. 
1984).  The technique involves briefly occluding the airway at end inspiration 
which results in a brief apnoea and invokes the Hering-Breuer inflation reflex 
(HBIR).  After the occlusion is terminated passive expiration occurs, i.e. there 
is no expiratory respiratory muscle activity.  The time constant (Trs), the time 
for 63% of the tidal volume to leave the lung, can then be measured from the 
slope of the plot of expiratory volume against expiratory flow (Milner & 
Rafferty 2003).  Crs is calculated from the formula: change in volume/change 
in pressure, measured after extrapolating the flow volume slope to zero.  Rrs 




A pneumotachograph (Mercury F10L; GM Engineering, Kilwinning, UK) 
attached to a differential pressure transducer (range: ± 0.2 kPa, MP 45, 
Validyne engineering, California, USA) was used to measure airflow.  Airway 
pressure was measured from a side-port on the pneumotachograph using a 
differential pressure transducer (range: ± 10 kPa, MP 45, Validyne 
                                                                                                                                                                   
 95 
 
engineering, California, USA).  The signals from the transducers were 
amplified (Validyne CD280, Validyne engineering, California, USA) and 
acquired, analysed and displayed in real time on a computer (Dell, UK) 
running a custom made software program written using Labwindows software 
(National Instruments, Texas, USA) with analogue-to-digital sampling at 100 
Hz (DAQCard 16XE-50, National Instruments, Texas, USA).  Flow was 




Prior to each measurement, airway pressure was calibrated using a digital 
pressure meter (Comark C9505IS, Welwyn Garden City, UK) and flow 
through the pneumotachograph was calibrated using a flow meter (0-12 
L/min, Platon, Roxspur M&C Ltd, Hants, UK). 
 
2.3.3.3 Validation of transducer linearity 
 
The airway pressure transducer was assessed for linearity over the range of 
± 45 cmH2O using a digital pressure meter (Comark C9505IS, Welwyn 
Garden City, UK).  Applied pressure was compared to the voltage output 
from the amplifier using BioBench software (version 1.0, National 
Instruments, Texas, USA). The airway pressure transducer had a linear 
response (r2 >0.99) (Figure 2.6). 
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The linearity of the flow transducer and associated pneumotachograph were 
measured  using a flow meter (Platon, 0-12L, Roxspur M&C Ltd, Hants, UK) 
attached to the pneumotachograph. Flow was passed through the 
pneumotachograph in one litre per minute increments across the range 10 
L/min in both directions (inspiratory and expiratory) and the results plotted 
against the flow delivered by the flow meter. The pneumotachograph had a 
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Figure 2.7: Plot of flow against voltage produced by the 




























2.3.3.4 Assessment of the frequency response 
 
The frequency response of the airway pressure transducer was assessed by 
measuring the response of the system to a quasi-instantaneous drop in 
pressure by bursting a balloon attached to the end of the pneumotachograph.  
The response time (Tr) (the time taken for pressure to fall from 90% to 10%) 
was 28 milliseconds. The frequency response was calculated from the 
equation: 
 
Frequency response =1/3Tr  
and was 11.9 Hz. 
 
The frequency response of the flow transducer and pneumotachograph was 
assessed by measuring the response of the system to a quasi-instantaneous 
drop in pressure by bursting a slowly deflating balloon (which therefore gave 
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a constant flow) attached to the end of the pneumotachograph.  The 
response time was 30 milliseconds. The frequency response was calculated 
as above and was 11.1 Hz. 
 
2.3.3.5 In vivo assessment  
 
A facemask (Rendell Baker, Laerdal, Norway) connected to the 
pneumotachograph was placed over the mouth and nose of the sleeping 
infant. A rim of silicone putty (Promedics, Port Glasgow, UK) was placed 
around the edge of the facemask to ensure a good seal. End inspiratory 
airway occlusions were performed by manually occluding the distal end of the 
pneumotachograph.  End inspiration was identified from the flow signal. Only 
occlusions during which there was no flow, a mouth pressure plateau of at 
least 100 milliseconds and a linear flow-volume plot following the occlusion 
were considered acceptable (Gappa et al. 2001).  
 
Briefly occluding the airway and maintaining the lung volume above end 
expiratory volume, induced the Hering-Breuer inflation reflex (HBIR) and 
passive expiration occurred when the occlusion was released (Figure 2.8).  
The resulting relaxed expiratory flow volume curve and the pressure time 
trace were analysed to calculate the expiratory time constant (Trs), Crs and 
Rrs.  A linear segment in the decelerating flow volume curve was selected, 
and a least squares best fit line was drawn and extended to cross the volume 
axis at zero flow to correct for any dynamic elevation of FRC.  The Trs was 
measured from the slope of the best fit line on the expiratory flow volume 
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curve. Crs was calculated from the extrapolated expired volume intercept, 
divided by the change in airway pressure; i.e. difference between plateau 
pressure during the occlusion and end expiratory pressure (zero).  Rrs was 
calculated by rearranging the formula: Trs = Crs x Rrs.  The flow volume curve 
was analysed using the computer software and only those with a linearity of 
0.99 for at least 40% of the curve were used (Figure 2.9). Eight to ten 
occlusions were recorded and the mean value calculated. At least ten 
breaths were allowed between occlusions.  The resistance of the apparatus 
was known and was subtracted from the result.   
 
The reproducibility of Rrs and Crs was tested on six infants with two sets of 
tests carried out on the same day.  These results demonstrated good short 
term reproducibility with a co-efficient of variation percentage (standard 
deviation) of 9.1% (2.9) and 10.7% (3.7) respectively and a mean difference 
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Figure 2.8: Diagram showing an occlusion at end inspiration and the 
resulting Hering-Breuer inflation reflex 
 
 
Figure 2.9: The resulting flow/volume loop from Figure 2.8 and the 
measurement of Crs and Rrs 
 
                                                                                                                                                                   
 101 
 
2.4 Lung function at one year corrected age 
 
Infants attended the Amanda Smith lung function laboratory for lung function 
testing at one year corrected age.  If they were clinically well and had been 
free of respiratory symptoms for at least three weeks they underwent lung 
function testing.  Infants were sedated with 80 mg/kg of Chloral hydrate and 
were tested supine and naked except for a nappy.  The infants were 
monitored by pulse oximetry (Datex-Ohmeda 3800, Hatfield, UK) throughout 
the lung function testing and afterwards until they were awake. FRC by 
helium gas dilution, FRC and LCI by the MBW technique and Crs and Rrs by 
the single breath occlusion technique were measured as at 36 weeks PMA 
(section 2.3).  In addition, whole-body plethysmography was performed.  
 




A custom built infant plethysmograph (Department of Medical Engineering, 
Hammersmith Hospital, London, UK) with a total volume of 90 L, and 
containing a heated, humidified, re-breathing bag system was used (Figure 
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Figure 2.10: Schematic diagram of the equipment and transducers for 
the plethysmograph 












The constant volume plethysmograph had a fixed leak which improved 
thermal and pressure stabilisation characteristics. The plethysmograph 
contained a re-breathing bag system, which consisted of a four litre highly 
compliant, heat resistant, plastic re-breathing bag.  The distal end of the bag 
was connected to a perspex ring on the top of the plethysmograph which 
held the bag open and also had a valve, through which the gas in the bag 
could be refilled with warmed, humidified air between measurements.  The 
proximal end of the bag was connected to a shutter block, which allowed the 
infant to be switched from breathing air inside the box to the air inside the 
bag, and a second valve which allowed airway occlusions to be performed. 
The shutter block was connected to a Fleisch pneumotachograph (Fleisch, 
 
Supply of warm  
humidified air 
Rebreathing bag containing 
servo-controlled heater with fan 
Shutter block 
Heated pneumotachograph 
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Hechinger, Germany) and mask connector.  Suspended within the re-
breathing bag was a thermostatically controlled heating element and fan to 
circulate the air. 
 
Pressure at the airway opening was measured by a differential pressure 
transducer (range ± 10 kPa, MP 45, Validyne engineering, California, USA) 
connected to a port in the facemask connector, which also incorporated a 
thermistor to measure airway temperature. The facemask connector was 
attached to a heated Fleisch pneumotachograph (Fleisch, Hechinger, 
Germany) from which airflow was measured. The pneumotachograph was 
connected to a differential pressure transducer (range ± 0.2 kPa, MP 45, 
Validyne engineering, California, USA). Pressure changes within the 
plethysmograph were measured by a differential pressure transducer (range 
± 0.2 kPa, MP 45, Validyne engineering, California, USA). All signals were 
amplified (CD18 carrier amplifiers, Validyne engineering, California, USA) 
and the flow signal was integrated electronically to give volume (FV 156 
Integrator, Validyne engineering, California, USA). The resultant four 
channels of data were acquired, analysed and displayed in real time on a 
computer (Gateway, Dublin, Ireland) running a custom written software 
program (Bodybox, Medical Engineering, Keighley, UK) with analogue-to-
digital sampling at 200 Hz (PC-LPM-16PnP, National Instruments, Texas, 
USA).  Equipment (including facemask) dead space volume (41.5 mL, 
measured by water displacement) was automatically subtracted by the 
computer software in the calculation of FRCpleth. A vent in the wall of the 
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plethysmograph was opened between measurements to improve the speed 




All channels were calibrated before each measurement.  Airway pressure 
was calibrated using a digital pressure meter (Comark C9505IS, Welwyn 
Garden City, UK).  Flow through the pneumotachograph was calibrated using 
a flow meter (0-12 L/min, Platon, Roxspur M&C Ltd, Hants, UK) and volume 
was calibrated with a 100 mL calibration syringe (5510, Hans-Rudolph Inc, 
Montana, USA). Box pressure was calibrated in terms of volume.  Bags of 
saline equivalent to the patient’s weight were placed inside the 
plethysmograph and an electric, sinusoidal pump (Parvalux electric motors 
Ltd, Bournemouth, UK) with a stroke volume of 19.2 ml was attached to the 
plethysmograph and pumped air in and out resulting in a pressure change 
within the plethysmograph. 
 
2.4.1.3 Validation of transducer linearity 
 
The airway pressure transducer was assessed for linearity over the range of 
± 45 cmH2O using a digital pressure meter (Comark C9505IS, Welwyn 
Garden City, UK).  Applied pressure was compared to the voltage output 
from the amplifier using BioBench software (version 1.0, National 
Instruments, Texas, USA).  The airway pressure transducer had a linear 
response (r2 >0.99) (Figure 2.11). 
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The flow transducer and pneumotachograph were similarly assessed for 
linearity using a flow meter (0-12 L/min, Platon, Roxspur M&C Ltd, Hants, 
UK) attached to the pneumotachograph.  Inspiratory and expiratory flows 
were measured over the range 10 L/min in both directions (inspiratory and 
expiratory).  The flow transducer and pneumotachograph had a linear 









                                                                                                                                                                   
 106 
 
Figure 2.12: Plot of flow against voltage produced by the 


























2.4.1.4 Leak measurement 
 
The plethysmograph had a small leak to the atmosphere to assist thermal 
and pressure equilibration. The incidence of slowly occurring pressure 
changes such as thermal drift due to the re-breathing bag heater and body 
heat unrelated to respiratory movements could thus be dampened. Rapidly 
injecting 50 mL of air into the plethysmograph and measuring the time taken 
for the plethysmograph pressure transducer reading to return to baseline 
measured the time constant of the leak. The time constant (the time taken for 
the pressure change to reduce by 63%) was 11.7 seconds.  This was within 
the range recommended by the ERS/ATS guidelines; 10 - 14 seconds 
(Stocks et al. 2001). 
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2.4.1.5 Assessment of the frequency response of the system 
 
The frequency response of the pressure transducers and the plethysmograph 
were measured by balloon burst experiments. It has been recommended that 
the frequency response for lung function equipment should be at least 10 Hz 
(Frey et al. 2000).  To measure the frequency response of the airway 
pressure transducer a balloon was connected to the transducer using the 
tubing employed in the plethysmograph and the pressure changes during the 
balloon bursts were recorded using Chart software (ADInstruments Pty Ltd, 
Castle Hill, Australia) with analogue-to-digital sampling at 40kHz (Powerlab 
16s, analogue-to-digital converter, ADInstruments Pty Ltd, Castle Hill, 
Australia).  Frequency response = 1/3Tr, the response time was five 
milliseconds, and therefore the airway pressure transducer frequency 
response was 66.7 Hz. 
 
The frequency response of the box pressure transducer/plethysmograph was 
measured by bursting a balloon inside the plethysmograph. The balloon was 
inflated through the port in the top panel of the plethysmograph while leaving 
the vent open. Once the balloon was inflated, the vent was closed creating a 
positive pressure within the plethysmograph. The balloon was partially inside 
and partially outside the plethysmograph, therefore forming a seal around the 
port it passed through. The balloon was then burst and the pressure change 
within the plethysmograph as measured by the box pressure transducer was 
recorded using Chart software (ADInstruments Pty Ltd, Castle Hill, Australia) 
with analogue-to-digital sampling at 40kHz (Powerlab 16s, analogue-to-digital 
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converter, ADInstruments Pty Ltd, Castle Hill, Australia).  The response time 
of the pressure transducer/plethysmograph was 23 milliseconds and 
therefore the total frequency response was 14.5 Hz. 
 
The flow transducer/plethysmograph frequency response was measured as 
for the box pressure transducer/plethysmograph as above.  The balloon was 
inflated through the port in the top panel of the plethysmograph while leaving 
the vent open. Once the balloon was inflated, the vent was closed creating a 
positive pressure within the plethysmograph. The balloon was partially inside 
and partially outside the plethysmograph, therefore forming a seal around the 
port it passed through. The balloon was allowed to slightly deflate giving a 
constant flow, and was then burst and the drop in flow across the 
pneumotachograph was recorded using Chart software (ADInstruments Pty 
Ltd, Castle Hill, Australia) with analogue-to-digital sampling at 40kHz 
(Powerlab 16s, analogue-to-digital converter, ADInstruments Pty Ltd, Castle 
Hill, Australia).  The response time of the flow transducer/plethysmograph 
was 27 milliseconds and therefore the total frequency response was 12.3 Hz. 
 
2.4.1.6 In vitro accuracy of the measurement of volume 
 
The accuracy of the measurement of volume by the plethysmograph was 
assessed using a lung model which consisted of a glass bottle attached to 
the pneumotachograph via the mask support using a T-shaped connector 
(Figure 2.13). 
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Figure 2.13: Schematic diagram of the lung model within the 
plethysmograph 
Adapted from PhD thesis by S. Broughton, King’s College London, 2009. 
 
The volume of the lung model was varied by the addition of identical spacers 
between the T-shaped connector and the mask support.  The volume of the 
lung model was determined by water displacement. Fine copper wire wool 
was placed inside the lung model to minimise the adiabatic effect.  A 
sinusoidal motorised pump (Parvalux electric motors Ltd, Bournemouth, UK) 
with a stroke volume of nine mL and a rate of 30 cycles per minute was 
attached to the lung model.  At the start of testing, the plethysmograph was 
sealed, the electric pump was started and the vent closed.  No 
measurements were made for ten minutes to allow temperature equilibration 
within the plethysmograph. An occlusion was performed when the piston of 
the pump was at the maximum inspiratory position and was maintained for 
three cycles of the pump. The signals were viewed on the computer screen 
to ensure the changes in box and lung model pressures were in phase and 
                                                                                                                                                                   
 110 
 
that at the time of occlusion there was no flow through the 
pneumotachograph. The measured volume of the lung model was calculated 
by relating the pressure within the lung model to the pressure changes within 
the plethysmograph.  The plethysmograph was tested at five volumes (175, 
232, 268, 335 and 402 ml), selected to encompass the range of lung volumes 
expected in infants at one year corrected age. The mean (SD) difference in 
the expected and measured volumes was 1.5 (6.8) mL, which is a smaller 
volume than would be clinically meaningful, demonstrating good agreement 
between the measured and expected volumes (Figure 2.14). 
 
Figure 2.14: Bland and Altman plot of expected and measured volumes 
(mL) for the plethysmograph 
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2.4.1.7 In vitro accuracy of the measurement of resistance 
 
The lung model was identical to that used to assess the accuracy of volume 
by the plethysmograph (section 2.4.1.6, Figure 2.13) except known calibrated 
resistances (Hans Rudulph Inc, Kansas City, Missouri, USA) of 20 and 50 
cmH2O/L/sec were placed between the lung model and the mask connector 
either individually or in series to create resistances of 20, 50 and 70 
cmH2O/L/sec.  The lung volume of the model used was 288 mL, equivalent to 
the FRC of an infant at one year corrected age.  
 
For each resistance measured, ten acceptable measurements (see section 
2.4.1.8) were recorded. The computer software calculated the resistance 
from the inspiratory flow trace from 0 to 50% of peak flow (Thomas et al. 
2002) and the coefficient of variation was calculated for each set of 
measurements (Table 2.2). 
 
Table 2.2: In vitro results of the resistance of the lung model 
Data are presented as mean (SD) or %. 
Added resistance Measured resistance Co-efficient of variation 
20 cmH2O/L/s 20.9 (1.4) 6.7% 
50 cmH2O/L/s 51.1 (0.8) 1.6% 
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2.4.1.8 In vivo assessment of FRCpleth and airway resistance 
 
The infant was placed supine inside the plethysmograph and the facemask 
(Rendell Baker, Laerdal, Norway) with a rim of silicone putty (Promedics, Port 
Glasgow, UK) was placed on the infant’s face covering the mouth and nose 
(Figure 2.10).  The FRCpleth was calculated from a minimum of three end-
inspiratory occlusions. End-inspiratory occlusions, rather than end-expiratory, 
were used as they have been shown to result in less glottic activity during 
respiratory efforts against the occlusion (Yüksel & Greenough 1994).  At the 
time of the occlusion FRCpleth is calculated from the equation: 
 
FRCpleth = (box pressure/airway pressure) x atmospheric pressure 
 
Occlusions were considered acceptable if the Vpleth and airway pressure were 
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Figure 2.15: Data from the plethysmograph showing an end inspiratory 
occlusion 
The blue line is airway pressure, the red line is airway volume, the pink line is 
plethysmograph volume and the green line is airway flow. 
 
 
Seventy two infants had acceptable FRCpleth measurements, the mean intra-
subject co-efficient of variation for FRCpleth was 3.2 %. 
 
After measuring FRCpleth, airway resistance (Raw) was measured.  The 
infant’s tidal breathing was diverted to the heated and humidified re-breathing 
bag.  Individual breaths acquired during periods of re-breathing from a single 
recording were displayed as x/y plots of Vpleth/flow by the computer.  Only 
technically acceptable breaths, that is the loop was closed or nearly closed at 
points of zero flow, were used in the analysis (Stocks et al. 2001).  Inspiratory 
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Raw was calculated electronically by applying a regression line to the portion 
of the loop between 0 and 50% maximal inspiratory flow (Thomas et al. 2002) 
(Figure 2.16). 
 
Figure 2.16: An x/y plot of Vpleth/flow during re-breathing, showing 
measurement from 0-50% of maximum inspiratory flow 
 
 
During all Raw measurements, the computer calculated the apparatus 
resistance of the selected portion of the individual breath by relating the 
change in airway pressure to the change in flow and then subtracted this 
value from the total measured resistances (Thomas et al. 2002).  At least 
fifteen resistance results were obtained from each infant. 
 
The reproducibility of FRCpleth and Raw was tested on five infants with two 
sets of tests carried out on the same day.  These results demonstrated good 
                                                                                                                                                                   
 115 
 
short term reproducibility with a co-efficient of variation percentage (standard 
deviation) of 3.6% (4.1) and 14.6% (5.3) respectively and a mean difference 
of 1.5 mL/Kg and 0.8 cmH2O/L/s respectively. 
 
2.5 Healthcare utilisation and cost of care analysis 
 
2.5.1 Neonatal healthcare utilisation and cost of care 
 
Infants’ and their mothers’ hospital notes and the King’s College Hospital 
(KCH) neonatal database were reviewed to find the number of days each 
infant spent at each level of neonatal care (i.e. intensive care [ICU], high 
dependency [HDU], special care [SCBU] or maternity ward) as defined by the 
British Association of Perinatal Medicine guidelines (British Association of 
Perinatal Medicine 2001).  Maternity ward costs included days the mother 
and infant stayed on a postnatal ward for a reason relating to the infant (e.g. 
intravenous antibiotics, phototherapy, blood sugar monitoring) but not those 
relating to the mother (e.g. blood pressure monitoring, wound care post 
caesarean section). Costs (UK £) for each level of care were obtained from 
the NHS reference costing scheme (2007-8) (£974, £750, £421, and £474 for 
ICU, HDU, SCBU and maternity ward respectively) (Department of Health 
2009), thus: 
 
Total neonatal costs = (days ICU x £974) + (days HDU x £750) + (days 
SCBU x £421) + (days maternity ward x £474). 
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2.5.2 Follow up healthcare utilisation and cost of care 
 
At one (both cohorts) and two (2008 cohort only) years corrected age, the 
infants’ hospital and GP records were examined to determine healthcare 
utilisation during infancy.  Hospital records were examined for hospital re-
admissions, Accident and Emergency (A and E) attendances, out-patient 
attendances and any medications prescribed.  GP records were examined for 
hospital re-admissions, A and E attendances, number of out-patient hospital 
appointments, number of GP attendances, number of referrals to community 
support services and all medication prescribed.  All visits to practice nurses 
or routine visits to health visitors, for example for immunisations, were not 
recorded as these were considered the usual costs for infants.  Follow up 
costs after neonatal discharge were calculated using the NHS reference 
costing scheme (2007-8) (Department of Health 2009) and the British 
National Formulary for Children (BNFC) (Royal College of Paediatrics and 
Child Health 2008).  The NHS reference costing scheme gives national 
average costs for in- and out-patient hospital attendances and GP 
attendances (Department of Health 2009).  This includes all costs routinely 
associated with the diagnosis requiring attendance (e.g. medical and non-
medical personnel, medication used during the admission, medication given 
to the patient on discharge and medical equipment).  For in-patient 
admissions the number of days for each admission was multiplied by the 
national average cost for the diagnosis leading to admission.  A respiratory 
attendance to hospital or GP was defined as an appointment with a 
healthcare professional relating to a LRTI (i.e. not an URTI).  From the BNFC 
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the lowest price relating to the medicine prescribed was used.  Daily home 
oxygen costs were obtained from the local authority the patient lived in. 
Palivizumab was considered an out-patient rather than a neonatal cost. 
 
Potential sources of bias when examining health care costs include the 
incorrect classification of diagnoses leading to incorrect attributable costs, the 
use of average costs from the NHS reference costing scheme may not be 
appropriate for the local healthcare service, the difficulty in the statistical 
analysis of heavily skewed data and time-horizon bias, which should be 
avoided as infants will be followed up to one or two years corrected age. 
 
2.6 Respiratory health related questionnaires and diary cards 
 
Parents completed a diary card (Appendix 1) for one month when their infant 
was 11 (both cohorts) and 23 (2008 cohort only) months corrected age, 
indicating each day whether their infant coughed, wheezed, used any 
respiratory related medications (e.g. inhalers, oral steroids, antibiotics) or 
visited any healthcare professional for an acute problem (i.e. not including 
routine out-patient appointments).  In addition, parents completed a 
respiratory health related questionnaire (Appendix 2) about their infant at one 
(both cohorts) and two (2008 cohort only) years corrected age.   
 
The internal validity of the respiratory-related questionnaire (for the questions 
“has you child coughed in the last year”, “has your child wheezed in the last 
year”, “has you child used any respiratory medications”, “has your child used 
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bronchodilators, preventers or antibiotics” and “has your child been 
diagnosed with asthma”) was assessed by calculating Cronbach’s alpha 
using IBM SPSS Statistics (version 19, New York, USA).  The Cronbach’s 
alpha was 0.753 which indicated a good level of internal consistency for the 
respiratory related questionnaire.  Removal of either of the questions “has 
you child coughed in the last year” or “has your child been diagnosed with 
asthma” would have minimally improved the internal validity of the 
questionnaire (increasing the Cronbach’s alpha to 0.756 or 0.769 
respectively). 
 
The internal validity of the diary card (using all five questions) was assessed 
by calculating Cronbach’s alpha using IBM SPSS Statistics (version 19, New 
York, USA).  The Cronbach’s alpha was 0.625 which indicated an acceptable 
level of internal consistency for the diary card.  Removal of any of the 
questions would not have improved the overall validity of the diary card. 
 
2.7 Virus identification 
 
Nasopharyngeal aspirates (NPAs) were obtained from infants with signs of a 
LRTI, either in the community or in hospital. Approximately one mL of normal 
saline was gently instilled into each nostril of the infant.  After approximately 
one minute a size eight or ten suction catheter (Unomedical, Worcs, UK), 
connected to a tracheal suction set (Unomedical, Worcs, UK), was inserted 
approximately five cm into each nostril in turn and the suction unit (Laerdel, 
Stavanger, Norway) turned on. The saline and any mucus was suctioned 
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from each nostril as the catheter was slowly withdrawn.  Up to five mL of 
0.9% saline was then suctioned through the catheter to move any mucus 
stuck in the catheter into the tracheal suction set.  The sample was then 
stored at 4oC until processed. 
 
2.7.1 Nucleic acid extraction 
 
The NPA was mixed with sterile Phosphate buffered saline (PBS), and any 
mucus broken up with a Pasteur pipette.  This was then centrifuged to 3000 x 
g for ten minutes.  The mucus and excess PBS was poured off and the pellet 
produced was resuspended in one mL of lysis buffer (QIAGEN, Crawley, 
UK), dispensed into a Sarstedt vial, and stored at 4oC until processed.    
 
Nucleic acid was extracted from the samples using the commercially 
available QIAsymphony cabinet and QIAsymphony virus midi kit (QIAGEN, 
Crawley, UK). It was possible to extract nucleic acid from 96 samples per 
run.  A negative control (RNA free water) was included in every 24 samples 
to test for cross contamination.  The sample (400 L) initially underwent lysis 
to inactivate the RNases and obtain intact viral nucleic acid.   The sample 
was then buffered and the nucleic acid bound to magnetic particles.  These 
were then washed off using another buffer and finally the nucleic acid (120 
L) was eluted in RNase free buffer.  This was stored at -80oC until PCR was 
undertaken. 
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2.7.2 Real-time reverse transcriptase PCR  
 
2.7.2.1 Previously developed real-time PCR assays 
 
Three multiplex assays and two monoplex assays were already available and 
in routine clinical use at the commencement of this thesis (Heim et al. 2003; 
Auburn et al. 2011).  All NPAs were initially tested for ten viruses by the KCH 
virology department as routine clinical work. Nine RNA viruses were tested 
by real time reverse transcriptase PCR (rt RT-PCR) in three multiplexes with 
a monoplex RNA internal control (IC) as described by Auburn et al (2011).  
The multiplexes tested were: 
 
Multiplex 1: Influenza A and B and human metapneumovirus 
Multiplex 2: Parainfluenza virus types 1, 2 and 3 
Multiplex 3: RSV A, RSV B and rhinovirus 
Monoplex:  RNA internal control 
 
The primers were all used at five pmoles and the probes at one pmole.  The 
samples were tested using a Rotor-Gene 6000 real-time thermal cycler 
(QIAGEN, Crawley, UK) and the following conditions: 
1. Hold at 50oC for 30 minutes (reverse transcription) 
2. Hold at 95oC for 15 minutes (TaqMan polymerase activation and 
reverse transcriptase inactivation) 
3. 50 cycles of: 
a. Step 1- 95oC hold for 30 secs (denaturation) 
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b. Step 2- 57oC hold for 30 secs, acquiring to cycle A (FAM, 
IRD700, HEX, ROX) (annealing and extension) 
 
Adenovirus (DNA virus) was tested by real-time PCR (rt-PCR) in monoplex 
along with a DNA IC.  The adenovirus primers were used at ten pmoles and 
the probe at two pmoles.  The DNA IC primers were used at five pmoles and 
the probe at one pmole.  The samples were tested using a Rotor-Gene 6000 
real-time thermal cycler (QIAGEN, Crawley, UK) and the following conditions: 
1. Hold at 95oC for 15 minutes 
2. 45 cycles of: 
a. Step 1- 95oC hold for 15 secs 
b. Step 2- 57oC hold for 20 secs, acquiring to cycle A (Cy5, ROX) 
c. Step 3- 65oC hold for 20 secs 
 
Each reaction included the IC, allowing monitoring of each sample for 
potential inhibition. This prevented the reporting of false negative results, 
since in a true negative the internal control will amplify, whereas if the internal 
control fails to amplify, this would potentially indicate inhibitory compounds in 
the sample, also preventing the amplification of the nucleic acid from any 
potential pathogen in the sample. 
 
2.7.2.2 Development of a new multiplex real-time PCR assay 
 
A new multiplex rt-PCR assay was developed to identify the DNA virus 
human bocavirus (HBOV), the two RNA viruses enterovirus (EV) and 
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parechovirus (PEV), and a bacteriophage MS2 RNA IC.  The primers and 
probes (Metabion, Martinsried, Germany) used in the assays were previously 
published and are shown in Table 2.3.   
 
The primers and probes were initially tested in monoplex to ensure they 
identified the target sequence and the product size was confirmed by post 
PCR agarose gel electrophoresis (Figure 2.17). 
 
Figure 2.17: Agarose gel plate demonstrating detection of a PEV DNA 
product 
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Table 2.3: Sequences of the primers and probes used for the new multiplex real-time (reverse transcriptase) PCR 
assay 
 
Virus Primer/Probe Sequences and labels Reference 
HBOV 
(NP1) 
Forward primer 5’-AGA GGC TCG GGC TCA TAT CA-3’ (Lu et al. 2006) 
Reverse primer 5’-CAC TTG GTC TGA GGT CTT CGA A-3’ (Lu et al. 2006) 
TaqMan Probe HEX-AGG AAC ACC CAA TCA RCC ACC TAT CGT CT-
BHQ3 
(Lu et al. 2006) 
EV Forward primer 5’-CAT GGT GYG AAG AGT CTA TTG AGC TA-3’ (Brittain-Long et al. 2008) 
Reverse primer 5’-GGA CAC CCA AAG TAG TCG GTT C-3’ (Brittain-Long et al. 2008) 
TaqMan Probe FAM-CGG CCC CTG AAT GCG GCT AAT C-BHQ1 (Brittain-Long et al. 2008) 
PEV Forward primer 5’-GTA ACA SWW GCC TCT GGG SCC AAA AG-3’ (Nix et al. 2008) 
Reverse primer 5’-GGC CCC WGR TCA GAT CCA YAG T-3’ (Nix et al. 2008) 
TaqMan Probe IRD700-CCT RYG GGT ACC TYC WGG GCA TCC TTC-
BHQ3 
(Nix et al. 2008) 
MS2 IC Forward primer 5’-TGG CAC TAC CCC TCT CCG TAT TCA CG-3’ (Rolfe et al. 2007) 
Reverse primer 5’-GTA CGG GCG ACC CCA CGA TGA C-3’ (Rolfe et al. 2007) 
TaqMan Probe ROX-CAC ATC GAT AGA TCA AGG TGC CTA CAA GC-
BHQ2 
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The sequences for the primers and probes for HBOV were obtained from the 
study by Lu et al (2006).  That study (Lu et al. 2006) developed two real-time 
PCR assays targeting two HBOV genes; NP1 and NS1.  Prior to deciding 
which assay to use in the multiplex we tested 23 known positive HBOV 
samples from the virology laboratory at the Royal Infirmary Hospital in 
Edinburgh (RIE) and compared the cycle threshold (Ct) values from the two 
assays.  Those results were then compared with the Ct results from RIE’s 
different assay that targeted the NS1 gene.  The results of these 
comparisons are shown in Table 2.4. 
 
Table 2.4: Comparison of the Ct values of the assays for HBOV 
 (Lu et al. 2006) RIE 
Sample 
Number 
NP1 NS1 NS1 
1 35.09 34.70 38.57 
2 34.81 32.84 36.27 
3 28.08 37.29 39.87 
4 30.93 30.23 34.15 
5 39.17 36.60 42.71 
6 33.90 31.78 36.66 
7 26.72 24.93 28.50 
8 31.50 29.56 32.74 
9 19.55 18.44 21.04 
10 33.13 32.11 35.63 
11 38.19 Not detected 42.33 
12 36.21 37.46 39.52 
13 38.61 36.77 38.96 
14 27.80 27.72 28.05 
15 35.12 33.31 35.95 
16 38.65 34.92 42.78 
17 38.53 35.27 41.60 
18 37.76 34.59 37.30 
19 36.10 43.21 38.98 
20 36.40 36.89 41.90 
21 38.50 Not detected 41.58 
22 36.23 Not detected 38.84 
23 36.43 34.06 39.10 
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As the assay targeting the NP1 gene identified every sample and had Ct 
values that were lower for every sample than the Edinburgh assay we 
decided to use the NP1 assay in the multiplex (Table 2.3).  The primers and 
probes for HBOV (NP1), EV, PEV, and MS2 were combined into a multiplex 
which was demonstrated to detect all four targets without any inhibition. 
 
2.7.2.3 PCR protocol and methodology 
 
For HBOV, EV, and PEV the primers were all used at five pmoles and the 
probes at three pmoles.  For the MS2 bacteriophage the primers and probe 
were all used at two pmoles.  Real-time PCR was performed using QIAGEN 
Quantitech Multiplex RT-PCR kits (QIAGEN, Crawley, UK).  The multiplex 
reaction mix consisted of 4 L of detection mix (1 L [5 pmoles of each 
primer and 3 pmoles of each probe] of each of the HBOV, EV, and PEV 
monoplex detection mixes, and 1 L [2 pmoles of each primer and probe] of 
the MS2 bacteriophage monoplex detection mix), 12.5 L of RT-PCR 
reaction mix, 0.5 L of QIAGEN RT enzyme, 1 L of MS2 bacteriophage 
RNA and 7 L of purified nucleic acid template, giving a total reaction volume 
of 25 L. 
 
The samples were tested using a Rotor-Gene 6000 real-time thermal cycler 
(QIAGEN, Crawley, UK) and the following conditions: 
1. Hold at 50oC for 30 minutes (reverse transcription) 
2. Hold at 95oC for 15 minutes (TaqMan polymerase activation and 
reverse transcriptase inactivation) 
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3. 50 cycles of: 
a. Step 1- 95oC hold for 15 secs (denaturation) 
b. Step 2- 60oC hold for 45 secs, acquiring to cycle A (FAM, 
IRD700, HEX, ROX) (annealing and extension) 
 
All the negative controls (RNA free water) tested negative after rt-PCR 
suggesting no cross contamination between the samples.  All positive 
samples (Figure 2.18) were re-tested to confirm the initial result and all were 
still positive on repeat testing.  None of the samples demonstrated any 
inhibition. 
 
Figure 2.18: Example of the output from the Rotor-Gene 6000 for 60 
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2.8 Genetic analysis 
 
Blood or buccal swabs were obtained from infants prior to neonatal 
discharge.  Either one mL of blood was collected into an EDTA tube and 
stored at -20oC until testing, or three buccal swabs (Heinz-Herenz, Hamburg, 
Germany) were obtained at least 30 minutes after feeding by firmly scraping 
the inside of each cheek and between the gums and lips.  The swabs were 
placed in a sterile polypropylene tube (Greiner Bio-One GmBH, Gloucs, UK) 
and stored at -20oC.  The samples were then sent on dry ice to the National 
Institute for Public Health and the Environment (RIVM) in Bilthoven, The 
Netherlands for testing. 
 
2.8.1 DNA extraction 
 
DNA was isolated from blood samples or buccal swabs. Genomic DNA was 
extracted from blood by digestion with proteinase K, followed by salting out 
with potassium acetate and chloroform/isoamyl alcohol extraction. DNA from 
the buccal swabs was extracted using the QIAcube instrument and the 
QIAamp DNA Blood Mini Kit (QIAGEN, Venlo, The Netherlands).  Nine 
hundred microlitres of sample gave 120 L of purified DNA.  The DNA 
concentration was determined using a nanodrop spectrophotometer (Thermo 
Fisher Scientific, Wilmington, USA).  DNA samples were then diluted with TE 
Buffer (10 mM Tris, 1 mM EDTA) to give a final concentration of 20 ng/L 
(range 10-25 ng/L).  The purified DNA was stored at -20oC until analysed. 
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2.8.2 Single nucleotide polymorphism analysis 
 
2.8.2.1 Single nucleotide polymorphisms to be analysed 
 
Eleven single nucleotide polymorphisms (SNPs) were chosen to be tested.  
This number was chosen to ensure sufficient statistical power and to reduce 
the probability of false positive associations due multiple statistical testing.  
The SNPs were chosen as they had previously been associated with severe 
RSV infection, with RSV in premature babies or with prematurity and BPD 
(Table 2.5).  The choice of SNPs to analyse was purposefully delayed until 
near the end of the study in order to be able to test for any new SNPs that 
may be found to be relevant to RSV infection during the course of the study. 
                                                                                                                                                                   
 129 
 
Table 2.5: SNPs tested and the associated gene and process 
SNP Gene Process Association Reference 
rs2787094 A disintegrin and 
metalloprotease 33 
(ADAM33) 
Airway remodelling RSV hospitalisation in 
premature infants and 
preschool lung function and 
wheeze 
(Siezen et al. 2009; 
Simpson et al. 2005) 
rs1800872 IL10 Anti-inflammatory cytokine that 
inhibits TH1 responses and 
influences antigen presentation 
and mast cell proliferation 
(adaptive immunity) 
RSV hospitalisation, RSV 
hospitalisation requiring ICU 
and HRV hospitalisation 
(Janssen et al. 2007; 
Hoebee et al. 2004; 
Wilson et al. 2005; 
Helminen et al. 2008) 
rs2243191 IL19 Member of the IL10 cytokine 
family (adaptive immunity) 
Recurrent wheeze at one year 
of age after RSV bronchiolitis 
(Ermers et al. 2011) 
rs334353  Transforming growth 
factor- receptor-1 
(TGFR1) 
Airway remodelling and 
adaptive immunity 
RSV hospitalisation in 
premature infants 
(Siezen et al. 2009) 
rs10735810 Vitamin D receptor (VDR) Innate immunity RSV hospitalisation (Janssen et al. 2007) 
rs1060826 Nitric oxide synthase type 
2A (NOS2A) 
Innate immunity and airways 
mucosal response 
RSV hospitalisation (Janssen et al. 2007) 
rs2233409 Nuclear factor-κ-B 1A 
(NFκB1A) 
Innate immunity RSV hospitalisation in 
premature infants 
(Siezen et al. 2009) 
rs1805723 Killer cell lectin-like 
receptor subfamily G 
member 1 (KLRG1) 
Regulation of specific humoral 
and cell-mediated immunity 
Prematurity Unpublished data from 
Bont et al. 
rs2664349 Matrix metalloproteinase-
16 (MMP16) 
Alveolarisation of the lung Prematurity and BPD (Hadchouel et al. 2008) 
rs2664352 MMP16 Alveolarisation of the lung Prematurity and BPD (Hadchouel et al. 2008) 
rs1124 Pulmonary surfactant 
protein C (SFTPC) 
Stabilisation of the phospholipid 
film 
Prematurity and RDS (Lahti et al. 2004) 
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2.8.2.2 SNP analysis methodology 
 
Extracted DNA samples were diluted with TE Buffer to 7 ng/µL and sent to 
KBioscience (Herts, UK) for genotyping with the KASPar technology  to test 
nine SNPs (ADAM33 rs2787094, IL10 rs1800872, IL19 rs2243191, KLRG1 
rs1805723, MMP16 rs2664349, MMP16 rs2664352, NFκB1A rs2233409, 
SFTPC rs1124, and TGFR1 rs334353).  The sequences of DNA containing 
the SNPs are shown in Table 2.6.  Two other SNPs (VDR rs10735810 and 
NOS2A rs1060826) were tested at the RIVM using the primers and probes 
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Table 2.6: DNA sequences for the nine SNPs analysed by KBioscience 
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Table 2.7: Primers, probes and assay number used to test for the VDR and NOS2A SNPs 
 
SNP Assay number Primers Probes 
VDR rs10735810 N/A Forward 5’-GGG TCA GGC AGG GAA GTG-3’ 
Reverse 5’-TGG CCT GCT TGC TGT TCT T-3’ 
VIC-ATTGCCTCCATCCCTGT 
FAM-TGCCTCCGTCCCTGT 
NOS2A rs1060826 C_9458082_10 N/A N/A 
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Real-time PCR was performed using TaqMan Genotyping Master Mix 
(Applied Biosystems, Carlsbad, USA).  The reaction mix consisted of 2.5 
L of TaqMan genotyping master mix, 0.25 L of TaqMan primers and 
probes (giving a final concentration of 0.9 M for each primer and 0.2 M 
for each probe), 1.25 L of nuclease-free water, and 1 L of sample DNA 
(at a concentration of 20 ng/L), giving a total reaction volume of 5 L. 
 
The samples were tested using the ABI 7500 Fast Real-Time PCR 
System (Applied Biosystems, Carlsbad, USA) and the following 
conditions: 
1. Hold at 95oC for 10 minutes 
2. 40 cycles of: 
a. Step 1- 95oC hold for 15 secs 
b. Step 2- 60oC hold for 60 secs, acquiring channels VIC, FAM 
and ROX 
The genotypes were determined by reading the fluorescent signal of FAM 
and VIC from the end-products.  Figures 2.19 and 2.20 show the scatter 
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Figure 2.19: Scatter plot of fluorescence signal after rt-PCR for the 
SNP TGFR1 rs334353 (from KBioscience) 
The three genotypes are visible as three distinct clusters. In the left lower 
corner all negative controls are visible. 
 
Figure 2.20: Scatter plot of fluorescence signal after rt-PCR for the 
SNP VDR rs10735810 (from RIVM) 
The three genotypes can be seen as separate clusters with the negative 
controls in the left lower corner. 
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2.9 Statistical analysis 
 
Continuous data were tested for normality using the Shapiro-Wilk test.   
Normally distributed data were assessed for statistical significance using 
the one way ANOVA test and non-normally distributed data using the 
Kruskal-Wallis test.  Multiple comparisons were performed using the one 
way ANOVA test with a post hoc Bonferroni test or the Kruskal-Wallis test 
with a post hoc Dunn’s or ANOVA test.  Categorical data were analysed 
using either the Chi squared test or Fisher’s exact test as appropriate. 
Statistical analysis was performed using IBM SPSS Statistics (version 19, 
New York, USA). 
 
Cost of care data were summarised using means, rather than medians to 
preserve the total sum of costs (Thompson & Barber 2000) and 
regression models were fitted using generalised linear models (Barber & 
Thompson 2004) using Stata (version 11.1, Texas, USA).  
 
2.9.1 Sample size calculation 
 
In a previous study (Broughton et al. 2007), 59 parents of 126 infants 
(46%) who had been recruited into a follow up study (Broughton et al. 
2005) consented for their infants to have lung function studies at one year 
of age.  The planned sample size for an overarching study investigating 
respiratory morbidity following respiratory virus LRTIs was 160 infants, as 
that would likely yield at least 72 infants whose parents would consent for 
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them to have lung function assessment at one year.  In the previous 
study (Broughton et al. 2007), there was a difference at one year, 
between infants who had had or had not had a RSV LRTI equivalent to 
one standard deviation in the airway resistance results.   In that study 
(Broughton et al. 2007), a greater proportion of parents whose infants 
who had a RSV LRTI compared to those who had not, consented for their 
infant to have lung function studies. Assuming a ratio of 2:1, with 72 
infants recruited, it would be possible to detect a difference equivalent to 
0.7 standard deviations in the airway resistance results with 80% power 
and at the 5% significance level, that is, a smaller difference than that 
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Chapter 3: Genetic predisposition of 
RSV infection related respiratory 


























Respiratory syncytial virus (RSV) infects almost all children by two years 
of age. Studies have demonstrated that some infants born at term may be 
genetically predisposed to developing severe RSV lower respiratory tract 
infections (LRTIs), that is they were hospitalised with the RSV LRTI (Hull 
et al. 2000; Hoebee et al. 2003; Hoebee et al. 2004; Janssen et al. 2007; 
Mailaparambil et al. 2008). Only one study (Siezen et al. 2009) has 
investigated prematurely born infants; two single nucleotide 
polymorphisms (SNPs) in IFN and ADAM33 were found to be associated 
with an increased risk of developing severe RSV infection (Siezen et al. 
2009).  The aim of this study was to determine if prematurely born infants 
may have a genetic predisposition to symptomatic RSV LRTIs regardless 
of whether the infants were hospitalised with the LRTI.  
 
Prematurely born infants may be predisposed to symptomatic RSV LRTIs 
by abnormal premorbid lung function (Broughton et al. 2006). Amongst 
infants born prior to 32 weeks of gestational age, those who subsequently 
developed a RSV LRTI compared to controls had a higher resistance of 
the respiratory system (Rrs) at 36 weeks post menstrual age (PMA) 
(Broughton et al. 2006). A further aim, therefore, was to determine if any 
possible genetic predisposition to symptomatic RSV LRTIs was 
associated with reduced premorbid lung function in prematurely born 
infants.   
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RSV LRTIs in prematurely born infants are associated with chronic 
respiratory morbidity and lung function abnormalities at follow up 
(Broughton et al. 2005; Broughton et al. 2007; Greenough et al. 2009).  
An additional aim, therefore, was to determine if some prematurely born 




A prospective cohort study was undertaken in which infants born less 
than or equal to 36 weeks of gestational age were eligible for entry if they 
were born prior to the onset of the RSV season in 2008 or 2009. 
Consecutive infants, whose parents gave informed written consent, were 
recruited.  Blood or buccal swabs were obtained from the infants prior to 
maternity unit discharge.  Following discharge from the neonatal or 
maternity unit, infants were followed prospectively until one year 
corrected age.  The parents were asked to contact the research team 
when their infant was symptomatic with signs consistent with a LRTI; that 
is cough, wheeze, and/or shortness of breath.  In addition, parents were 
telephoned every two weeks by researchers to ascertain whether their 
infant had been or was symptomatic. A researcher visited the home on 
each occasion that an infant had a LRTI and a nasopharyngeal aspirate 
(NPA) was obtained if the LRTI was confirmed. NPAs were also obtained 
from all infants hospitalised with an LRTI. Real time reverse transcriptase 
polymerase chain reaction (PCR) was performed on the NPAs for 11 
virus types (influenza A and B, RSV A and B, human metapneumovirus, 
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rhinoviruses, parainfluenza viruses 1–3, enteroviruses and parechovirus) 
and real-time PCR was performed for human bocavirus and adenovirus 
as described in section 2.7. 
 
The infants underwent lung function measurements at 36 weeks PMA 
whilst still inpatients on the neonatal or maternity unit.  Functional residual 
capacity by helium gas dilution (FRCHe) and compliance (Crs) and 
resistance (Rrs) of the respiratory system were measured as described in 
section 2.3. The infants also underwent lung function measurements at 
one year corrected age. FRCHe, Crs, Rrs, FRC by the multiple breath 
wash-in/out technique (FRCMBW) and lung clearance index (LCI) were 
assessed as described in section 2.3. FRC (FRCpleth) and airway 
resistance (Raw) by plethysmography were also assessed as described in 
section 2.4.  Infants were assessed if they had not been symptomatic with 
a respiratory tract infection during the previous three weeks.  
 
Parents completed a respiratory diary for one month when their infant 
was 11 months corrected age and filled in a respiratory health related 
questionnaire about their infant when the infant was one year of corrected 
age as described in section 2.6.  In addition, the infants’ hospital notes 
were reviewed and all hospitalisations in the first year after birth 
documented as described in section 2.5.  
 
As part of the cohort study, blood or buccal swabs were obtained from the 
infants prior to maternity unit discharge. Either one mL of blood was 
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collected into an EDTA tube or three buccal swabs were obtained and 
stored at -20oC until testing.  The samples were then sent on dry ice to 
the National Institute for Public Health and the Environment (RIVM) in 
Bilthoven, the Netherlands for testing.  DNA was isolated from the blood 
samples or buccal swabs as described in section 2.8.  Extracted DNA 
samples were diluted with TE Buffer to 7 ng/µL and sent to KBioscience 
(Herts, UK) for genotyping to test nine SNPs (ADAM33 rs2787094, IL10 
rs1800872, IL19 rs2243191, KLRG1 rs1805723, MMP16 rs2664349, 
MMP16 rs2664352, NFκB1A rs2233409, SFTPC rs1124 and TGFR1 
rs334353) and two other SNPs (VDR rs10735810 and NOS2A 
rs1060826) were tested in the Netherlands as described in section 2.8.   
The SNPs were chosen as they had previously been associated with an 
increased risk of severe RSV infection in infants born at term (Hoebee et 
al. 2004; Wilson et al. 2005; Janssen et al. 2007; Helminen et al. 2008) or 
born prematurely (Siezen et al. 2009), an increased risk of developing 
RDS (Lahti et al. 2002), a decreased risk of developing BPD (Hadchouel 
et al. 2008), an increased risk of recurrent wheeze at one year of age 
after RSV LRTI (Ermers et al. 2011) or reduced preschool lung function 
(Simpson et al. 2005).  The genotype distributions of all polymorphisms 




A sample size of 160 for the whole prospective cohort study was planned 
to give 90% power at the 5% level to detect a difference between groups 
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in the 36 week PMA lung function results equivalent to at least one 
standard deviation.   
 
The infants were divided into two groups:  
(i) Infants who had at least one symptomatic LRTI from which 
RSV was detected from the NPA (RSV LRTI group) 
(ii) Infants who did not have RSV detected from an NPA (control 
group) 
  
Data were tested for normality using the Shapiro-Wilk test.   Birth weight 
was normally distributed and differences were assessed for statistical 
significance using the independent student’s t-test.  All other variables 
were non-normally distributed and differences were assessed for 
statistical significance using either the Mann-Whitney U test, the Kruskal-
wallis test, the Chi squared or Fisher’s exact test.  Post hoc analysis was 
performed on the genotype data using ANOVA if the initial analysis 
demonstrated a significant difference in the results. Statistical analysis 




Two hundred and fifty one infants were eligible for inclusion into the over 
arching study (Figure 3.1, Appendix 5).  One hundred and forty eight 
infants completed this part of the study; they had a median gestational 
age of 34 (range 23-35) weeks and birth weight of 1885 (range 534-3610) 
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g.  Forty infants (27%) were of Caucasian origin, 37 (25%) black 
Caribbean, 31 (21%) black African, seven (5%) Asian, three (2%) 
Hispanic and 30 (20%) mixed ethnicity.  Fifteen (10%) infants developed 
BPD; that is they were oxygen dependent beyond 28 days of life.  Six 
infants received palivizumab, one of whom was subsequently hospitalized 
with an RSV LRTI, but did not have lung function assessment at one 
year. 
 
Twenty nine infants developed a RSV LRTI, ten required hospitalization. 
Compared to infants who did not develop a RSV LRTI, those that did 
were born at a lower gestational age (p=0.024), had a lower birth weight 
(p=0.038) and a smaller proportion were breastfed (p=0.042) (Table 3.1).   
 
There was an increased risk of developing a RSV LRTI associated with 
the C allele of the ADAM33 gene (p=0.04), but not with any other SNPs 
(Table 3.2).  Differences in the ADAM33 gene at the allele level between 
the infants admitted and not admitted to hospital for RSV LRTI and 
controls did not reach statistical significance (p=0.07) (Table 3.3).  To 
determine whether the increased risk of RSV LRTI associated with the 
ADAM33 gene was associated with premorbid lung function, the lung 
function results at 36 weeks PMA were related to the ADAM33 genotype 
and allele distributions in all infants regardless of whether they had 
developed RSV LRTIs.  No significant differences were found in any of 
the lung function results at 36 weeks PMA between the ADAM33 
genotypes (Table 3.4) or allele distributions (data not shown). 




There was a significant difference at the genotype level in the IL10 SNP 
(p=0.045) with regard to parental reported wheeze. Post hoc analysis 
demonstrated that significantly fewer infants with the AA genotype had 
parental reported wheezing than the AC genotype (p=0.045).  There was 
a significant difference at the allele level in the IL10 SNP (AA versus AC 
and CC) in the proportion of infants with parental reported wheeze (17% 
versus 73%, p=0.022). There were significant differences at the genotype 
level in the ADAM33 SNP (CC versus CG versus GG) with regard to the 
number of acute visits to hospital and/or GP (median [range]: 0 [0] versus 
1 [0-5] versus 0 [0], p=0.038), but there were no post hoc significant 
differences between genotypes.  There were significant differences at the 
genotype level in the NOS2A SNP (CC versus CT versus TT) with regard 
to the number of days of cough (median [range]: 0 [0-13] versus 12.5 [0-
30] versus 7 [0-14], p=0.028), with post hoc analysis demonstrating that 
the CT genotype was associated with significantly more days of cough 
than the CC genotype (p=0.023).  There were significant differences at 
the allele level in the ADAM33 SNP (CC and CG versus GG), with regard 
to the number of parental reported acute visits to hospital and/or GP 
(median [range]: 0 [0] versus 0.5 [0-5], p=0.040).  There were significant 
differences in the SFTPC SNP (AA and AG versus GG), with regard to 
the number of parental reported acute visits to hospital and/or GP 
(median [range]: 1 [0-5] versus 0 [0-1], p=0.031) and in the NOS2A SNP 
(CC versus CT and TT) with regard to the number of days of cough 
(median [range]: 0 [0-13] versus 12.5 [0-30], p=0.011). 




Seventy infants had lung function measurements at one year of corrected 
age.  There were significant differences in the lung function results at one 
year corrected age with regard to the MMP16 (rs2664349), MMP16 
(rs2664352), NOS2A and SFTPC genes and differences with regard to 
the VDR gene were at borderline significance (Table 3.5). 
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251 Eligible infants 
74 Parents refused consent 
177 Infants recruited 
15 Infants lost to follow up 
168 Infants prospectively 
followed from discharge 
6 Infants unsatisfactory lung 
function measurements at 36 
weeks PMA 
3 Infants died 
5 Infants inadequate 
DNA samples 
148 Infants completed the study 
153 Infants followed to one 
year corrected age 
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Table 3.1: Demographic data according to RSV LRTI status 
Data are presented as median (range) or n (%). 
 RSV LRTI Controls p 
n 29 119  
Gestational age (weeks) 33 (23-36) 34 (24-36) 0.024 
Birth weight (g) 1756 (610-2650) 1950 (534-3610) 0.038 
Males 14 (48%) 67 (56%) 0.53 
Antenatal smoking 4 (14%) 20 (17%) >0.99 
Antenatal steroids 24 (83%) 78 (66%) 0.078 
Surfactant 7 (24%) 24 (20%) 0.62 
Duration of ventilation (days) 1 (0-81) 1 (0-113) 0.34 
Bronchopulmonary dysplasia 3 (10%) 12 (10%) >0.99 
Family history of atopy 15 (52%) 81 (68%) 0.13 
Breastfed 19 (66%) 99 (83%) 0.042 
Number of siblings 1 (0-4) 1 (0-5) 0.34 
Palivizumab 1 (3%) 5 (4%) >0.99 
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Table 3.2: Associations at the genotype and allele levels according to RSV status 
Data are presented as n (%) or median (range) 
  Association at the genotype level Association at the allele level 
Gene rs number Genotype RSV Control p Allele RSV Control p OR 


















0.04 1.89 (1.01-3.56) 
0.53 (0.28-0.99) 
Pulmonary surfactant 














54 (23 %) 
184 (67%) 
0.10 0.47 (0.18-1.15) 
2.14 (0.87-5.49) 



































0.19 0.67 (0.36-1.25) 
1.26 (0.64-2.50) 















0.29 1.38 (0.74-2.57) 
0.73 (0.39-1.35) 

















0.53 0.80 (0.40-1.57) 
1.26 (0.64-2.50) 
Nitric oxide synthase 


















0.63 1.20 (0.61-2.33) 
0.84 (0.43-1.64) 

















0.85 0.87 (0.38-1.96) 
1.14 (0.51-2.62) 
Killer cell lectin-like 
receptor subfamily G 




































0.87 1.07 (0.53-2.16) 
0.93 (0.46-1.90) 
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Table 3.3: ADAM33 genotype and allele associations by RSV hospitalisation status 
Data are presented as n (%). 
 
  Association at the genotype level Association at the allele level 
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Table 3.4: Lung function results at 36 weeks PMA by ADAM33 
genotype 
Data presented as median (range). 
 
Lung function test Genotype Lung function results p value 
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Table 3.5: Statistically significant genotype distributions in infants with RSV LRTI related to lung function results 
at one year corrected age 
Data presented as median (range)  
Gene Genotype* Lung function test Lung function results p 
MMP16 (rs2664349) GG (n=3) 
AG (n=6) 
AA (n=4) 




MMP16 (rs2664349) A (n=4) 
G (n=9) 
LCI 7.0 (6.7-7.1) 
7.3 (6.5-8.2) 
0.031 
MMP16 (rs2664349) A (n=4) 
G (n=9) 
FRCMBW (ml/kg) 27 (20-31) 
19 (13-26) 
0.045 
NOS2A C (n=14) 
T (n=2) 
Crs (ml/cmH2O/kg) 1.6 (1.2-2.5) 
1.2 (1.2-1.2) 
0.039 
NOS2A C (n=14) 
T (n=2) 
FRCMBW (ml/kg) 21 (16-31) 
14 (12-14) 
0.03 
NOS2A C (n=14) 
T (n=2) 
LCI 7.1 (6.5-7.6) 
8.0 (7.7-8.2) 
0.03 
MMP16 (rs2664352) C (n=9) 
G (n=5) 
FRCHe:pleth 0.82 (0.68-0.97) 
0.97 (0.84-0.99) 
0.027 
SFTPC A (n=4) 
G (n=12) 
Crs (ml/cmH2O/kg) 1.2 (1.2-1.5) 
1.6 (1.2-2.5) 
0.025 
VDR A (n=9) 
G (n=7) 
Crs (ml/cmH2O/kg) 1.6 (1.2-2.5) 
1.3 (1.2-1.9) 
0.050 
*The number of infants with lung function results with a particular genotype, some infants did not complete all tests




This study has demonstrated a polymorphism in the ADAM33 gene was 
associated with an increased risk of developing RSV LRTIs in prematurely 
born infants, regardless of whether hospital admission was required. 
Previously, it has been demonstrated that the ADAM33 gene C allele was 
associated with an increased risk of severe symptomatic RSV infection 
(Siezen et al. 2009).   This study, however, did not find any significant 
association with premorbid lung function and the ADAM33 SNP, suggesting 
genetic predisposition may act via a mechanism other than abnormal 
premorbid lung function. The ADAM33 SNP in a population based birth 
cohort study of children born at term was reported to be associated with 
reduced specific airways resistance at five, but not three years of age 
(Simpson et al. 2005), although no increased risk of wheezing or a doctor 
diagnosis of asthma at either time point was demonstrated (Simpson et al. 
2005).  In this study of prematurely born infants there were significant 
differences at the allele level in the ADAM 33 SNP with regard to the number 
of acute visits to the hospital and/or GP, although not in lung function results 
at one year.   
 
Despite studying a relatively small number of patients, this study 
demonstrated that SNPs in several genes were associated with chronic 
respiratory morbidity and lung function abnormalities at follow up in infants 
who had RSV LRTIs.  The C allele in the IL10 SNP was associated with an 
increased risk of parental reported wheeze at one year corrected age.   Two 
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studies of previously healthy, term born infants hospitalised for RSV infection 
found no association between that IL10 SNP and post-bronchiolitic wheeze 
at follow up at one (Schuurhof et al. 2011) and six (Ermers et al. 2007) years 
of age. Another study (Nuolivirta et al. 2009) investigating a different IL10 
SNP also failed to find any association with post-bronchiolitic wheeze at 15 
months follow up.  The discrepancies with those results (Ermers et al. 2007; 
Nuolivirtai et al. 2009; Schuurhof et al. 2011) and the current study suggest 
that post-bronchiolitic wheeze may have a different genetic aetiology in 
infants born at term compared to those born prematurely.  This study also 
found an increased risk of cough at one year corrected age in infants with the 
CC and CT genotypes of the NOS2A SNP.  In addition, the NOS2A T allele 
was associated with significantly more days of cough and the TT genotype 
was associated with reduced lung function at follow up (significantly lower 
Crs, higher LCI and lower FRCMBW).  SNPs in the NOS2A gene have been 
associated with an increased risk of developing severe RSV infection 
(Janssen et al. 2007), but also with reduced lung function and an increased 
risk of asthma in adolescent children born at term (Islam et al. 2010).  
 
The surfactant protein C (SFTPC) SNP has been associated with an 
increased predisposition to RDS in prematurely born infants (Lahti et al. 
2002).  The A allele in the SFTPC SNP in this study was associated with 
reduced  lung function at follow up and an increased number of acute visits to 
hospital or the GP amongst the infants who had RSV LRTIs, but not the 
development of symptomatic RSV LRTIs.  SNPs in MMP16 (rs2664349 and 
rs2664352) have been previously associated with a reduced risk of 
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developing BPD in prematurely born infants (Hadchouel et al. 2008).  The 
reduced FRCMBW, increased LCI and reduced FRCHe:pleth associated with 
those two SNPs in this study are lung function abnormalities compatible with 
previous BPD.   
 
The minor T allele in the SNP (rs10735810) in the VDR gene has been 
associated with an increased risk of developing severe RSV LRTI requiring 
hospitalisation in term born, Caucasian Dutch and black South African infants 
(Janssen et al. 2007; Kresfelder et al. 2011).  In addition, amongst Canadian 
infants less than two years of age of Caucasian or Aboriginal descent, a 
different VDR polymorphism (the FokI ff genotype) was associated with an 
increased risk of developing acute LRTIs, 82% of which were RSV positive 
(Roth et al. 2008).  SNPs in the VDR gene have also been shown to result in 
an increased risk of developing asthma (Raby et al. 2004; Saadi et al. 2009) 
and reduced lung function in knock-out mice (Berndt et al. 2011).  Although, 
in this study of an ethnically diverse population of prematurely born infants 
we did not find any significant associations of SNPs in the VDR gene with the 
development of RSV LRTIs, the TT genotype of the VDR SNP was 
associated with reduced lung function following a RSV LRTI.   
 
This study has a number of strengths and some limitations.  A cohort of 
ethnically diverse, prematurely born infants documenting viral LRTIs both in 
the community and in hospital was prospectively followed.  The ethnic 
diversity of our population may have influenced our results as ethnic 
differences in genotype may increase the risk that associations occur by 
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chance. Amongst the infants with RSV LRTIs, there were no significant 
differences in ethnic origin for each of the 11 SNPs, but the numbers in each 
group were too small to result in a meaningful conclusion.  This study, as in 
others, cannot comment on non symptomatic RSV infections. Chronic 
respiratory morbidity was assessed using both respiratory health related 
questionnaires and diary cards and documented hospitalisations from the 
infants’ hospital records, as well as measuring lung function at one year 
corrected age in a subset of infants.  Lung function testing was undertaken at 
36 weeks PMA, hence assessing infants before they were exposed to RSV 
infection.  The majority of the population were born moderately prematurely, 
but it has been well documented that moderately prematurely born infants 
can suffer severe RSV infections and adverse consequences (Sampalis 
2003; Palmer et al. 2010; Shefali-Patel et al. 2012), hence the results are 
likely to be generalisable to all prematurely born infants.  In the statistical 
analysis, however, there was no correction for multiple testing so it is 
possible certain of the results could be due to chance and hence, the results 
should be considered as hypothesis generating.   
 
In conclusion, despite a relatively small study population, the results of this 
study suggest prematurely born infants may have a genetic predisposition to 
developing symptomatic RSV LRTIs which does not appear to be influenced 
by premorbid reduced lung function.  In addition, the results suggest that in 
prematurely born infants those genetic mechanisms appear distinct from the 
genetic mechanisms underlying chronic respiratory morbidity and reduced 
lung function at follow up following RSV LRTIs.  Further work is necessary to 
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determine whether certain polymorphisms could be used to inform targeted 
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Chapter 4: Lung function prior to viral 
lower respiratory tract infections in 
























Respiratory syncytial virus (RSV) infection in previously healthy infants 
(Stokes et al. 1981; Hall et al. 1984; Noble et al. 1997; Korppi et al. 2004) 
and those born prematurely (Broughton et al. 2007) is associated with lung 
function abnormalities at follow up.  The abnormalities include elevated 
thoracic gas volume and airway resistance at one year of age (Stokes et al. 
1981; Broughton et al. 2007), airways obstruction in children (Hall et al. 1984; 
Noble et al. 1997) and lower forced expiratory volume over one second and 
maximal expiratory flow at 25% of forced vital capacity in young adults 
(Korppi et al. 2004).  It is possible, however, that those lung function 
abnormalities at follow up may reflect that infants who develop symptomatic 
LRTIs have diminished premorbid lung function. In one study (Young et al. 
1995), term born infants who developed bronchiolitis in the first year after 
birth compared to those who did not, had a non-significant trend to a lower 
maximal flow at functional residual capacity (VmaxFRC) at five weeks of age, 
that is, before they developed bronchiolitis.  In addition, in the Tucson 
Children’s Respiratory Study, compared with controls, infants who had 
wheezing LRTIs in their first year had lower respiratory conductances prior to 
the LRTI (Martinez et al. 1988) and infants who had wheezy LRTIs in the first 
three years had lower premorbid Vmax FRCs prior to the LRTI (Martinez et al. 
1991).  Among infants born before 32 weeks of gestation, those who 
developed a RSV LRTI had a significantly higher resistance of the respiratory 
system at 36 weeks postmenstrual age (PMA) compared to those who did 
not (Broughton et al. 2006).  The symptomatic “RSV LRTI” group, however, 
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had similar resistance results to the “RSV negative LRTI” group (Broughton 
et al. 2006), perhaps suggesting that diminished lung function in prematurely 
born infants might predispose to other viral LRTIs, as well as RSV LRTI, but 
the numbers of infants included in the study was small (n=39) (Broughton et 
al. 2006).  The aim of this study, therefore, was to test in a larger cohort, the 
hypothesis that diminished premorbid lung function would predispose 
prematurely born infants not only to symptomatic RSV LRTIs, but also other 
viral LRTIs.  In addition, the study aimed to determine whether infants who 
developed severe LRTIs, that is, they required hospitalisation, had poorer 
lung function than those who did not require hospitalisation for the LRTI.  The 
results of such a study would be important to determine whether assessment 
of lung function might be useful to identify a high risk group who could be 
targeted for prophylaxis against viral infections.  As a consequence, this 
study related premorbid lung function in prematurely born infants to the 
occurrence of LRTIs.  Infants with a wide range of gestational ages have 
been studied, so additionally it was possible to determine whether maturity at 




Infants born at less than 36 weeks of gestational age were eligible for entry 
into the study if they were born prior to the onset of the RSV season in 2008 
or 2009.  The RSV season was defined as 1 October to 31 March, consistent 
with the UK experience (Clark 2000).  Consecutive infants, whose parents 
gave informed written consent, were recruited.  Lung function (FRCHe, 
                                                                                                                                                                   
 161 
FRCMBW, LCI, Crs and Rrs) was performed at 36 weeks PMA as described in 
section 2.3.  The mean intrasubject coefficient of variation for FRCHe was 5%, 
Crs 12%, Rrs 11%, FRCMBW 16% and LCI 13%.  Following neonatal unit 
discharge, infants were followed prospectively as described in section 2.1, 
during their first RSV season.  For this study, real time reverse transcriptase 
polymerase chain reaction (PCR) was performed on the NPAs for nine 
viruses (RSV A and B, human metapneumovirus, rhinovirus, influenza A and 
B, parainfluenza 1-3) in three multiplexes with a monoplex varicella zoster 
virus (VZV) RNA internal control as described in section 2.7.  Adenovirus was 
tested by real-time PCR in monoplex with the VZV internal control as 




The infants were divided into four groups: 
(i) Infants who never had a symptomatic LRTI - no LRTI. 
(ii) Infants who had symptomatic LRTI(s), but no viruses were 
detected from the NPA - viral negative LRTI. 
(iii) Infants who had at least one LRTI, from which RSV was detected 
from the NPA - RSV LRTI 
(iv) Infants who had symptomatic LRTI(s) with viruses other than RSV 
detected from the NPA - other viral LRTI. 
 
Data were tested for normality using the Shapiro-Wilk test.   Birth weight and 
FRC results were normally distributed and differences were assessed for 
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statistical significance using the one way analysis of variance (ANOVA), all 
the other results were not normally distributed, hence difference were 
assessed for statistical significance using the Kruskal-Wallis test.  Multiple 
comparisons were performed using a one way ANOVA with a post hoc 
Bonferroni test or the Kruskal-Wallis test with a post hoc Dunn’s test.  The 
relationship between Rrs and the occurrence of either RSV LRTI or other viral 
LRTI correcting for gestational age was assessed using analysis of 
covariance.  The threshold for significance was p<0.05.  To give an estimate 
of the value of lung function as a predictor of subsequent severe RSV LRTI 
(i.e. hospitalisation) areas under receiver operating characteristic curves 
were calculated and compared using SPSS (version 19, New York, USA) for 
those factors which differed significantly between infants with RSV LRTI who 
were and were not hospitalised. Other statistical analysis was performed 
using GraphPad Prism (version 5, La Jolla, CA, USA).  
 
4.4 Sample size 
 
In a previous study (Broughton et al. 2006) it was found there was a 
difference in the lung function results equivalent to one standard deviation 
(SD) between the groups.  The planned sample size, therefore, was 160 
infants to ensure there were at least 20 infants in each of the RSV and other 
viral LRTI groups to give 90% power at the 5% level to detect a difference in 
the lung function results equivalent to at least one standard deviation 
between each of those two groups and the no LRTI group. 
 




Two hundred and fifty one infants were eligible for inclusion into the study 
(Figure 4.1, Appendix 5).   
 















Seventy four parents did not consent to their infant taking part in the study 
and nine parents consented, but then defaulted from follow up.  One infant 
had a tracheostomy and lung function measurements were not possible and 
five infants had unsatisfactory lung function recordings. One infant died 
before discharge and two infants died shortly after discharge.  The 159 (88 
251 Eligible infants 
74 Parents refused consent 
177 Infants recruited 
9 Infants lost to follow up 
159 Infants prospectively studied 
6 Infants satisfactory lung function 
measurements not possible 
3 Infants died 
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males) infants who completed the study had a median GA of 34 (interquartile 
range [IQR] 31-35) weeks and a median birth weight of 1890 (IQR 1446-
2308) g.  The infants who completed the study were of lower GA (median GA 
34 versus 35 weeks, p=0.03) and birth weight (median birth weight 1890 
versus 2132 g, p=0.08) than those who did not take part.  No other data was 
collected from infants who were not recruited into the study.  Overall, 32 
(20%) mothers had had an antenatal infection and 110 (69%) had received 
antenatal steroids. Thirty two (20%) infants had received surfactant, 55 (35%) 
infants had had a postnatal infection and 16 (10%) developed BPD.  Seven 
infants received palivizumab (Table 4.1). One of the seven infants who 
received palivizumab was admitted to hospital and that was because of a 
RSV LRTI.   Two infants had a nosocomial infection due to rhinovirus while 
on the neonatal unit, in both cases this was after lung function testing. One of 
the infants subsequently developed a RSV LRTI and their results were 
analysed in the RSV group; the other did not subsequently have an RSV 
infection and their results were analysed in the other viral LRTI group. 
 
The only significant differences in the demographics of the four groups were 
with regard to birth weight (p=0.02) and the number of infants receiving 
surfactant (p=0.03) (Table 4.1).  Those differences were due to the other viral 
LRTI group being of lower birth weight (p<0.05) and a greater proportion of 
them having received surfactant (p<0.05) than the no LRTI group. 
  
On 138 occasions, 73 infants had a LRTI and on 94 occasions a virus was 
detected (Table 4.2).  Twenty seven infants had at least one RSV positive 
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LRTI (some also had other viral LRTIs), eleven required hospital admission 
(nine for RSV LRTI [one of those infants required intensive care] and two for 
non-respiratory causes).  The infants who were admitted compared to those 
who were not were born at an earlier GA (median, [IQR] 30 [29-33] versus 34 
[33-35] weeks, p=0.004), were of lower birth weight (1446 [1020-1815] 
versus 1852 [1515-2100] g, p=0.047), had required more days of ventilation 
on the neonatal unit (6 [1.3-220] versus 0 [0-1], p=0.011) and more days of 
supplementary oxygen on the neonatal unit (7 [1-49] versus 0 [0-1] days, 
p=0.011) and a greater proportion had had BPD (33% versus 0%, p=0.013).  
They, however, had not had more NPAs taken (p=0.22).  The age at LRTI 
presentation also did not differ significantly between those who were and 
were not admitted, the mean corrected age in both groups being 4.2 months 
(p=0.91). 
 
Thirty one infants suffered at least one other viral LRTI, but not a RSV LRTI; 
three required hospital admission (two for a LRTI and one for a non-
respiratory cause).  There were no significant differences between those who 
were and were not admitted with regard to GA at birth, birth weight, duration 
of ventilation and supplementary oxygen on the neonatal unit, BPD, number 
of NPAs taken and age at LRTI presentation. Fifteen infants had LRTIs with 
no virus identified, four required hospital admission (two for LRTI and two for 
non-respiratory causes).  Eighty six infants did not have a LRTI and four 
required hospital admission (all for non-respiratory causes).  Eleven infants 
had at least one dual infection and two had a triple infection (RSV A/human 
metapneumovirus/rhinovirus and RSV B/parainfluenza 1/adenovirus).  The 
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infant with the triple infection due to RSV A/human 
metapneumovirus/rhinovirus was the only infant who was admitted to an 
intensive care unit.   
 
The only significant differences between the lung function results of the four 
groups (Table 4.3 and Figure 4.2), even after correcting for GA, were the 
uncorrected Crs results (p=0.031), but post hoc testing demonstrated no 
significant differences between the groups.   The infants who were admitted 
to hospital with a RSV LRTI compared to those who were not had higher Rrs 
results (median 88 [IQR 76-100] cmH2O/L/sec versus median 70 [IQR 63-76] 
cmH2O/L/sec) (p=0.033) and lower median uncorrected Crs (2.4 [IQR 1.9-2.8] 
versus 3.0 [IQR 2.2-3.6] mL/cmH2O, p=0.027), but the FRC results were 
similar (p=0.13).  Calculation of the areas under the receiver operating 
characteristic curves (AUC) regarding hospitalisation for RSV LRTI revealed: 
gestational age AUC=0.829 (p=0.005), birth weight AUC=0.718 (p=0.063), 
days in oxygen AUC=0.791 (p=0.13), BPD AUC=0.650 (p=0.20), Rrs 
AUC=0.735 (p=0.045) and uncorrected Crs AUC=0.756 (p=0.029).  There 
were no significant differences between the AUCs for gestational age and Rrs 
(p=0.50) or for gestational age and uncorrected Crs (p=0.55)   The infants 
who were admitted to hospital with another viral LRTI, compared to those 
who were not, had higher Rrs results (only two infants were admitted, their Rrs 
results were 103 and 129 cmH2O/L/sec versus median 80 [IQR 66-92] 
cmH2O/L/sec [p=0.039]) and tended to have lower uncorrected compliance 
results (1.6 and 1.9) mL/cmH2O versus 2.8 [IQR 2.4-3.7] mL/cmH2O, 
p=0.052, but the FRC results were similar (p=0.67). 
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Figure 4.2: Scatter plot showing the resistance of the respiratory 
system results related to viral LRTI status 
Individual data are shown.  The horizontal lines represent the medians of 
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Table 4.1: Demographic data 







































Males 46 (56%) 9 (60%) 14 (52%) 17 (55%) 0.97 
Antenatal smoking 14 (16%) 2 (13%) 4 (15%) 7 (23%) 0.82 
Antenatal steroids 52 (60%) 11 (73%) 22 (81%) 25 (81%) 0.07 
Surfactant 12 (14%) 2 (13%) 6 (22%) 12 (39%) 0.03 
Duration of 
ventilation (days) 
0 (0-2) 1 (0-1.5) 1 (0-5) 1 (0-4.5) 0.25 
Bronchopulmonary 
dysplasia  
6 (7%) 1 (7%) 3 (11%) 6 (19%) 0.25 
Parental atopy 43 (50%) 6 (40%) 9 (33%) 12 (42%) 0.42 
Day care 2 (2%) 0 (0%) 1 (4%) 2 (6%) 0.61 
Number of siblings 1 (0-2) 2 (1-2) 1 (0-2) 1 (0-2) 0.17 
Palivizumab 1 (1%) 1 (7%) 1 (4%) 4 (13%) 0.05 
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Table 4.2: Number of viruses detected by PCR 
Data are displayed as the number of occasions a virus was detected.   
Infants may have had more than one LRTI. 
 
Viruses RSV LRTI group Other viral LRTI group 
RSV A 8 0 
RSV B 19 0 
Rhinovirus 8 21 
Adenovirus 4 8 
Human Metapneumovirus 1 5 
Influenza A 1 3 
Influenza B 1 2 
Parainfluenza 1 3 3 
Parainfluenza 2 0 1 
Parainfluenza 3 0 6 
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Table 4.3: Lung function results 
















































FRCHe (mL/kg) 26 (26-28) 25 (22-27) 24 (21-28) 24 (22-29) 0.54 




27 (23-32) 24 (22-27) 25 (21-28) 25 (21-29) 0.63 



















































Infants who developed RSV or other viral LRTIs and were subsequently 
hospitalised had significantly poorer lung function at 36 weeks PMA than 
those who developed LRTIs but were not hospitalised.  There were, however, 
no overall significant differences in the lung function results between infants 
who developed a RSV or other viral LRTI and those who had no LRTI in the 
RSV season.  Those results might appear to conflict with those in the 
literature (Martinez et al. 1988; Young et al. 1995; Broughton et al. 2006) 
(Table 4.4).  In the study by Young et al, however,  virology results were only 
available for the two infants who were admitted to hospital, both were RSV 
positive; the other 15 infants who were not admitted had a doctor diagnosis 
of bronchiolitis (Young et al. 1995).  There were no significant differences in 
the Rrs or Crs results between their groups and there was only a non-
significant trend for those who subsequently developed bronchiolitis to have 
a lower Vmax FRC than those who did not (p=0.06).  In another study of term 
born infants (Martinez et al. 1988), no virological results were reported and 
comparison was made between infants who did and did not subsequently 
develop a wheezing respiratory illness.  The risk of having a wheezing illness 
was 3.7 times higher among infants whose values for total respiratory 
conductance were in the lowest third, but this was not statistically significant 
(p=0.06) (Martinez et al. 1988).  Those results (Martinez et al. 1988) could be 
interpreted as indicating that diminished lung function predicts those who 
wheeze with a LRTI rather than those predisposed per se to a viral LRTI.  In 
a very prematurely born group, it has been demonstrated that Rrs was 
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significantly higher in those who subsequently developed a RSV LRTI 
compared to the rest of the cohort (Broughton et al. 2006).  The infants 
included in that study had worse lung function than those presently 
examined, reflecting a greater proportion had had bronchopulmonary 
dysplasia; six of the 15 infants with RSV LRTI had required hospital 
admission.  This study, which included infants with a broader range of 
gestational ages, highlights Rrs results to be significantly higher in those 
infants who were admitted to hospital with a RSV or another viral LRTI, that 
is, they were likely to have had more severe infection.  
 
Infants with RSV or other viral LRTIs who were hospitalised compared to 
those who were not had significantly worse premorbid lung function, that is 
higher Rrs results and significantly lower Crs results (not corrected for body 
weight).  In the RSV LRTI group, those who were admitted to hospital 
compared to those who were not were born at a significantly earlier 
gestational age and of lower birth weight and required significantly longer 
durations of ventilation and supplementary oxygen and a significantly greater 
proportion had developed BPD.  It is, therefore, not surprising that they had 
significantly worse lung function at 36 weeks PMA.  Comparison of the areas 
under the ROCs demonstrated no significant differences in the AUCs for 
gestational age and either Rrs or Crs i.e. they performed similarly.  This study 
thus suggests lung function testing at 36 weeks PMA may not only indicate a 
group at highest risk, but also indicates a mechanism by which prematurely 
born infants develop severe RSV LRTIs, that is, they are more likely to 
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develop a severe RSV LRTI if they have significantly poorer premorbid lung 
function. 
 
Lung function was assessed by measuring Crs, Rrs, FRCHe, FRCMBW and LCI.  
The FRC and Crs results were corrected for body weight, as length can be 
difficult to measure accurately in small infants.  In the ‘thinnest’ infants, FRC 
and Crs may be overestimated when a weight correction is used compared to 
length.  For the uncorrected data the median Crs, but not FRC results differed 
significantly in the RSV group between those who were and were not 
admitted, further emphasising they had worse lung function.  In addition, 
there was a non-significant trend in corrected Crs between the four groups.  A 
possible explanation is that infants with poorer lung function may be more 
likely to be symptomatic with a LRTI. Rrs and LCI results are not routinely 
corrected for either body weight or length.  Rrs results differed significantly in 
both the RSV and the other viral groups between those who were and were 
not admitted but there were no significant differences between the groups in 
the LCI results.   There was a wide range of results reflecting the wide spread 
of gestational ages of the infants examined.  The low intra-observer 
coefficients of variability in FRCHe, Crs and Rrs demonstrate these results to 
be reliable.  There were, however, much higher intra-observer coefficients of 
variability for the FRCMBW and LCI results suggesting those data are less 
reliable.   
 
The study has a number of strengths. A large cohort of infants was 
prospectively followed and thus the study had sufficient numbers to be able 
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to appropriately compare results from infants with RSV LRTI or other viral 
LRTI to those with no LRTI.  The infants, however, were only prospectively 
followed during the RSV season and it is possible the infants suffered other 
viral infections subsequently.  In addition, only two infants were admitted to 
hospital with other viral LRTI and thus it would be important to determine 
whether our results are replicated in a larger number of infants admitted to 
hospital with ‘other’ respiratory viral infections.  PCR techniques were used 
that could detect ten respiratory viruses.  The PCR techniques are more 
sensitive than conventional virus isolation or immunoflourescence techniques 
for the diagnosis of respiratory virus infections in children (Kuypers et al. 
2006; van de Pol et al. 2007; Bonroy et al. 2007).  A further strength of the 
study is that parents were asked to contact the research team whenever their 
infant was symptomatic and, in addition, they were reminded by two weekly 
telephone calls.  As a consequence, it was possible to document LRTIs not 
only in hospital but also in the community. 
 
In conclusion, these results suggest that, overall, prematurely born infants 
are not predisposed by diminished premorbid lung function to RSV or other 
viral LRTIs, but rather it predisposes them to hospitalisation if they develop a 
viral LRTI.   
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Table 4.4 Previous studies reporting lung function prior to lower respiratory tract infections in infancy 










Lung Function test results 
(Young et al. 
1995) 
253 Term 45 RSV (n=2)  Bronchiolitis 
(n=10) 















Term 48 Virology not 
reported  
 LRTI with wheeze 
(n=24) 
No LRTI  
(n=88) 
p value 
Tme/TE (%) 25.4 (6.9) 31.2 (9.2) 0.01 
Conductance 
(L/s/cmH2O) 
0.028 (0.006) 0.035 (0.009) 0.04 
FRCHe (mL) 97.1 (20.8) 103.2 (16.7) 0.63 
VmaxFRC (mL/s) 118.6 (51.2) 131.2 (47.9) 0.50 
 
(Broughton 
et al. 2006) 
39 28 36 RSV (n=15)  RSV LRTI 
(n=15) 
No RSV LRTI 
(n=24) 
p value 
Rrs (cmH2O/L/s) 126 (62) 89 (28) 0.01 
Crs (mL/cmH2O/kg) 1.0 (0.5) 1.0 (0.5) 0.82 
FRCHe (mL/kg) 22 (4) 22 (3) 0.94 
 
Key:  NS= Non-significant; GA= Gestational age 
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Chapter 5: Lung function of preterm 



























Prematurely born children frequently suffer chronic respiratory morbidity 
at follow up; frequent troublesome symptoms requiring treatment and 
lung function abnormalities even into adolescence and young adulthood 
(Ali & Greenough 2012).  It is possible that viral infections may contribute 
to that increased morbidity, as greater healthcare utilisation and lung 
function abnormalities at school age have been reported following 
respiratory syncytial virus (RSV) lower respiratory tract infections (LRTI) 
(Greenough et al. 2009).  Poorer lung function at 36 weeks postmenstrual 
age (PMA), however, was found in very prematurely born infants who 
developed an RSV LRTI (Broughton et al. 2006).  It may then be that 
RSV LRTIs occur in those destined to have reduced lung function at 
follow up because of poorer premorbid lung function.   Indeed, term born 
infants who developed viral bronchiolitis in infancy had reduced lung 
function soon after birth, that is before they had had viral bronchiolitis, 
and similar levels of reduced lung function at 11 years of age (Turner et 
al. 2002).  The aim of this study was to determine whether viral LRTIs 
affect prematurely born infants’ lung function at follow up, by undertaking 




Infants born at less than 36 weeks of gestational age (GA) were eligible 
for entry into the study if they were born prior to the onset of the RSV 
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season in either 2008 or 2009.  The RSV season was defined as 1st 
October to 31st March, consistent with UK experience (Clark 2000).  After 
discharge from the neonatal/maternity unit infants were prospectively 
followed until one year corrected age as described in section 2.1.  NPAs 
were tested for 13 viruses by real time PCR as described in section 2.7.  
The infants underwent lung function measurements (FRCHe, FRCMBW, 
LCI, Crs and Rrs) at 36 weeks postmenstrual age (PMA) prior to neonatal 
or maternity unit discharge as described in section 2.3.  Infants also 
underwent lung function assessment (FRCpleth, Raw, FRCHe, FRCMBW, LCI, 




Infants who had a LRTI but no virus was detected from the NPA were 
excluded from the analysis. 
 
The remaining infants were divided into two groups:  
(i) Infants who never had a symptomatic LRTI (no LRTI group) 
(ii) Infants who had at least one symptomatic LRTI from which  
either RSV or another respiratory virus was detected from the 
NPA (viral LRTI group). 
 
For continuous variables, the t-test and Mann-Whitney U test were used 
as appropriate to explore any differences between the two groups. Chi-
squared and Fisher’s exact test were used as appropriate for binary 
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variables using IBM SPSS Statistics (version 19, New York, USA). 
Multivariable regression models were developed by Professor Janet 
Peacock and Jessica Lo using Stata (v.12.1 TX, USA).  They were used 
to examine the association between viral status and lung function at one 
year corrected age after adjusting for possible confounders and after 
checking that the model residuals were approximately normally 
distributed. Principal component analysis was used to summarise the 
confounder variables and provide parsimonious regression models. 
Neonatal factors only were adjusted for in the first stage and both infant 
and neonatal factors were adjusted for in the second stage. For details 
regarding the variables used, see footnote under Table 5.4. 
 
5.4 Sample size 
 
A sample size of at least 30 in each of the two groups allowed the 
detection of a difference in the means of the lung function test results of 
0.85 standard deviations (SDs), with 90% power and two-sided 5% 
significance.  In a previous study (Broughton et al. 2007), a difference of 
one SD was detected between the lung function results of infants who 




Two hundred and fifty one infants were eligible for inclusion into the study 
and 70 infants were included in this part of study (Figure 5.1, Appendix 
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5).  Three (4%) infants received palivizumab, none of whom were 
admitted to hospital because of a RSV LRTI.  Thirty-eight infants did not 
have a symptomatic LRTI (no LRTI group). Thirty-two infants had a viral 
LRTI (Table 5.1). Fourteen infants had a least one RSV LRTI but the 
majority of them also had another viral LRTI (rhinovirus, adenovirus, 
human metapneumovirus or enterovirus).  Twelve infants had a dual viral 
LRTI and three a triple viral LRTI.  Five infants in the no LRTI group and 
six infants in the viral LRTI group (RSV n=5) were admitted to hospital.   
There were significant differences between the two groups with regard to 
their birth weight (p=0.006), exposure to antenatal steroids (p=0.036), 
duration of supplemental oxygen (p=0.023) and the duration (p=0.009) 
and cost of neonatal unit stay (p=0.009) (Table 5.2).    
 
There were no significant differences in the lung function results of the 
two groups at 36 weeks PMA (Table 5.3).  At one year corrected age, the 
Rrs (p=0.024) and the Raw results (p=0.0068) differed significantly 
between the two groups (Table 5.3).  After full adjustment, the difference 
for Rrs of 6.9 cmH2O/L/sec was reduced to 5.2 cmH2O/L/sec and was no 
longer statistically significant (Table 5.4). The difference in the Raw results 
between the groups was reduced from 6.0 to 4.69 cmH2O/L/sec, but 
remained statistically significant (p=0.021) (Table 5.4).  The median 
(range) time between between the last viral LRTI and lung function 
testing in infants who developed a viral LRTI was 6 (1-15) months.  There 
were no significant correlations between the time between the occurrence 
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of the viral LRTI and the lung function test and any of the lung function 
test results at one year corrected age.  
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251 eligible infants 
74 parents refused consent 
177 infants recruited 
15 infants lost to follow up 
168 infants prospectively 
followed from discharge 
6 Infants satisfactory lung 
function measurements not 
possible at 36 weeks PMA 
3 infants died 
75 infants did not have lung 
function measured at one year 
corrected age: 
-parents refused consent 
-sedation failure or contraindication 
to sedation 
-equipment failure 
-poor quality data 
78 infants underwent lung 
function testing at one year 
corrected age 
153 infants followed to one 
year corrected age 
8 infants viral negative LRTI 
 
70 infants included in this study 
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Table 5.1: Number of viruses detected by real time PCR 
Data are displayed as the number of occasions a virus was detected. 
Some infants may have had more than one viral LRTI. 
 
 Viruses detected 
RSV A 5 
RSV B 11 
Rhinovirus 9 
Adenovirus 7 
Human Metapneumovirus 4 
Influenza A 3 
Influenza B 2 
Parainfluenza 1 3 
Parainfluenza 2 1 
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Table 5.2: Infant characteristics by viral LRTI status 
Data are displayed as median (range), mean [SD] or n (%). 
 No LRTI group Viral LRTI group p 
N 38 32  
Gestational age (weeks) 34 (28–35) 32 (24–35) 0.17 
Born < 32 weeks of 
gestational age 
8 (21%) 13 (41%) 0.075 
Birth weight (g) 2098 (900–3174) 1667 (670–3154) 0.006 
Small for gestational age 4 (11%) 7 (22%) 0.32 
Male 22 (58%) 17 (53%) 0.69 
Antenatal smoking 5 (13%) 9 (28%) 0.14 
Antenatal steroids 22 (58%) 26 (81%) 0.036 
Surfactant 6 (16%) 11 (34%) 0.071 
Duration of ventilation 
(days) 
0 (0–15) 2 (0–90) 0.036 
Duration of supplemental 
oxygen (days) 
0 (0–58) 2 (0–377) 0.023 
Bronchopulmonary 
dysplasia 
3 (8%) 7 (22%) 0.17 
Family history of atopy* 26 (68%) 21 (60%) 0.80 
Family history of asthma 5 (16%) 9 (24%) 0.78 
Number of siblings 1 (0–5) 1 (0–5) 0.39 
Breastfed 35 (92%) 25 (78%) 0.17 
Palivizumab given 0 (0%) 3 (9%) 0.091 
Duration of neonatal unit 
stay (days) 
18 (2–117) 29 (3–188) 0.009 
Cost of neonatal unit 
stay (UK £) 
11831 [14400] 24262 [31524] 0.009 
 
*atopy = asthma, eczema and/or hayfever 
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Table 5.3: Lung function results at 36 weeks PMA and one year 
corrected age by virus status 
 
Data are displayed as mean (SD) [range]. 
 No LRTI group Viral LRTI group p 
n 38 32  
At 36 weeks PMA    
Postmenstrual age 
(weeks) 
35 (1.2) [34-41] 36 (1.6) [34–41] 0.018 
Weight (g) 
 
2176 (373)  
[1598–3274] 
2067 (377)  
[1200–3154] 
0.23 
FRCHe (mL/Kg) 25.5 (3.5) [19–34] 23.7 (6.2) [7.9–35] 0.12 
FRCMBW (mL/Kg) 26.5 (26.6) [19-42] 25.1 (25.0) [10-35] 0.24 
LCI 9.7 (9.9) [6.6-13.4] 10.0 (9.7) [6.0-14.1] 0.21 
Crs (mL/cmH2O/Kg) 1.48 (0.36) [0.72–2.3] 1.39 (0.39) [0.72–2.4] 0.23 
Rrs (cmH2O/L/s) 72.5 (20) [48–122] 79.4 (21) [43–133] 0.11 
At one year corrected age   
Corrected age 
(months) 
12.7 (2.1) [5.9–16] 13.2 (2.3) [5.4–19] 0.70 
Days between 
assessments 
416 (64) [215–514] 424 (72) [199–618] 0.93 
Weight (kg) 9.9 (1.7) [6.4–16] 9.5 (1.3) [7.2–12] 0.48 
Length (cm) 78 (3.3) [72–85] 78 (4.1) [71–87] 0.75 
FRCHe (mL/kg) 24.6 (3.9) [17–32] 24.9 (3.7) [18–33] 0.81 
FRCMBW (mL/Kg) 21.1 (20.7) [13-32] 21.7 (21.2) [13-31] 0.97 
LCI 7.3 (7.3) [6.2-9.5] 7.1 (7.1) [5.5-8.2] 0.70 
Crs (mL/cmH2O/kg) 1.87 (0.72) [0.25–4.0] 1.78 (0.45) [1.2–2.7] 0.71 
Rrs (cmH2O/L/s) 43.4 (9.9) [28–67] 50.3 (13.9) [34–89] 0.024 
FRCpleth (mL/kg) 26.1 (4.3) [19–36] 27.9 (6.5) [20–48] 0.41 
Raw (cmH2O/L/s) 17.2 (5.5) [9.7–33] 23.2 (9.5) [11–45] 0.0068 
FRCHe:pleth ratio 0.88 (0.07) [0.74–1.0] 0.87 (0.09) [0.68–1.0] 0.73 
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Table 5.4: Difference in lung function between groups (viral LRTI and 
no LRTI) after regression modelling to adjust for confounding neonatal 
and infant factors  
The results are expressed as the mean (95% CI). 
 
 
Difference in lung 
function between 
viral groups after 
adjusting for 
neonatal factors* p 
Difference in lung 
function between viral 
groups after adjusting 
for neonatal and infant 
factors* p 
FRC (mL/kg) 0.52 (-1.52, 2.55) 0.61 0.28 (-1.81, 2.36) 0.79 
Rrs (cmH2O/L/s) 5.84 (-0.11, 11.8) 0.054 5.21 (-0.86, 11.3) 0.091 
Crs 
(mL/cmH2O/kg) -0.026 (-0.32, 0.27) 0.86 -0.031 (-0.34, 0.28) 0.84 
FRCpleth (mL/kg) 1.59 (-1.36, 4.54) 0.29 1.43 (-1.49, 4.34) 0.33 
Raw (cmH2O/L/s) 5.50 (1.31, 9.68) 0.011 4.69 (0.74, 8.63) 0.021 
FRCHe:pleth ratio -0.01 (-0.05, 0.03) 0.58 -0.01 (-0.05, 0.03) 0.69 
 
* Neonatal factors were: gender, gestational age, birth weight, exposure to 
antenatal steroids and use of surfactant. Principal component analysis 
reduced these 5 factors to 3 components. Infant factors were: days of 
ventilation, BPD status, breastfed, palivizumab given and duration of stay in 













This study has demonstrated that, even after adjustment, the viral LRTI 
compared to the no LRTI group had significantly worse lung function at one 
year corrected, that is, after they had had viral LRTIs.  There were, however, 
no significant differences in the lung function at 36 weeks PMA, that is, 
before the viral LRTIs.  Those results then suggest the viral LRTIs were 
responsible for the deterioration in lung function.  Higher airway resistance 
results have previously been reported at one year corrected following RSV 
LRTIs in a very prematurely born cohort born at a median of 28 weeks of GA 
(Broughton et al. 2007).  In this study, RSV LRTI results have not been 
reported separately, as the majority of the infants who had had a RSV LRTI 
also had another viral LRTI.  The current infants who had suffered viral 
LRTIs were born at a median GA of 32 weeks and only six of them had been 
hospitalised.  Hence, the results highlight that even mild viral LRTIs in 
moderately prematurely born infants are associated with reduced lung 
function at follow up. 
 
No significant diffferences were found in FRCpleth between the two groups.  
One previous study (Seidenberg et al. 1989) found differences in FRCpleth 
between infants with and without viral LRTIs in infants, but only the results of 
the 14 infants with viral LRTIs were compared with six controls.  Other 
studies (Stokes et al. 1981; Henry et al. 1983; Caswell et al. 1990) have 
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found an elevated FRCpleth at follow up compared to the reference ranges 
but comparison was not made with a contemporaneous control group in any 
of these studies. In this study it is possible the infants in the viral LRTI group 
had smaller lungs that were relatively hyperinflated and thus there were no 
significant differences in FRCpleth between the two groups, but there were no 
significant differences in the FRCHe or FRCMBW. 
 
Most studies demonstrating lung function abnormalities at follow up have 
reported only infants who were hospitalised because of their LRTI (Stokes et 
al. 1981; Henry et al. 1983; Hall et al. 1984; Cassimos et al. 2008; Sigurs et 
al. 2010).  There have, however, been some studies of term born infants 
which have included non hospitalised infants (Tepper et al. 1992; 
McConnochie et al. 1985; Stein et al. 1999).  In one study, infants who had 
mild bronchiolitis were demonstrated not to be at increased risk between the 
ages of 8 and 12 years for airway hyperreactivity or abnormalities in lung 
function (McConnochie et al. 1985).  Similarly, in another study, although 
RSV LRTIs were associated with an increased risk of wheeze at age six, the 
risk decreased markedly with age and was no longer significant at age 13 
(Stein et al. 1999).  Reduced maximal flow at FRC (VmaxFRC) and increased 
airway responsiveness to metacholine challenge, however, were 
demonstrated in 18 infants during infancy, nine of whom were not 
hospitalised, ten months after an episode of bronchiolitis (Tepper et al. 
1992).  In none of those studies were there attempts to identify respiratory 
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viruses.  Those results (Tepper et al. 1992; McConnochie et al. 1985; Stein 
et al. 1999) may mean that viral LRTIs cause chronic morbidity only in early 
childhood.  Further longitudinal studies are required to test that hypothesis, 
as it is possible that rhinovirus LRTIs may have longer term adverse effects.  
In the COAST study (Guilbert et al. 2011), infants at high risk of developing 
wheeze (at least one atopic parent) were followed up. Infants who wheezed 
with a rhinovirus infection in the first three years after birth were 
demonstrated to have reduced lung function as assessed by spirometry at 
five to eight years of age compared to those infants without a rhinovirus 
“wheezy” illness.  In another study (Kotaniemi-Syrjänen et al. 2008), 
hospitalisation for “wheezy” rhinovirus infections in the first two years after 
birth was a risk factor for reduced lung function (increased bronchial 
responsiveness to exercise) at eight years of age.  In the current study the 
rhinovirus results have not been analysed separately but, of note, the viral 
LRTI group had had rhinovirus LRTIs on nine occasions. 
 
Some studies have shown a decline in lung function during infancy in 
prematurely born infants (Hofhuis et al. 2002; Hoo et al. 2002).  In one (Hoo 
et al. 2002), there was a decline in small airway function as assessed by 
VmaxFRC over the first few months after birth in infants born between 32 and 
35 weeks of GA who had no initial respiratory problems.  In another, which 
included very prematurely born infants who had BPD, there was a decline in 
VmaxFRC between 6 and 12 months in those who had initially been 
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supported by conventional ventilation (Hofhuis et al. 2002).  In this study, Rrs, 
Crs and LCI results, improved between 36 weeks PMA and one year 
corrected age in both groups.    
 
This study has a number of strengths and some limitations.  Consecutive 
infants were recruited whose parents gave informed consent.  The infants 
tended to be relatively “mature” prematurely born infants and hence, not 
surprisingly, only a small proportion was admitted to hospital because of the 
LRTI.  Infants were followed prospectively and hence LRTIs were “captured” 
regardless of whether the infants required hospitalisation or the infants 
remained in the community.  A wide variety of respiratory viruses was tested 
for, which highlighted that the majority of infants who had RSV LRTIs also 
had other viral LRTIs.  Hence, it is not possible report whether there was any 
impact of RSV LRTIs alone on lung function at follow up.  The multiple 
breath wash-in/out data at 36 weeks corrected age had a high co-efficient of 
variation (FRCMBW 16% and LCI 13%). Comparisons of the results at 36 
weeks postnatal age and one year corrected age, therefore, were not 
attempted.   
 
In conclusion, these results suggest viral LRTIs, regardless of 
hospitalisation, adversely affect prematurely born infants’ lung function at 
follow up.  This may make them at greater risk of poorer outcomes with 
subsequent viral LRTIs.   
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Chapter 6: Pandemic influenza A (H1N1) 
virus 2009 in a prospectively followed 
























Pandemic influenza A (H1N1) virus was first reported in the United Kingdom 
in April 2009, with peaks of infection occurring in July and October 2009 
(Health Protection Agency 2010b).  Children less than five years of age and 
those with pre-existing lung disease were at the greatest risk for 
hospitalisation and mortality because of H1N1 (Jain et al. 2009; Sachedina & 
Donaldson 2010).  Infants born prematurely have an increased risk of 
hospitalisation for lower respiratory tract infections (LRTIs) because of 
respiratory syncytial virus (RSV) in the first two years after birth than infants 
born at term (Boyce et al. 2000).  The primary aim of this study, therefore, 
was to test the hypothesis that prematurely born infants would be more likely 
to be hospitalised with H1N1 or other viral LRTIs than term born infants. 
 
Pandemic influenza A H1N1 immunisation became widely available in 
October 2009. The Department of Health and Joint Committee on 
Vaccination and Immunisation advised immunising children older than six 
months who were in high-risk groups, for example, those with a chronic lung 
disease such as bronchopulmonary dysplasia (BPD). A secondary aim of the 
study was to determine the rate of uptake of H1N1 immunisation in 
prematurely born infants and whether it was higher in those with BPD. 
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6.2 Methods  
 
Prematurely born infants born at less than 36 weeks of gestational age (GA) 
were eligible for entry into the study if they were born between April and 
September in 2008 or 2009, that is, outside the RSV season. Consecutive 
infants, whose parents gave informed written consent, were recruited.  After 
discharge from the neonatal/maternity unit infants were prospectively 
followed as described in section 2.1.  Multiplex real-time reverse 
transcription polymerase chain reaction (PCR) was performed on the NPAs 
for nine virus types (influenza A and B, RSV A and B, human 
metapneumovirus, rhinoviruses, parainfluenza viruses 1–3) and real-time 
PCR was performed for adenoviruses as described in section 2.7. A 
separate multiplex real-time reverse transcriptase PCR that was in routine 
clinical use was used to test all samples over the pandemic period for 
influenza A (H1N1)v 2009.  The multiplex tested for the haemaglutinin (H1) 
gene, a matrix gene and an MS2 phage internal control to test for inhibition 
of any samples. The primers and probes (all synthesised by Metabion, 
Martinsried, Germany) for the H1 and matrix genes and MS2 phage internal 
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Table 6.1: Sequences of the primers and probes used for the pandemic 
influenza A (H1N1)v 2009 PCR assays 
Gene Primer/Probe Sequences 
H1 Forward primer 5' TTA CCA GAT TTT GGC GAT CTA YT 3' 
H1 Reverse primer 5' CCA GGG AGA CTA SCA RTA CCA 3' 
H1 TaqMan Probe 5' 6 FAM-ACW GTC GCC AGT TC-MGBFQ 
Matrix Forward primer 5' GAC CRA TCC TGT CAC CTC TGA C 3' 
Matrix Reverse primer 5' AGG GCA TTY TGG ACA AAK CGT CTA 3' 
Matrix TaqMan Probe Cy5-TGC AGT CCY CGC TCA CTG GGC ACG-BHQ 3 
MS2 Forward primer 5' TGG CAC TAC CCC TCT CCG TAT TCA CG 3' 
MS2 Reverse primer 5' GTA CGG GCG ACC CCA CGA TGA C 3’ 
MS2 TaqMan Probe 5' ROX- CAC ATC GAT AGA TCA AGG TGC CTA CAA GC-
BHQ 2' 
 
The primers were used at 10 pmoles and the probes at 5 pmoles for the H1 
and matrix gene assays and the primers and probes were both used at 2 
pmoles for the MS2 phage assay.  The samples were tested using a Rotor-
Gene 6000 real-time thermal cycler (QIAGEN, Crawley, UK) and the 
following conditions: 
 1. Hold at 50oC for 30 minutes (reverse transcription) 
2.  Hold at 95oC for 15 minutes (TaqMan polymerase activation 
and reverse transcriptase inactivation) 
3. 40 cycles of: 
i. Step 1- 94oC hold for 30 secs (denaturation) 
ii. Step 2- 60oC hold for 30 secs, acquiring to cycle A 
(FAM, CY5, ROX) 
 
Parents were contacted, and the GPs’ and hospital notes were reviewed to 
investigate how many of the infants had received the pandemic influenza A 
H1N1 immunisation. Data collected on the prematurely born cohort from 
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April 2009, the start of the pandemic, until the end of March 2010, when only 
sporadic H1N1 cases were reported locally, were analysed for this study. 
 
To ascertain the hospitalisation rate of term-born infants, the King’s College 
Hospital (KCH) virology database was interrogated. All infants attending the 
emergency department had an NPA taken only if they required 
hospitalisation. All NPAs were tested as described above.  The hospital 
records of all children with NPAs in which viruses were detected were then 
examined to determine which children were less than two years of age and 
born at term. Data concerning the number of children less than two years of 





Differences were assessed for statistical significance using Fisher’s exact 
test.  Statistical analysis was performed using SPSS version 15 (SPSS Inc., 




In all, 251 infants were eligible for entry into the study, but 74 parents 
refused consent and 27 did not complete the follow-up period. Those who 
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did or did not complete the study had similar gestational ages and birth 
weights.  In total, 150 prematurely born infants with a median (range) GA of 
34 (23–35) weeks and birth weight of 1880 (534–3446) g were prospectively 
followed; 16 had BPD (oxygen dependent beyond 28 days) (Jobe & 
Bancalari 2001). In all, 94 infants were born between April and September 
2008 and 56 infants between April and September 2009. Only one (0.7%) 
infant developed a LRTI in which pandemic influenza A (H1N1)v 2009 RNA 
was detected in the NPA; he required hospitalisation. He was born at 24 
weeks of GA, had BPD, and was two months post-term when he developed 
H1N1 infection. He was admitted to a paediatric ward for one night, but did 
not require any respiratory support. He had not received the pandemic 
influenza A H1N1 immunisation. Eight (5.3%) other infants were hospitalised 
with other known viral LRTIs (five RSV, one rhinovirus, one adenovirus, and 
one dual infection with adenovirus and rhinovirus), but tested negative for 
H1N1. Six infants had received palivizumab, including two infants who were 
hospitalised for a LRTI (one H1N1 and one RSV LRTI). During the study 
period, there were approximately 4513 children aged less than two years in 
the KCH catchment area. Three (0.07%) of the children born at term were 
admitted to KCH and had pandemic influenza A H1N1 virus infection. A 
further 29 (0.6%) term born children were admitted with other viral LRTIs (22 
RSV, two human metapneumovirus, two parainfluenza type 1, one 
parainfluenza type 3, one influenza type B, and one dual infection of RSV 
and adenovirus). The rate of hospitalisation for pandemic influenza A H1N1 
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virus infection did not differ significantly between prematurely and term-born 
infants (0.7% versus 0.07%, p=0.12), but prematurely born infants had a 
higher rate of hospitalisation for other known viral LRTIs (5.3% versus 0.6%, 
p<0.0001), including RSV LRTIs (3.3% versus 0.5%, p<0.002). Fourteen 
(9.3%) infants in the prematurely born cohort received the H1N1 
immunisation, including four (25%) of 16 infants with BPD. Significantly more 
prematurely born infants with BPD received the H1N1 immunisation 




The results demonstrate that hospitalisation rates for pandemic influenza A 
H1N1 virus infections for prematurely born and term born infants did not 
differ significantly, but prematurely born infants had significantly higher rates 
of hospitalisation for other viral, including RSV, LRTIs.  The study was 
particularly interested in the impact of RSV infection, and hence included 
only infants who had been exposed to an entire RSV season on discharge 
from the NICU. If infants born between September and April had been 
assessed, it is possible that higher rates of hospitalisation may have been 
found. Only one prematurely born infant was admitted because of H1N1 
infection however, thus it is not possible to speculate on the influence of 
postnatal age in prematurely born infants with regard to the risk for H1N1 
hospitalisation. The number of controls included in the study was adjusted to 
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take into account that the prematurely born infants were recruited only in six 
months of the year. A further limitation of this study was that some infants 
from other boroughs may have been admitted to KCH and infants born at 
KCH may have been admitted elsewhere. This is the first study in which 
pandemic influenza A H1N1 virus LRTI hospitalisations were prospectively 
collected in prematurely born infants. It was also found that pandemic 
influenza A H1N1 immunisation uptake was low in the prematurely born 
infants. 
 
During the peak of the pandemic (July 2009), approximately 300 per 100,000 
(0.3%) children aged less than one year attended their GP per week with an 
influenza-like-illness; a similar proportion of the children aged one to four 
years also attended their GP (Health Protection Agency 2010b).  Miller et al 
(2010) reported 21.3% of children aged less than five years of age in London 
showed serological evidence of having had H1N1 infection. Certain of those 
children (Miller et al. 2010), however, may have been asymptomatic or had 
mild pandemic influenza A H1N1 virus infections not requiring 
hospitalisation, as samples were analyzed from children having blood tests 
for any reason. This study reports the hospitalisation rate for pandemic 
influenza A H1N1 virus LRTIs in term-born infants, and this was very similar 
to that reported for children less than five years of age (28 per 100,000; 
0.028%) (Health Protection Agency 2010a). 
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Only 9.3% of the prematurely born cohort received the pandemic influenza A 
H1N1 immunisation. Although the proportion of infants with BPD receiving 
the immunization was higher (25%), these findings suggest that targeting of 
high-risk groups needs to be more effective. 
 
In conclusion, pandemic influenza A H1N1 virus LRTI was not, but other viral 
LRTIs were, associated with a higher hospitalisation rate in prematurely born 
compared with term born infants. These data suggest that prematurity per se 
might not be a risk factor for increased hospitalisation with pandemic 
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Chapter 7: Rhinovirus infection and 























Respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) 
are associated with increased chronic respiratory morbidity and healthcare 
utilisation in prematurely born infants who did (Greenough et al. 2009) or did 
not (Broughton et al. 2005; Broughton et al. 2007) develop 
bronchopulmonary dysplasia (BPD).  Amongst those who had had BPD, 
healthcare utilisation and the related cost of care were increased up to seven 
years of age and lung function was lower than that of controls at ten years of 
age (Greenough et al. 2009).   In term born children, rhinovirus (HRV) 
infection has also been associated with chronic respiratory morbidity 
(Lemanske et al. 2005; Jackson et al. 2008; Jartti & Korppi 2011; Guilbert et 
al. 2011; Midulla et al. 2012).  There is some evidence that HRV infection 
may also have long term adverse effects on prematurely born infants, in that 
eight prematurely born infants with BPD who developed HRV LRTIs 
subsequently had a sustained worsening of their clinical status, requiring the 
addition of new therapies for prolonged periods of time (Chidekel et al. 
1997).   As a consequence, it was hypothesised that prematurely born 
infants with or without BPD who suffered a HRV LRTI would suffer increased 
healthcare utilisation in infancy and have greater health related cost of care.  
The aim of this study was to test that hypothesis.  In addition, the study 
aimed to determine whether the magnitude of any increase in healthcare 
utilisation and the health related cost of care was similar to that associated 
with RSV LRTI.  
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 7.2 Methods  
Infants born less than 36 weeks of GA in 2008 or 2009 were eligible for entry 
into the study if they were born prior to the onset of the RSV season.  The 
RSV season was defined as 1 October to 31 March, consistent with the UK 
experience.  Following neonatal unit discharge, infants were followed 
prospectively until one year of corrected age as described in section 2.1.  A 
researcher visited the home on every occasion that an infant had a LRTI and 
a nasopharyngeal aspirate (NPA) was obtained if the LRTI was confirmed by 
the researcher. NPAs were obtained on each occasion an infant was 
admitted with an LRTI.  Real time PCR was performed on the NPAs for 13 
viruses as described in section 2.7. 
Follow up costs after neonatal discharge were calculated using the NHS 
reference costing scheme (2007-8) (Department of Health 2009) and the 
British National Formulary for Children (2008) as described in section 2.5.  
The respiratory costs were also reported and these were defined as costs 
related to a LRTI episode regardless of whether this was incurred in hospital 
or the community, e.g. a general practitioner (GP) attendance. Regarding 
healthcare utilisation, all visits to practice nurses or routine visits to health 
visitors, for example for immunisations, were not recorded as these were 
considered usual care for infants.  To calculate the cost of care, the NHS 
reference costing scheme was used which gives national average costs for 
in- and out-patient hospital attendances and GP attendances.  For 
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admissions, the number of days for each admission was multiplied by the 
national average cost for the diagnosis leading to admission. 
Parents completed a respiratory diary card for one month when their infant 
was 11 months of corrected age and a respiratory health related 
questionnaire about their infant when the infant was one year of corrected 
age as described in section 2.6. 
7.3 Analysis 
The infants were divided into four groups: 
(i) Infants who never had a symptomatic LRTI (no LRTI). 
(ii) Infants who had at least one LRTI from which HRV was detected 
from the NPA (HRV LRTI) 
(iii) Infants who had at least one LRTI from which RSV was detected 
from the NPA (RSV LRTI). 
(iv) Infants who had LRTI(s) with HRV and RSV detected from NPA(s) 
(HRV/RSV LRTI).  
The results of infants who had other viral LRTIs, but not a HRV or RSV LRTI 
or had a symptomatic LRTI, but no virus was detected, were excluded from 
the analysis. 
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7.4 Statistical analysis 
Baseline factors were compared across the four groups using the Kruskal-
Wallis test with post-hoc tests adjusted for multiple comparisons using IBM 
SPSS Statistics (version 19, New York, USA).  Further analysis was then 
carried out by Professor Janet Peacock and Jessica Lo using Stata (version 
12.1 TX, USA).  The cost data were summarised using means, rather than 
medians to preserve the total sum of costs (Thompson & Barber 2000).  
Cost data were fitted to a generalised linear model with a gamma distribution 
and identity link for the total cost data and a Poisson distribution with robust 
standard error and identity link for the respiratory cost data (Barber & 
Thompson 2004).  To account for the differences in the demographics of the 
three groups, an adjusted analysis was performed with adjustment initially 
for birth weight, GA, antenatal steroid use and surfactant use, and then for 
those variables plus BPD. Principal components analysis was first used to 
reduce the birth weight, GA, antenatal steroid use and surfactant use data to 
two principal components that explained approximately 80% of the total 
variability in those factors. Those two components were then used as 
covariates in a further generalised linear model to obtain adjusted estimates. 
Adjustment was not possible for the respiratory data as none of the models 
would converge due to the dominance of nil costs in the no LRTI group. 




Two hundred and fifty one infants were eligible for inclusion into the study 
(Figure 7.1, Appendix 5).   
Figure 7.1:  Flow diagram of recruitment 
 
The 153 (84 males) infants who completed the study had a median GA of 34 
(range 23-35) weeks and a birth weight of 1890 (range 534-3610) g.  Twenty 
infants developed HRV LRTIs, 17 developed RSV LRTIs, 12 developed both 
HRV/RSV LRTIs and 74 infants had no LRTI.  Thirty infants had other viral 
or viral negative LRTIs and their results were excluded from the analysis.  Of 
the 12 infants developing both HRV/RSV LRTIs, nine had HRV or RSV 
detected during two separate LRTIs and three infants had detection of HRV 
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and RSV during one LRTI.  The HRV LRTI group had a median of two 
LRTIs, the RSV LRTI group a median of one LRTI and the HRV/RSV LRTI 
group a median of two LRTIs (p<0.001 across the three groups with post hoc 
analysis showing no significant difference between the HRV and the 
HRV/RSV LRTI groups, p=0.95, but significant differences between both 
those groups and the RSV LRTI group (p<0.01, p<0.01). 
The significant differences in the demographics (Table 7.1) between the four 
groups were in GA (there was significant variability overall between the 
groups but there were no significant differences between pairs of groups), 
birth weight (the HRV LRTI group was significantly lighter at birth than the no 
LRTI group, p<0.05), antenatal steroid use (a significantly greater proportion 
of the mothers in the RSV group had received antenatal steroids than the no 
LRTI group, p<0.05), surfactant use (a greater proportion of the HRV/RSV 
LRTI group had received surfactant than either the RSV LRTI [p<0.05] or the 
no LRTI groups [p<0.05]), BPD (there was significant variability overall 
between the groups but there were no significant differences between pairs 
of groups) and palivizumab use (a significantly greater proportion of the HRV 
LRTI group had received palivizumab than the no LRTI group, p<0.05). 
Nine infants (12%) of the no LRTI group had hospital admissions (all for non-
respiratory causes), two (10%) of the HRV LRTI group had hospital 
admissions (one for a HRV LRTI and one for a non-respiratory cause), 
seven (41%) of the RSV LRTI group had hospital admissions (five for RSV 
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LRTI, one for another viral LRTI and one for a non-respiratory cause) and six 
(50%) of the HRV/RSV LRTI group had hospital admissions (two for a 
HRV/RSV LRTI, three for a RSV LRTI and one for a HRV LRTI). 
The HRV LRTI group had more total (p<0.05) and respiratory related 
(p<0.05) out-patient attendances and general practitioner (GP) respiratory 
related attendances (p<0.05) than the no LRTI group and more respiratory 
related out-patient attendances than the RSV LRTI group (p<0.05).  The 
RSV LRTI group had more total (p<0.05) and respiratory related (p<0.05) 
hospitalisations than the no LRTI group and more total (p<0.05) and 
respiratory related (p<0.05) hospitalisations than the HRV LRTI group.  The 
RSV LRTI group had more total (p<0.05) and respiratory related (p<0.05) A 
and E attendances than the no LRTI group (Table 7.2).  The HRV/RSV 
group had more total and respiratory related hospitalisations than both the 
no LRTI (p<0.05) and HRV LRTI (p<0.05) groups.  The HRV/RSV LRTI 
group had more total (p<0.05) and respiratory related (p<0.05) A and E 
attendances than the no LRTI group (Table 7.2).  The HRV/RSV LRTI group 
had more total out-patient attendances than the no LRTI group (p<0.05) 
(Table 7.2). 
Analysis of the diary card data highlighted that the HRV/RSV LRTI group 
had more days of inhaler use than any of the other three groups (p<0.05, 
p<0.05 and p<0.05) (Table 7.3). Analysis of the respiratory health-related 
questionnaire data (Table 7.4) demonstrated that a greater proportion of the 
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HRV LRTI group wheezed than the no LRTI group (p<0.001).  A greater 
proportion of the HRV/RSV LRTI group wheezed (p<0.001) and used 
bronchodilators (p<0.01) or preventers (p<0.001) than the no LRTI group 
(Table 7.4).  A greater proportion of the HRV/RSV LRTI group used 
preventers compared to the RSV LRTI group (p<0.001) (Table 7.4). 
There were significant differences overall across the four groups in the mean 
costs for out-patient attendances, GP respiratory attendances and 
medication (Table 7.5).  The costs for out-patient attendances were greater 
in the HRV LRTI group compared to the no LRTI group (p<0.05) and 
compared to the RSV LRTI group (p<0.05).  There were no significant 
differences between the four groups on post hoc analysis for the costs for 
GP respiratory attendances or medications. 
Compared to the no LRTI group, the HRV/RSV LRTI group had the highest 
mean cost (difference = £7035), then the HRV LRTI group (difference = 
£1086), followed by the RSV LRTI group (difference = £678).  These 
differences were reduced after adjusting for birth weight, GA, antenatal 
steroid and surfactant use, but overall the differences remained statistically 
significant.  Further adjustment for BPD in addition, reduced the differences 
slightly more, but the overall differences in costs between groups remained 
significant (p=0.045) (Table 7.6).   The health related cost of care of the HRV 
LRTI group was similar to that of the RSV LRTI group (p=0.83) (Table 7.6).   
The ordering of costs was the same for total respiratory costs and the 
                                                                                                                                                                   
209 
 
differences in mean costs were statistically significant (p=0.003) (Table 7.7).  
Adjustment for neonatal factors for total respiratory costs was not possible 
as models with possible confounders would not converge.   
 
Table 7.1: Demographic data according to LRTI status 
Data presented as median (range) or n (%). 
   No LRTI HRV LRTI RSV LRTI HRV/RSV 
LRTI 
p* 





















Males 39 (53%) 9 (45%) 9 (53%) 5 (42%) 0.85 
Antenatal smoking 11 (15%) 4 (20%) 2 (12%) 2 (17%) 0.91 
Antenatal steroids 40 (54%) 16 (80%) 16 (94%) 8 (67%) 0.014 
Surfactant 11 (15%) 7 (35%) 1 (6%) 6 (50%) 0.005 
Duration of 
ventilation (days) 
0 (0-82) 1 (0-103) 1 (0-17) 1.5 (0-81) 0.39 
Bronchopulmonary 
dysplasia 
4 (5%) 5 (25%) 0 (0%) 3 (25%) 0.008 
Family history of 
atopy 
52 (70%) 13 (65%) 8 (47%) 7 (58%) 0.32 
Day Care 2 (3%) 0 (0%) 1 (6%) 1 (8%) 0.52 
Number of siblings 1 (0-5) 1 (0-5) 1 (0-4) 1 (0-4) 0.91 
Palivizumab 0 (0%) 3 (15%) 0 (0%) 1 (8%) 0.005 
  
*The p values relate to the difference between the four groups, post hoc p 
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Table 7.2:  Healthcare utilisation to one year corrected age according to 
LRTI status 
Data are presented as median [mean] (range). 










n                          74 
Admissions 
20 17 12  
Total 0 [0.1] (0-2) 0 [0.1] (0-1) 0 [0.6] (0-3) 1 [1.8] (0-11) 0.001 
Respiratory 0 [0] (0-0) 0 [0.1](0-1) 0 [0.4] (0-1) 0 [1.3] (0-11) <0.001 
A and E attendances     
Total 0 [0.7] (0-6) 1 [1.2] (0-5) 1 [1.6] (0-8) 1 [2.5] (0-14) 0.015 
Respiratory 0 [0.1] (0-3) 0 [0.3] (0-4) 0 [0.7] (0-3) 1 [1.9] (0-12) <0.001 
Outpatient attendances     
Total 2 [3.3]  
(0-14) 




5 [7.3] (1-15) 0.002 
Respiratory 0 [0] (0-0) 0 [1.1] (0-9) 0 [0] (0-0) 0 [0.8] (0-8) <0.001 
General Practice attendances    
Total 5 [5.3](0-20) 6 [6.8](1-15) 5 [6.1](2-14) 9 [8.3](3-15) 0.069 
Respiratory 0 [0.4] (0-2) 1 [1.4] (0-4) 1 [0.8](0-3) 1 [1.8](0-6) 0.002 
  
* The p values relate to the difference between the four groups, post hoc p 
values are given in the results section text. 
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Table 7.3: Diary card data at one year corrected age according to LRTI status 












Days of cough 0 [3.3] (0-31) 0.5 [4.9] (0-18) 0 [6.5] (0-23) 3 [7.8] (0-30) 0.40 
Days of wheeze 0 [0.7] (0-12) 0 [2.4] (0-27) 0 [0.1] (0-1) 0 [4.4] (0-30) 0.035 
Days using antibiotics 0 [0] (0-2) 0 [0] (0-0) 0 [0.6] (0-7) 0 [1.1] (0-5) 0.042 
Days using inhalers 0 [0] (0-0) 0 [1.9] (0-30) 0 [0] (0-0) 0 [4.3] (0-30) <0.001 
  * The p values relate to the difference between the four groups, post hoc p values are given in the results section 
text. 
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Table 7.4: Respiratory health related questionnaire data according to LRTI status 












Did your child cough in the first year? 66 (93%) 19 (100%) 17 (100%) 12 (100%) 0.47 
Did your child wheeze in the first year? 11 (15%) 13 (68%) 8 (47%) 9 (75%) <0.001 
Did your child use any medication for a 
chest problem in the first year? 
17 (24%) 10 (53%) 9 (19%) 7 (58%) 0.008 
       Bronchodilators (e.g. salbutamol)? 6 (8%) 6 (32%) 6 (35%) 6 (50%) <0.001 
       Antibiotics? 13 (18%) 9 (47%) 7 (37%) 6 (50%) 0.01 
       Preventers (e.g. steroids, montelukast)? 0 (0%) 2 (11%) 0 (0%) 3 (25%) 0.001 
Has your child ever been diagnosed with 
asthma by a doctor? 
0 (0%) 0 (0%) 0 (0%) 1 (8%) 0.10 
 * The p values relate to the difference between the four groups, post hoc p values are given in the results section 
text. 
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Table 7.5:  Costs of care (UK £) to one year corrected age according to 
LRTI status 



































































































































1 Generalised linear model did not converge and so the p value is unobtainable 
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Table 7.6:  Unadjusted and adjusted mean total costs (UK £) according 




































 Overall p 
value: 
p=0.040 






1086 54 to 2019 323 -441 to 
1087 





678 -141 to 
1497 





7035 2497 to 
11573 
5851 1789 to 
9912 
5769 1711 to 
9828 
 1 Difference in means between the reference group and each other group in turn 
2 Adjustment for birth weight, GA, antenatal steroid use and surfactant use 
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Table 7.7:  Unadjusted mean difference in overall respiratory costs (UK 
£) according to LRTI status 
  
  Unadjusted mean 
difference1 (UK £) 
95% CI for difference 
No LRTI 
(n=74) 






79 to 1346 
RSV LRTI 
(n=17) 
418 98 to 738 
HRV/RSV LRTI 
(n=12) 
4125 -952 to 9203 
 1 Difference in means between the reference group and each other group in turn. 
An adjusted model could not be fitted due to convergence problems 
  
  





This study has demonstrated that prematurely born infants developing HRV 
LRTIs had increased health related cost of care during infancy compared to 
infants who did not develop a LRTI. The results demonstrating the HRV LRTI 
group suffered chronic respiratory morbidity are in keeping with previous 
findings in eight prematurely born infants (Chidekel et al. 1997). In that 
series, however, all of the infants were born very prematurely, had had BPD 
and were hospitalised with the HRV LRTI (Chidekel et al. 1997). The 20 
infants in the HRV group presently studied, however, were born at a higher 
GA, only 25% had had BPD and only one of the 20 infants had been 
hospitalised with the HRV LRTI.  
 
The HRV/RSV group, as the RSV group, had significantly more admissions 
and A and E attendances than the no LRTI group. It has been previously 
reported that infants who develop a dual infection either with RSV and human 
metapneumovirus (Semple et al. 2005) or RSV and HRV (Richard et al. 
2008) were more likely to develop a severe LRTI, as evidenced by 
requirement for a PICU admission. In this study, however, only three of the 
infants had HRV and RSV detected during the same LRTI. The higher 
admission rate of the HRV/RSV group may reflect a functional predisposition 
to severe viral LRTIs.  It has previously been shown that very prematurely 
born infants who developed a RSV LRTI and subsequent chronic respiratory 
morbidity had significantly worse premorbid lung function (Broughton et al. 
2006).  In infants born at term, poorer premorbid lung function, that is a 
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higher resistance of the respiratory system in the first two months after birth, 
was associated with an increased risk of the occurrence and duration of 
HRV-associated wheeze during infancy (van der Zalm et al. 2011). It is thus 
possible that poorer premorbid lung function might explain the chronic 
respiratory morbidity of the HRV group. In infants born at term, HRV seems 
to preferentially affect the lower airways, causing bronchiolitis in atopic 
children prone to wheezing (Einarsson et al. 1996; Gern & Busse 1999; Gern 
et al. 2000). It has been suggested that the reduced interferon-gamma (IFN-
γ) responses in infancy in children with atopy may partly explain why atopy is 
a risk factor for HRV-induced wheezing (Jartti & Korppi 2011). Interferon 
responses in early life are inversely associated with the severity of viral 
respiratory illnesses (Papadopoulos et al. 2002). In addition, infants with low 
ex-vivo IFN-γ responses in early life are more likely to have frequent viral 
respiratory illnesses, including those associated with wheezing (Copenhaver 
et al. 2004). In this study, skin prick testing was not performed on the infants 
as parents of prematurely born infants frequently refuse skin prick testing in a 
research setting, as do prematurely born children (Greenough et al. 2009). 
There were not, however, any significant differences between the groups in 
family history of atopy or the proportion of infants who had eczema. Whether 
atopy predisposes prematurely born infants to HRV LRTIs needs further 
investigation.  
 
This study has a number of strengths and some limitations. A large cohort of 
prematurely born infants was prospectively followed from birth to one year of 
corrected age. It was possible to investigate symptomatic LRTIs, not only in 
                                                                                                                                                                   
218 
 
hospitalised infants, but also in those with LRTIs in the community. This is 
important, as it has previously been demonstrated that infants with RSV LRTI 
not requiring hospitalisation also suffer increased respiratory morbidity 
(Broughton et al. 2005). In addition, the NPAs were tested by real time 
multiplex PCR assays that had the advantage of high sensitivity to detect a 
wide range of respiratory viruses (Copenhaver et al. 2004; Kuypers et al. 
2006). A limitation of the study, however, is that NPAs were only obtained 
when the infants were symptomatic and thus it is not possible to comment as 
to whether asymptomatic respiratory viral infections increase healthcare 
utilisation at follow up. HRV can be shed from the respiratory tract for several 
weeks after an acute infection (Peltola et al. 2013) and thus it is possible a 
sample testing positive for HRV was not cause of the acute infection LRTI at 
the time the sample was taken but was from a recent, previous infection. 
Both the HRV LRTI and the HRV/RSV LRTI groups had a median of two 
LRTIs, but the RSV LRTI group had a median of one LRTI which might have 
influenced differences in the cost of care. The HRV LRTI and RSV LRTI 
groups, however, had similar costs of care, but the type of healthcare 
utilisation which resulted in the increased cost of care compared to the no 
LRTI group differed between the two groups. Infants were recruited before 
the RSV season to ensure all infants were exposed to a whole RSV season. 
All infants, however, were followed for one year so seasonal variations 
between viruses would not affect the results. The groups differed significantly 
in respect to certain of their demographics; the no LRTI group were more 
mature at birth, of higher birth weight and less likely to have received 
antenatal steroids. The findings of increased health related costs of care 
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compared to the no LRTI group, however, remained statistically significant 
after adjusting for neonatal factors.  
 
In conclusion, HRV LRTIs in prematurely born infants were associated with 
an increased health related cost of care during infancy. The increased health 
related cost of care in the HRV LRTI group was due to more out-patient and 
respiratory related general practitioner attendances and a greater proportion 
of the group wheezed at follow up whereas in the RSV LRTI group it was due 
to more hospital admissions. Those data suggest the HRV LRTI group 
suffered greater chronic respiratory morbidity than the RSV LRTI group. 
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Chapter 8: Respiratory outcome of 
prematurely born infants following human 


























Human rhinoviruses (HRVs) are a common cause of lower respiratory tract 
infections (LRTIs) in both term (van der Zalm et al. 2011) and prematurely 
(Miller et al. 2012) born infants.  HRVs had been classified into two genetic 
groups (HRV-A and HRV-B) comprising over 100 serotypes, with HRV-A 
being more prevalent than HRV-B.  A further HRV group (HRV-C) has 
subsequently been identified by genomic nucleotide sequencing (Lee et al. 
2007).  HRV-C group viruses have been reported to have a similar 
prevalence to HRV-A in hospitalised (Fry et al. 2011; Iwane et al. 2011), 
ambulatory (Arden et al. 2010) and asymptomatic patients (Fry et al. 2011; 
Iwane et al. 2011).  There are, however, conflicting data as to whether HRV-
A or HRV-C infections causes more severe acute disease (Miller et al. 2009; 
Jin et al. 2009; Xiang et al. 2010).  HRV LRTIs have also been associated 
with chronic respiratory morbidity in infants born at term or prematurely 
(Chidekel et al. 1997; Jackson et al. 2008; Guilbert et al. 2011).  The aim of 
this study was to assess whether HRV group A or C viruses were associated 
with chronic respiratory morbidity and increased healthcare utilisation in 




Infants born less than 36 weeks of gestation were eligible for entry into the 
study if they were born prior to the onset of the RSV season in 2008 or 2009.  
The RSV season was defined as from October 1st to March 31st as per UK 
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experience (Clark 2000).  After neonatal/maternity unit discharge infants 
were followed until one year corrected age as described in section 2.1.  Real 
time polymerase chain reaction (PCR) had been performed on the NPAs for 
13 viruses as described in section 2.7.  For the purposes of this study, the 
nucleic acid from the stored clinical specimens was subtyped for HRV A, B 
and C by Dr Ina Lauinger and Dr William Tong. RNA extraction was carried 
out using the QIAamp Viral RNA Mini Kit (Qiagen) according to the 
manufacturer's instructions. cDNA synthesis and PCR amplification of the 
VP4/VP2 region for typing was carried out as previously described (Lauinger 
et al. 2012). PCR products were cleaned with microClean (Microzone) before 
cycle sequencing with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) on the automated sequencer 3130xl Genetic Analyzer (Applied 
Biosystems). Sequence analysis was carried out using the software BioEdit 
(version 7.0.9) and MEGA5 (version 5.03).  Sequencing was performed in 
one direction using the forward primer.  More than 10% divergence in 
VP4/VP2 is required to identify a different HRV type (Simmonds et al. 2010; 
McIntyre et al. 2013); this is well above the contribution of any potential 
polymerase error.   
 
Parents completed a diary card for one month when their infant was 11 
months corrected age and a respiratory health related questionnaire about 
their infant when the infant was one year corrected age as described in 
section 2.6.  Follow up costs after neonatal discharge were calculated using 
the NHS reference costing scheme (2007-8) (Department of Health 2009) 
and the British National Formulary for Children (2008) as described in section 
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2.5.  The respiratory costs were also reported and these were defined as 
costs related to a LRTI episode regardless of whether this was incurred in 
hospital or the community, e.g. a general practitioner (GP) attendance.    
 
In addition, lung function (FRCHe, FRCMBW, LCI, Crs, Rrs, FRCpleth, Raw and 





Infants who had LRTIs for which no virus was detected were excluded from 
the analysis.  If an infant had a LRTI with a virus other than HRV-A or HRV-
C, but had not had an HRV-A or HRV-C LRTI they also were excluded from 
the analysis. 
 
The remaining infants were divided into three groups: 
(i) Infants who never had a symptomatic LRTI - no LRTI group (n=74) 
(ii) Infants who had a LRTI with HRV-A detected from the NPA – HRV-
A LRTI group (n=9) 
(iii) Infants who had a LRTI with HRV-C detected from the NPA – 
HRV-C LRTI group (n=13) 
 
Continuous data were tested for normality using the Shapiro-Wilk test and 
found not to be normally distributed.  Differences, therefore, were assessed 
for statistical significance using Kruskal-Wallis test with a post hoc ANOVA 
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test.  Categorical data were analysed using the Fisher’s exact test.  Statistical 





One hundred and fifty three infants with a median gestational age (GA) of 34 
(range 23-35) weeks and a birth weight of 1890 (range 534-3610) g were 
prospectively followed.  Thirty two infants developed 40 HRV LRTIs (Figure 
8.1, Appendix 5).  Of the 40 HRV LRTIs, there were 29 samples from 24 
infants with sufficient nucleic acid for subtyping (Table 8.1).  There were no 
significant differences in the demographics of the infants who did and did not 
have subtyping of their HRV LRTIs. Nine infants had a HRV-A LRTI (one 
infant had two different HRV-A serotype LRTIs [serotypes 80 and 56], the 
LRTIs were three months apart), one infant had a HRV-B LRTI (serotype 42) 
and 13 infants had a HRV-C LRTI (one infant had two different HRV-C 
serotype LRTIs [serotypes C40 and C12], the LRTIs were three months 
apart).  One infant had a HRV LRTI which was not possible to subtype and in 
three samples subtyping failed.  Six of the infants in the HRV-A group and 
three of the infants in the HRV-C group also had RSV LRTIs (either as dual 
infections or as a separate LRTI).  Other viral LRTIs in the HRV-A group 
were RSV A (n=5), RSV B (n=3), adenovirus (n=5), human metapneumovirus 
(n=1), influenza B (n=2), parainfluenza 1 (n=1), parainfluenza 3 (n=1), 
enterovirus (n=3), parechovirus (n=2) and for the HRV-C group were RSV A 
(n=2), RSV B (n=1), adenovirus (n=4), human metapneumovirus (n=2), 
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influenza A (n=1), influenza B (n=1), parainfluenza 1 (n=2), parainfluenza 3 
(n=2), enterovirus (n=7), parechovirus (n=1) and human bocavirus (n=2).  
 
 





















11 HRV LRTIs had 
insufficient sample 
for subtype testing 
Subtyping was performed for 29 
HRV LRTIs in 24 infants 
10 LRTIs in 9 
infants were 
HRV-A positive 
1 infant had a 
HRV-B LRTI 
14 LRTIs in 13 
infants were 
HRV-C positive 
1 HRV LRTI 






6 infants also had 
RSV LRTIs 
3 infants also 
had RSV LRTIs 
 
40 HRV LRTIs in 32 infants 
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Table 8.1:  HRV-A and HRV-C serotypes and the number of LRTIs in 








12 1 C2 1 
16 1 C3 2 
24 1 C5 1 
56 1 C12 1 
58 1 C14 1 
61 1 C25 1 
78 1 C36 1 
80 2 C39 1 
101-v1 1 C40 2 
  C pat18 1 
  C pat19 1 
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There were no statistically significant differences in the demographic data 
between the three groups, although both HRV groups tended to be lighter at 
birth (p=0.056) and a greater proportion of them tended to have received 
surfactant (p=0.050) or palivizumab (p=0.051) than the no LRTI group (Table 
8.2).  Three (33%) of the HRV-A LRTI group had hospital admissions (one for 
a RSV LRTI, one for a HRV-A/enterovirus dual LRTI and one had multiple 
admissions for viral LRTIs including RSV and HRV-A).  Three (23%) of the 
HRV-C LRTI group had hospital admissions (one for an adenovirus/human 
bocavirus dual LRTI, one for a RSV/human metapneumovirus/HRV 
[unsubtyped] triple LRTI and one for a non-respiratory cause).  Nine (12%) 
infants of the no LRTI group had hospital admissions, all for non-respiratory 
causes. 
 
Analysis of the diary card data demonstrated that the HRV-A LRTI group had 
significantly more days of antibiotic (p=0.021) and inhaler (p<0.0005) use 
than the no LRTI group (Table 8.3).  Exclusion of infants who had had a RSV 
LRTI from the analysis, however, demonstrated no significant differences 
between the HRV-A LRTI group and the no LRTI group (Table 8.4), but there 
were only three infants who had a HRV-A LRTI who did not also have a RSV 
LRTI.  Compared to the no LRTI group, infants in the HRV-C LRTI group 
tended to have more days of cough (p=0.06) and wheeze (p=0.06) (Table 
8.4).  Exclusion of the infants who had a RSV LRTI from the analyses 
revealed that the HRV-C LRTI group had significantly more days of wheeze 
(p=0.01) and more days of inhaler use (p=0.024) than the no LRTI group 
(Table 8.4). 
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Analysis of the respiratory health related questionnaire demonstrated that 
compared to the no LRTI group, infants in the HRV-A LRTI group were more 
likely to wheeze (p<0.0005), use respiratory medications (p<0.0005), 
bronchodilators (p=0.027), antibiotics (p=0.005) or a preventer (p=0.017) 
(Table 8.3).  Exclusion of infants who had had a RSV LRTI from the analysis, 
however, demonstrated no significant differences between the HRV-A LRTI 
group and the no LRTI group (Table 8.4).  Compared to the no LRTI group, 
infants in the HRV-C LRTI group were more likely to wheeze (p<0.0005), use 
respiratory medications (p<0.0005), bronchodilators (p<0.0005), antibiotics 
(p=0.008) or a preventer (p=0.002) (Table 8.3).  Exclusion of infants who had 
had a RSV LRTI from the analyses revealed that, compared to the no LRTI 
group, the ten remaining infants in the HRV-C LRTI group were more likely to 
wheeze (p<0.0005), use respiratory medications (p=0.001), bronchodilators 
(p<0.0005), antibiotics (p=0.002) or a preventer (p<0.0005) (Table 8.4).   
 
The respiratory cost of care was significantly greater for both the HRV-A 
(p=0.003) and the HRV-C (p<0.0005) LRTI groups compared to the no LRTI 
group.  When the infants who had had a RSV LRTI were excluded from the 
analysis, however, the respiratory cost of care compared to the no LRTI 
group was only significantly greater for the HRV-C LRTI group (p<0.0005) 
(Table 8.5).  The total cost of care compared to the no LRTI group was 
significantly greater only for the HRV-C LRTI group (p=0.017), but the 
difference was not statistically significant when infants who had a RSV LRTI 
were excluded from the analysis (Table 8.5). 
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The only significant difference in the lung function between the groups was in 
Raw where the HRV-C group had significantly higher Raw than the no LRTI 
group (p=0.046) but the difference was not statistically significant when 
infants who had a RSV LRTI were excluded from the analysis (p=0.16) (data 
not shown). 
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Table 8.2: Demographic data according to viral LRTI status 
Data are expressed as median (range) or n (%). 
  HRV-A LRTI HRV-C LRTI No LRTI p 
n 
 
9 13 74  














Males 4 (44%) 5 (39%) 39 (53%) 0.68 
 
Antenatal smoking 1 (11%) 2 (15%) 11 (15%) >0.99 
Antenatal steroids 7 (78%) 10 (77%) 40 (54%) 0.28 
Surfactant 4 (44%) 4 (31%) 11 (15%) 0.050 
Duration of ventilation 
(days) 




2 (22%) 2 (15%) 4 (5%) 0.09 
 
Family history of atopy 4 (44%) 8 (62%) 52 (70%) 0.27 
Number of siblings 1 (0-4) 1 (0-5) 1 (0-5) 0.51 
Breastfed 6 (67%) 10 (77%) 62 (84%) 0.39 
Palivizumab 1 (11%) 1 (8%) 0 (0%) 0.051 
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Table 8.3: Diary card and respiratory health related questionnaire data by HRV subtype 
Data presented as median (range) or n (%) responding yes to the question. 
 HRV-A LRTI HRV-C LRTI No LRTI p** 
                                                              Diary card data* 
n 9 8 49  
Days of cough 3 (0-30) 5 (0-17) 0 (0-31) 0.032 
Days of wheeze 0 (0-30) 0.5 (0-7) 0 (0-12) 0.009 
Days using antibiotics 0 (0-5) 0 (0-0) 0 (0-2) 0.021 
Days using inhalers 0 (0-30) 0 (0-30) 0 (0-0) 0.001 
Days of acute GP/hospital attendance 0 (0-5) 0 (0-3) 0 (0-1) 0.050 
                                                                Respiratory health related questionnaire data * 
n 9 13 71  
Did your child cough in the first year? 9 (100%) 13 (100%) 66 (93%) >0.99 
Did your child wheeze in the first year? 7 (78%) 10 (77%) 11 (15%) <0.0005 
Did your child use any medication for a 
chest problem in the first year? 
7 (78%) 9 (69%) 17 (24%) <0.0005 
     Bronchodilators (e.g. salbutamol)? 4 (44%) 7 (54%) 6 (8%) <0.0005 
     Antibiotics? 6 (67%) 8 (62%) 13 (18%) <0.0005 
     Preventers (e.g. steroids, montelukast)? 2 (22%) 3 (23%) 0 (0%) 0.001 
Has your child ever been diagnosed with 
asthma by a doctor? 
1 (11%) 0 (0%) 0 (0%) 0.097 
*Diary card and respiratory health-related questionnaire data were not available for all infants  
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Table 8.4: Diary card and respiratory health related data by HRV subtype excluding infants who had had a RSV 
LRTI 
Data presented as median (range) or n (%) responding yes to the question.  
 HRV-A LRTI HRV-C LRTI No LRTI p** 
                                                           Diary card data* 
n 3 7 49  
Days of cough 1 (0-3) 8 (0-17) 0 (0-31) 0.16 
Days of wheeze 0 (0) 1 (0-7) 0 (0-12) 0.01 
Days using antibiotics 0 (0) 0 (0-0) 0 (0-2) 0.90 
Days using inhalers 0 (0) 0 (0-30) 0 (0-0) 0.024 
Days of acute GP/hospital attendance 0 (0) 0 (0-3) 0 (0-1) 0.34 
                                                            Respiratory health related questionnaire data* 
n 3 10 71  
Did your child cough in the first year? 3 (100%) 10 (100%) 66 (93%) >0.99 
Did your child wheeze in the first year? 2 (67%) 8 (80%) 11 (15%) <0.0005 
Did your child use any medication for a 
chest problem in the first year? 
2 (67%) 8 (80%) 17 (24%) <0.0005 
     Bronchodilators (e.g. salbutamol)? 0 (0%) 6 (60%) 6 (8%) 0.001 
     Antibiotics? 62(67%) 7 (70%) 13 (18%) 0.001 
     Preventers (e.g. steroids, montelukast)? 0 (0%) 2 (22%) 0 (0%) 0.022 
Has your child ever been diagnosed with 
asthma by a doctor? 
0 (0%) 0 (0%) 0 (0%) >0.99 
*Diary card and respiratory health related questionnaire data were not available for all infants            
** The p values relate to the difference between the three groups, post hoc p values are given in the results section text. 
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Table 8.5:  Health related cost of care (UK £) by HRV subtype 
Data are presented as median [mean] (range). 
 
 HRV-A LRTI HRV-C LRTI No LRTI p* 
     
Respiratory costs  110 [3951] (0-31527) 74 [1465] (0-12685) 0 [27] (0-599) <0.0005 
Total costs  817 [5039] (529-33176) 1834 [3032] (494-14242) 720 [980] (0-4253) 0.008 
Results excluding infants who had had a RSV LRTI 
     Respiratory costs  64 [58] (0-110) 78 [636] (36-3357) 0 [27] (0-599) <0.0005 
     Total costs 817 [871] (529-1265) 1615 [2115] (494-5494) 720 [980] (0-4253) 0.052 
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Table 8.6:  Lung function results at one year corrected age by HRV subtype 
Data are presented as median (range). 
 
 HRV-A LRTI HRV-C LRTI No LRTI p* 
N** 4 8 38  
Corrected age (months) 13 (12.8-13.5) 13.5 (10.0-17.3) 13 (10-16) 0.42 
Weight (kg) 10.0 (8.2-10.9) 9.5 (7.8-10.9) 9.7 (7.4-12.2) 0.76 
Length (cm) 79.4 (72.0-81.5) 78.6 (71.3-82.6) 77.9 (71.8-83.1) 0.95 
FRCHe (mL/kg) 25 (22-26) 25 (20-32) 25 (17-32) 0.99 
FRCMBW (mL/Kg) 22 (18-28) 21 (17-26) 22 (13-32) 0.91 
LCI 7.3 (7.1-7.3) 7.2 (6.4-7.8) 7.2 (6.2-8.4) 0.98 
Crs (mL/cmH2O/kg) 1.5 (1.4-1.9) 2.0 (1.2-2.6) 1.7 (1.0-4.0) 0.82 
Rrs (cmH2O/L/s) 45 (42-48) 42 (38-67) 42 (31-67) 0.24 
FRCpleth (mL/kg) 23 (21-30) 26 (21-39) 25 (19-36) 0.79 
Raw (cmH2O/L/s) 20 (19-30) 22 (14-33) 16 (11-33) 0.026 
FRCHe:pleth ratio 0.84 (0.81-0.97) 0.89 (0.81-0.99) 0.89 (0.74-0.99) 0.86 
 
**The p values relate to the difference between the three groups, post hoc p values are given in the results section text 
** Not all infants had lung function tested. 





It has been demonstrated that infants who had a HRV-C LRTI compared to 
infants who did not have a LRTI were significantly more likely to wheeze and 
use respiratory medications and had a greater respiratory cost of care.  Initial 
analysis demonstrated HRV-A LRTIs were associated apparently with similar 
effects, but the significant differences compared to the no LRTI group 
disappeared once the infants who also had RSV LRTIs were excluded from 
the analysis, but there were only three infants who had an HRV-A LRTI and 
not an RSV LRTI.  The significant differences between the HRV-C and no 
LRTI groups remained after excluding infants who had had a RSV LRTI.  
Indeed, exclusion of the infants who also had had a RSV LRTI revealed 
HRV-C LRTIs were associated with significantly more days of wheeze and 
use of an inhaler.  Initial analysis demonstrated HRV-C LRTIs were 
associated with reduced lung function (higher Raw) at follow up, however, this 
difference disappeared after excluding the infants who also had an RSV 
LRTI. These results, thus suggest HRV-C is associated with increased 
chronic respiratory morbidity during infancy in prematurely born infants. 
 
Certain studies (Miller et al. 2009; Arden et al. 2010), but not all have 
reported that HRV-C compared to HRV-A results in more severe initial 
illness.  In this study, three infants in both the HRV-A and HRV-C groups 
were admitted to hospital, but only one infant was admitted solely for a HRV-
A LRTI and none for a HRV-C LRTI, thus it is not possible to comment in this 
prematurely born population whether HRV-A or HRV-C is associated with 
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more severe acute disease.  During the same time period, only one infant 
had a HRV-B LRTI, suggesting HRV-B infections are less common than 
HRV-A or HRV-C infections in prematurely born infants, as has been found 
in infants and children hospitalised with LRTIs and controls without 
respiratory symptoms (Fry et al. 2011; Iwane et al. 2011).   
 
This study has a number of strengths and some limitations.  Respiratory 
morbidity was assessed using a variety of techniques; telephone calls, 
questionnaires and diary cards.  Certain similar questions were used during 
the follow up telephone calls and on the questionnaire.  The questionnaire 
gave information about the infant’s health throughout infancy, the diary card 
more detailed information for one month.  Strengths include that NPAs were 
collected whenever the infants had an LRTI, regardless of whether this was 
in hospital or in the community.  In addition, NPAs were tested for a wide 
range of respiratory viruses and, hence, it was possible to demonstrate that 
the apparent association of HRV-A LRTIs with chronic respiratory morbidity 
may be explained by the infants having also had RSV LRTIs.  A limitation is 
that the nucleic acid was subtyped only after other investigations had been 
undertaken and this meant there was insufficient nucleic acid for subtyping in 
eight of the 32 infants who had had HRV LRTIs.  The infants with and without 
subtyping of their HRV LRTIs, however, did not differ in their demographics.  
It is therefore likely the results are generalisable.  The infants with HRV-A 
and HRV-C infections had a variety of other viral LRTIs which may have 
increased their respiratory morbidity.  Analysis excluding all other respiratory 
viral LRTIs, except RSV LRTI, was not undertaken as there is very little 
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information on the long term outcomes of prematurely born infants following 
those infections.  After excluding infants who also had an RSV LRTI, which is 
known to increase chronic respiratory morbidity, it has been highlighted that 
HRV-C LRTIs were associated with an adverse outcome.   
 
In conclusion, it has been demonstrated that HRV-C LRTIs were associated 
with chronic respiratory morbidity during infancy in prematurely born infants.  
Whether there is a similar adverse outcome in infants born at term merits 
testing. 
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Chapter 9: Viral lower respiratory tract 
























A prospective study has demonstrated increased healthcare utilisation 
following RSV LRTI in the first year after birth (Broughton et al. 2005).  
Retrospective studies have demonstrated that infants born moderately 
prematurely had increased healthcare utilisation in the first two years after 
birth (Shefali-Patel et al. 2012) and those who had BPD may have a similar 
adverse outcome even at school age (Greenough et al. 2009).  Groothuis et 
al demonstrated that certain prematurely born infants with BPD who were in 
a home oxygen programme also required hospitalisation for RSV LRTI in the 
second year after birth and their hospitalisations were prolonged and 
complicated (Groothuis et al. 1988).  Those data (Groothuis et al. 1988; 
Greenough et al. 2009) then suggest that the cost of care in the second year 
may also be increased following RSV LRTIs.  The aim of this study was to 
test that hypothesis, as such data would inform the cost-benefit of 
prophylaxis in the second year.  It has also been demonstrated that 
rhinovirus (HRV) LRTIs increase healthcare utilisation in prematurely born 
infants after neonatal unit discharge (Miller et al. 2012). A subsidiary aim 
then of this study was to determine whether other viral LRTIs, in particular 
HRV, might also be associated with an increased health related cost of care 
in the second year after birth.  This study, therefore, determined healthcare 
utilisation and the health related cost of care in the first two years after birth 
in infants who developed a RSV LRTI, another viral LRTI or no LRTI in 
infancy and compared the costs in year one and year two.   
 





Infants born less than 36 weeks of gestation were eligible for entry into the 
study if they were born prior to the onset of the RSV season in 2008.  The 
RSV season was defined as from October 1st to March 31st as per UK 
experience (Clark 2000).  After neonatal/maternity unit discharge infants 
were followed until two years corrected age as described in section 2.1.  
Real time polymerase chain reaction (PCR) was performed on the NPAs for 
13 viruses as described in section 2.7.  Parents completed a diary card for 
one month when their infant was 23 months corrected age and a respiratory 
health related questionnaire when their infant was two years of corrected 
age, regarding whether their infant had cough and/or wheeze, use of 
respiratory related medications (e.g. inhalers, oral steroids, antibiotics) in 
their second year after birth and whether their infant had been diagnosed by 
a doctor as having asthma as described in section 2.6.   
 
Follow up costs after neonatal discharge were calculated using the NHS 
reference costing scheme (2007-8) (Department of Health 2009) and the 
British National Formulary for Children (2008) as described in section 2.5.  
The respiratory costs were also reported and these were defined as costs 
related to a LRTI episode regardless of whether this was incurred in hospital 
or the community, e.g. a general practitioner (GP) attendance.    
During the first year after birth, infants with bronchopulmonary dysplasia 
(BPD) who had required supplementary oxygen until at least one week 
before NICU discharge and were being discharged during the RSV season 
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were given palivizumab.  No infant received palivizumab in the second year 
after birth. 
9.3 Analysis 
The infants were divided into three groups: 
(i) Infants who did not have a symptomatic LRTI in the first two years 
(no LRTI group). 
(ii) Infants who had at least one RSV LRTI in the first year after birth.  
In the second year they could have had no LRTI, a RSV or another 
viral LRTI (RSV group). 
(iii) Infants who had at least one LRTI with viruses other than RSV 
detected from the NPA in the first year and no RSV LRTI in the 
second year (other viral group). 
A sub-analysis was undertaken of the infants who had had a HRV LRTI. 
Baseline factors were compared across the three groups using the Kruskal-
Wallis test with post-hoc tests adjusted for multiple comparisons.  The cost 
data were summarised using means, rather than medians to preserve the 
total sum of costs (Thompson & Barber 2000).  An attempt was made to 
analyse the cost data using the approach advocated by Barber and 
Thompson (Barber & Thompson 2004) by Professor Janet Peacock using 
Stata (version 12.1 TX, USA), however, due to a relatively small number of 
patients and the data being very skewed, a generalised linear model would 
not converge.  The cost data, therefore, were analysed using the Kruskal-
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Wallis test with post-hoc tests adjusted for multiple comparisons.  The 
number need to treat (NNT) was calculated assuming a 50% reduction in the 
hospitalisation rate if RSV prophylaxis had been given (1998). 
9.4 Results 
One hundred and thirty seven infants were eligible for inclusion into this part 
of the cohort study. Ninety seven infants were recruited, three infants died 
before discharge and 22 were lost to follow up (Figure 9.1, Appendix 5). 













Seventy two infants completed the two year follow up study, but certain 
infants were excluded from the analysis: those who had only viral negative 
LRTIs in the first year (n=6), infants who had no LRTI in the first year, but a 
viral negative LRTI (n=1), another viral LRTI (n=1) or a RSV LRTI (n=3) in 
137 eligible infants born in 2008 
40 parents refused consent 
97 infants recruited 
22 infants lost to follow up 
72 infants followed to two years corrected age 
3 infants died 
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the second year after birth and infants who had other viral LRTIs in the first 
year and a RSV LRTI in the second year after birth (n=2).  Thirteen of the 
infants developed RSV LRTIs (RSV group).  Twenty-one of the infants 
developed other viral LRTIs (viruses detected were: HRV n=16; enterovirus 
n=7; parainfluenza type 3 n=6; adenovirus n=5; human metapneumovirus 
n=4; parechovirus n=2; human bocavirus n=2; parainfluenza type 1 n=2; 
influenza A n=2; influenza B n=1.  Eight infants had dual infections and one a 
triple infection.  Twenty five infants had no LRTIs in either year (no LRTI 
group, n=25). The median GA of the infants included in this study was 34 
(23-35) weeks. There were no significant differences in the demographic 
data of the three groups (Table 9.1). 
There were no significant differences in the number of LRTIs in the first year 
(RSV group, median 2 [range 1-11] versus other viral LRTI group, median 2 
[range 1-4], p>0.99), but the RSV group had more LRTIs in the second year 
(median 1 [range 0-7]) than the other viral LRTI group (median 0 [range 0-2]) 
(p=0.017).   
 
In the first year, the RSV group had more total (p<0.0005, p<0.0005 
respectively) and respiratory related (p<0.0005, p=0.003 respectively) 
admissions and respiratory related A and E attendances (p=0.001, p<0.0005 
respectively) than the other viral group and the no LRTI group (Table 9.2).  
Three infants in the RSV group also developed RSV LRTIs in the second 
year, two were admitted. In the second year, the RSV group had more 
respiratory related hospital admissions (p=0.01, p=0.007 respectively) and A 
and E respiratory attendances (p=0.002, p=0.001 respectively) than the other 
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viral group and than the no LRTI group (Table 9.2).  Only the RSV LRTI 
group had respiratory admissions in either year: year one (n=6) and year two 
(n=2).  There were no significant differences in healthcare utilisation in the 
second year between the other viral group and the no LRTI group and 
between the infants with HRV LRTIs and the no LRTI group (data not 
shown). 
 
In the first year, the RSV group had higher costs than the other viral group 
for total (p<0.0005) and respiratory (p<0.0005) admission costs and A and E 
respiratory costs (p=0.001) and higher costs than the no LRTI group for total 
(p<0.0005) and respiratory (p=0.003) admissions, A and E total (p=0.029) 
and respiratory (p<0.0005) costs and overall total (p=0.01) and respiratory 
(p=0.041) costs (Table 9.3).  In the second year, the RSV group had 
significantly higher costs than the other viral group for respiratory admissions 
(p=0.01), A and E respiratory costs (p=0.002) and respiratory medications 
(p=0.042) and the no LRTI group for respiratory admissions (p=0.007), A and 
E respiratory costs (p=0.001), respiratory medications (p=0.004) and overall 
respiratory costs (p=0.012) (Table 9.3).  The three infants who had RSV 
LRTIs in the second year had significantly higher overall respiratory costs 
that year than those in the RSV group who did not have RSV LRTIs in the 
second year (mean [SD] cost £4788 [6556] versus £96 [109], p=0.011).  
There were no significant differences in cost of care between the other viral 
group and the no LRTI group or between those infants who had a HRV LRTI 
and the no LRTI group (data not shown).  Two of the 59 infants were 
admitted for a RSV infection in the second year after birth, that is, a RSV 
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admission rate of 3.4%.  Assuming prophylaxis would reduce the 
hospitalisation rate by 50%, the number needed to treat (NNT) was 59. 
 
All three groups had higher overall total costs in year one compared to year 
two (RSV p=0.017; other viral p=0.001, no LRTI p=0.004) (Table 9.3).  There 
were no significant differences in overall respiratory costs in any of the 
groups between the first and second years (RSV p=0.57; other viral p=0.61; 
no LRTI p=0.40) (Table 9.3). 
 
A greater proportion of the RSV group had wheeze (p=0.014) and a doctor 
diagnosis of asthma (p=0.041) in the second year than the no LRTI group 
(Table 9.4).  There were no significant differences between the RSV and 
other viral LRTI groups.  Too few parents completed the diary card at two 
years of corrected age to enable any meaningful analysis. 
 
Seventy three parents who completed the questionnaire when their child was 
two years corrected age also completed the same questionnaire when their 
infant was one year corrected age (data not shown).  Four parents gave 
inconsistent results for current smoking (in two cases in the first year 
reporting they were ex-smokers and in the second year reporting they were 
current smokers and in two cases reporting they were current smokers in the 
first year and never smoked in the second year).  Only the second two can 
really be described as giving ‘incorrect’ inconsistent results.  
                                                                                                                                                                   
246 
 
Table 9.1: Demographic data by viral LRTI status 
Data presented as median (range) or n (%). 
   RSV LRTI Other viral LRTI  No LRTI p 
n 13 21 25  
Gestational age 
(weeks) 
33 (23-35) 34 (26-35) 34 (29-35) 0.33 







Males 6 (46%) 9 (43%) 16 (64%) 0.33 
Antenatal smoking 3 (23%) 4 (19%) 2 (8%) 0.41 
Antenatal steroids 9 (69%) 16 (76%) 12 (48%) 0.13 
Surfactant 2 (23%) 5 (24%) 4 (16%) 0.77 
Duration of 
ventilation (days) 
0 (0-81) 0 (0-90) 0 (0-8) 0.82 
Bronchopulmonary 
dysplasia 
2 (15%) 3 (14%) 1 (4%) 0.35 
Family history of 
atopy 
7 (54%) 14 (67%) 14 (56%) 0.70 
Breastfed 11 (85%) 18 (86%) 23 (92%) 0.67 
Number of siblings 1 (0-3) 1 (0-5) 1 (0-4) 0.92 
Palivizumab in first 
year 
1 (8%) 1 (5%) 0 (0%) 0.33 
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Table 9.2: Healthcare utilisation by viral LRTI status 
Data presented as mean (median) [range].  
 
*The p values relate to the difference between the three groups, post hoc p 
values are given in the results section text. 
 
 










Admission     
Total 1 (0) [0-11] 0 (0) [0-0] 0 (0) [0-1] <0.0005 
Respiratory 1 (0) [0-11] 0 (0) [0-0] 0 (0) [0-0] <0.0005 
A and E     
Total 2 (1) [0-14] 1 (1) [0-4] 1 (0) [0-5] 0.06 
Respiratory 2 (1) [0-12] 0 (0) [0-2] 0 (0) [0-3] <0.0005 
Outpatient     
Total 5 (4) [0-14] 5 (3) [0-18] 3 (2) [0-11] 0.21 
Respiratory 1 (0) [0-8] 0 (0) [0-9] 0 (0) [0-0] 0.43 
GP     
Total 6 (5) [3-12] 6 (5) [1-15] 5 (5) [0-13] 0.50 
Respiratory 1 (0) [0-5] 1 (0) [0-4] 0 (0) [0-2] 0.19 
SECOND YEAR     
Admission     
Total 0 (0) [0-5] 0 (0) [0-3] 0 (0) [0-1] 0.06 
Respiratory 0 (0) [0-3] 0 (0) [0-0] 0 (0) [0-0] 0.004 
A and E     
Total 2 (1) [0-14] 1 (0) [0-3] 1 (0) [0-4] 0.39 
Respiratory 1 (0) [0-10] 0 (0) [0-1] 0 (0) [0-1] <0.0005 
Outpatient     
Total 1 (0) [0-9] 1 (1) [0-13] 1 (0) [0-8] 0.62 
Respiratory 1 (0) [0-6] 0 (0) [0-0] 0 (0) [0-5] 0.21 
GP     
Total 5 (3) [1-21] 5 (5) [0-12] 4 (4) [0-14] 0.26 
Respiratory 1 (1) [0-6] 1 (1) [0-2] 1 (0) 0-3] 0.16 
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Table 9.3: Cost of care (UK£) by viral LRTI status 
Data presented as mean [SD]  










Admission     
Total 3428 [7533] 0 [0] 120 [537] <0.0005 
Respiratory 3350 [7423] 0 [0] 0 [0] <0.0005 
A and E     
Total 248 [489] 77 [101] 52 [98] 0.035 
Respiratory 211 [464] 16 [54] 11 [56] <0.0005 
Outpatient     
Total 843 [1237] 869 [1357] 438 [393] 0.29 
Respiratory 323 [1165] 244 [1119] 0 [0] 0.43 
GP     
Total 296 [269] 340 [260] 228 [190] 0.21 
Respiratory 33 [72] 36 [50] 12 [24] 0.19 
Medication     
Total 343 [1096] 326 [902] 62 [114] 0.04 
Respiratory 259 [927] 201 [906] 2 [5] 0.42 
Overall     
Total 4816 [9286] 1285 [1363] 840 [827] 0.038 
Respiratory 3917 [8977] 296 [1119] 24 [59] 0.012 
SECOND YEAR     
Admission     
Total 824 [2691] 0 [0] 152 [715] 0.06 
Respiratory 824 [2691] 0 [0] 0 [0] 0.004 
A and E     
Total 240 [454] 56 [88] 57 [84] 0.34 
Respiratory 189 [383] 6 [28] 3 [16] <0.0005 
Outpatient     
Total 254 [508] 234 [520] 161 [319] 0.75 
Respiratory 88 [283] 0 [0] 34 [132] 0.22 
GP     
Total 212 [174] 410 [847] 172 [146] 0.27 
Respiratory 62 [79] 27 [27] 24 [38] 0.06 
Medication     
Total 64 [118] 231 [796] 25 [42] 0.16 
Respiratory 28 [65] 2 [7] 3 [7] 0.005 




*The p values relate to the difference between the three groups, post hoc p 
values are given in the results section text. 
 
Overall     
Total 1531 [3649] 700 [1329] 542 [1015] 0.46 
Respiratory 1164 [3382] 33 [46] 61 [158] 0.013 
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Table 9.4: Respiratory health related questionnaire by viral LRTI status 
Data presented as n (%) responding yes to the question.   
  RSV LRTI Other viral LRTI No LRTI p* 
n 13 21 25  
Did your child cough in the second year? 12 (92%) 20 (95%) 23 (92%) >0.99 
Did your child wheeze in the second year? 6 (46%) 3 (14%) 2 (8%) 0.021 
Did your child use any medication for a 
chest problem in the second year? 
6 (46%) 7 (33%) 5 (20%) 0.20 
       Bronchodilators (e.g. salbutamol)? 3 (23%) 2 (10%) 2 (4%) 0.45 
       Antibiotics? 6 (46%) 7 (33%) 4 (16%) 0.13 
       Preventers (e.g. steroids, montelukast)? 1 (8%) 0 (0%) 0 (0%) 0.22 
Has your child ever been diagnosed with 
asthma by a doctor? 
2 (15%) 0 (0%) 0 (0%) 0.046 
 
*The p values relate to the difference between the three groups, post hoc p values are given in the results section text. 
 





It has been demonstrated that prematurely born infants developing RSV 
LRTIs compared to those without LRTIs had significantly higher respiratory 
health related costs in years one and two.  This was associated with an 
increased respiratory related healthcare utilisation and a greater proportion of 
the infants who had had a RSV LRTI wheezed and had a doctor’s diagnosis 
of asthma in the second year after birth.  Nevertheless, the overall cost of 
care in year two compared to year one was significantly lower in the RSV 
group and also in the other two groups. 
 
The greater proportion of the RSV LRTI group having parental reported 
wheeze and a doctor diagnosis of asthma in the second year than the no 
LRTI group likely explains their higher costs for respiratory medications.  
Those results agree with previous studies in children born at term which have 
demonstrated an increased risk of asthma after RSV LRTI in infancy even in 
adolescence (Stein et al. 1999; Sigurs et al. 2010).   
 
Only infants in the RSV group required respiratory admissions in either year.  
In the second year two infants were admitted for RSV LRTIs giving a RSV 
admission rate of 3.4%.  Those results are in keeping with studies reporting 
admission rates in infancy; the incidence of hospitalisation for RSV infection 
amongst prematurely born infants has been reported to vary between 2.8% 
and 37%.  In a previous UK study (Thomas et al. 2000) assessing infants 
born prior to 32 weeks of gestation, a 4% rate was noted.  In the PICNIC 
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study, the overall hospitalisation rate was 3.6% for infants of 33-35 weeks of 
GA (Wang et al. 1995).  In a multicentre Italian birth cohort study (Lanari et 
al. 2011), 4.5% of infants born between 33 and 37 weeks of gestation were 
admitted during a six month period for a LRTI, including RSV LRTIs. 
 
In a multicentre randomised trial (1998), prophylaxis with palivizumab was 
associated with a 55% reduction in RSV hospital admissions, the greatest 
reduction occurred in the infants who did not have BPD.   In this study there 
was a RSV admission rate of 3.4% which meant that the NNT was 59 
assuming a 50% reduction in hospitalisation following prophylaxis.  Hence, 
the cost of RSV prophylaxis would exceed the cost of savings made by a 
reduction in RSV hospitalisation. A recent double-blind randomised trial 
(Blanken et al. 2013), however, has demonstrated that palivizumab resulted 
in a reduction in the total number of wheezing days in the first year after birth.  
Whether there is a similar impact in the second year after birth requires 
testing. Nevertheless, given the low costs of health related care in the second 
year, it still seems unlikely prophylaxis at the current price would be cost 
effective unless infants at high risk of further admissions with a RSV LRTI 
could be identified.  
 
To identify high risk infants approaches that could be taken include a clinical 
decision tree analysis including questions on demographics (e.g. gestational 
age at birth, birth weight, congenital cardiac disease, neurological 
impairment, immunodeficiency, maternal smoking, supplementary home 
oxygen or recently stopped requiring supplementary home oxygen, age at 
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start of the second RSV season), potential genetic markers (e.g. SNP in 
ADAM33 although this has only been investigated for infants developing RSV 
LRTI in the first year after birth) and lung function prior to the start of the 
second RSV season. 
 
During the course of this thesis, the indications for infants to receive 
palivizumab changed.  At the start of the study palivizumab was given to 
prematurely born infants with BPD who were being discharged during the  
RSV season either having very recently come off  supplementary oxygen or 
who would were receiving supplementary home oxygen.  By the end of the 
study the indications for palivizumab changed to a structured approach 
advised by the JCVI (Joint Committee on Vaccination and Immunisation 
2010) including the gestational age at birth and chronological age at the start 
of the RSV season.  Four infants in the cohort received palivizumab, if the 
subseqeunt guidelines had been followed five infants would have been 
eligible, i.e. one additional member.   
 
There were no significant differences in healthcare utilisation or health 
related cost of care between the other viral LRTI group and the no LRTI 
group in either year.  There were also no significant differences between 
those infants with HRV LRTIs and the no LRTI group, a possible explanation 
is none of the infants who had a HRV LRTI required hospital admission.  
Those results suggest that for prophylactic interventions for HRV LRTIs to be 
cost effective, a high risk group also needs to be identified. 
 
                                                                                                                                                                   
254 
 
This study had several strengths and some limitations. The prematurely born 
infants were prospectively followed from birth to two years of corrected age. 
Symptomatic LRTIs were investigated not only in hospitalised infants, but 
also in those with LRTIs in the community, which is important, as it has 
previously been demonstrated that infants with RSV LRTI not requiring 
hospitalisation also suffer increased respiratory morbidity (Broughton et al. 
2005).  Healthcare costs in the community as well as those relating to 
hospital attendances were documented. NPAs were tested by real-time PCR 
to detect a wide range of respiratory viruses. NPAs were only obtained, 
however, when the infants were symptomatic and thus it is not possible to 
comment as to whether asymptomatic LRTIs increase healthcare utilisation 
at follow-up, but this limitation applies to other studies.  The infants included 
in this study were generally born moderately prematurely, with a median GA 
of 34 weeks and few required hospitalisation in either years one or two, but 
they were consecutive infants born at less than 36 weeks of GA who were 
recruited if parental consent was obtained.  Only a proportion of the infants 
were followed to two years of corrected age, but they did not differ in their 
demographics to the overall population (data not shown), hence the results 
are generalisable.    
 
In conclusion, it has been shown that infants developing RSV LRTI in the first 
year after birth have increased healthcare utilisation and costs in both the 
first and second year after birth compared to those who had not developed a 
LRTI.  Nevertheless, if RSV prophylaxis in prematurely born infants is to be 
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Chapter 10: Discussion 
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10.1 Summary of the key results 
 
In chapter three, it was reported a single nucleotide polymorphism (SNP) in 
the ADAM33 gene was associated with the development of RSV LRTIs; this 
was not associated with a reduction in premorbid lung function.  In infants 
who developed RSV LRTIs, SNPs in genes coding for IL-10, NOS2A and 
SFTPC were associated with chronic respiratory morbidity and SNPs in 
genes coding for MMP16, NOS2A, SFTPC and VDR were associated with 
reduced lung function at one year corrected age, although correction for 
multiple comparisons was not undertaken. 
 
In chapter four, it was demonstrated that infants with RSV or other viral 
LRTIs who were hospitalised compared to those who were not had 
significantly worse premorbid lung function. 
 
In chapter five, it was reported that RSV LRTIs were associated with reduced 
lung function at one year corrected age, although there were no significant 
differences in lung function at 36 weeks PMA. 
 
In chapter six, it was reported that the hospitalisation rate of 150 prematurely 
born infants prospectively followed during the 2009 influenza A (H1N1) 
pandemic compared to that of term born infants, did not differ significantly for 
pandemic influenza A (H1N1)v 2009, but was higher for RSV and other viral 
LRTIs.  In addition, it was shown that pandemic influenza A (H1N1)v 2009 
immunisation uptake in the prematurely born infants was low (9.3%). 
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In chapter seven, it was reported that infants developing both HRV and RSV 
LRTIs had the highest adjusted mean healthcare costs of care, followed by 
the infants developing HRV LRTIs and then the infants developing RSV 
LRTIs, compared to infants not developing a LRTI.  The HRV group had 
more out-patient and more respiratory related general practitioner 
attendances and more wheezed at follow up than the no LRTI group and they 
had more respiratory related out-patient attendances than the RSV LRTI 
group. 
 
In chapter eight, it was reported that infants developing HRV-C LRTIs were 
more likely to wheeze and use respiratory medications and had more days of 
wheeze and use of an inhaler than the no LRTI group.  In addition, the 
respiratory cost of care was greater for the HRV-C LRTI group than the no 
LRTI group.  Initial analysis demonstrated HRV-A LRTIs were associated 
apparently with similar effects to HRV-C LRTIs, but the significant differences 
compared to the no LRTI group disappeared once the infants who also had 
RSV LRTIs were excluded from the analysis 
 
In chapter nine, it was reported that infants developing RSV LRTIs in the first 
year have increased healthcare utilisation and costs in both the first and 
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Siezen et al have also demonstrated the same SNP in the ADAM33 gene 
and a SNP in the IFN-γ gene was associated with an increased risk of 
hospitalisation with RSV infection in prematurely born infants compared to 
term born infants (Siezen et al. 2009).  Only one other study (Kresfelder et al. 
2011) has researched the other SNPs investigated in this thesis, the SNP in 
the VDR gene was associated with hospitalisation for RSV infection in black 
South African children (Kresfelder et al. 2011).  The differences between that 
study (Kresfelder et al. 2011) and this thesis may be explained by differences 
in ethnicity between the populations, maturity at birth and/or the small 
number of infants with RSV LRTI in this thesis.  Several other studies have 
subsequently identified other SNPs that are associated with RSV infection.  
SNPs in genes coding for IL-4 and IL-13 (Forton et al. 2009), IL-8 (Lu et al. 
2010), surfactant proteins A (El Saleeby et al. 2010) and D (Thomas et al. 
2009; Ampuero et al. 2011), IL1RL1 (Faber et al. 2012) and MMP3 
(Schuurhof et al. 2012) have been associated with hospitalisation or intensive 
care admission for RSV infection in infants mainly born at term and from a 
variety of ethnic backgrounds.  One study found no association between a 
SNP in TLR-4 and RSV infection (Löfgren et al. 2010) and two studies of a 
SNP in the RANTES gene yielded conflicting results (Tian et al. 2009; Hattori 
et al. 2011), one suggested the SNP was associated with RSV hospitalisation 
(Hattori et al. 2011) but the other not (Tian et al. 2009). 
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This thesis has demonstrated that prematurely born infants who had had 
RSV LRTIs, a SNP in the gene coding for IL-10 was associated with parental 
reported wheeze at one year corrected age and SNPs in the genes coding 
for NOS2A and SFTPC were associated with parental reported cough at one 
year corrected age.  A recent study (Schuurhof et al. 2011) investigated 
another IL-10 SNP in a cohort of 235 infants hospitalised for RSV 
bronchiolitis.  Although local IL-10 levels during the RSV infection were 
higher in infants who later developed physician diagnosed post-bronchiolitic 
wheeze, the IL-10 promoter SNP was not associated with the higher IL-10 
concentration in NPAs and no association was observed between the IL-10 
SNP and physician diagnosed post-bronchiolitic wheezing.  Four other 
studies have investigated the genetics of post-bronchiolitic wheeze.  A 
RANTES gene SNP was associated with recurrent wheezing (more than one 
episode of parental reported wheezing) up to three years after hospitalisation 
for RSV bronchiolitis (Tian et al. 2009).  Functional analyses of RANTES 
promoter activity demonstrated that the RANTES mutation (-403 G to A) 
increased the transcriptional activity of the RANTES promoter resulting in 
high serum RANTES levels (Tian et al. 2009).  Increased production of 
RANTES would be predicted to result in enhanced recruitment of 
proinflammatory cells to the target site, precipitating an amplified local 
inflammatory reaction (Meurer et al. 1993).  Two reports from a cohort of 129 
infants hospitalised with bronchiolitis at less than six months of age and 
followed up at 18 months of age, 68% of whom were RSV positive, 
highlighted that a SNP in the IFN-γ gene (Nuolivirta et al. 2009) and a 
mannose binding lectin gene polymorphism were associated with more 
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severe post-bronchiolitic wheezing requiring treatment with corticosteroids 
(Nuolivirta et al. 2012).  IFN-γ is a proinflammatory cytokine which also 
seems to have direct antiviral activity (Nuolivirta et al. 2009).  Production of 
IFN-γ is genetically controlled and the allele A at + 874 is associated with low 
production of IFN-γ.  The allele A at + 874 was not only associated with a 
significantly lower need for corticosteroids used to prevent or treat post-
bronchiolitic wheezing but also with protection from multiple respiratory 
infections (Nuolivirta et al. 2009). Mannose binding lectin (MBL) plays a 
central role in innate immunity, which is important in early infancy before 
establishment of adaptive immunity.  MBL responds as an acute phase 
reactant and promotes phagocytosis directly via the lecithin complement 
pathway.  MBL deficiency due to mutations in the MBL gene predisposes to 
respiratory infections (Nuolivirta et al. 2012).  This thesis also found SNPs in 
genes coding for MMP16 (rs2664349), NOS2A, Surfactant Protein C and 
VDR were associated with reduced lung function at one year corrected age in 
infants who had had a RSV LRTI but there have been no other studies on 
those SNPs. 
 
This thesis has documented reduced lung function (airways resistance 
measured by whole body plethysmography and resistance of the respiratory 
system measured by the single breath occlusion technique) at one year 
corrected age in prematurely born infants who had had a RSV LRTI.  A 
prospective study found that at 18 years adolescents born at term who had 
been hospitalised for RSV bronchiolitis in infancy had reduced lung function 
(reduced FEV1, FEV1/FVC and FEF25-75 z-scores) compared to infants who 
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had not been hospitalised for RSV bronchiolitis (Sigurs et al. 2010).  In 
contrast, however, a study of monozygotic twins who were discordant for 
hospitalisation due to RSV infection found no differences in lung function 
(FEV1 or sRaw) between the twin pairs at a mean of seven years of age 
(Poorisrisak et al. 2010).  A possible explanation for the lack of significant 
difference in lung function between the groups was the controls who were the 
twin siblings of the subject and may have had mild or asymptomatic RSV 
infection. 
 
This thesis has demonstrated increased healthcare utilisation and associated 
costs of care in prematurely born infants with RSV and rhinovirus LRTIs 
compared to those infants who did not develop a viral LRTI.  Several recent 
studies have also demonstrated increased healthcare utilisation and costs in 
children developing a RSV infection in infancy.  Palmer et al (2010) and 
Stewart et al (2009) retrospectively studied insurance claims data and 
demonstrated increased healthcare utilisation and associated costs in infants 
who developed RSV infection, whether it required in-patient or out-patient 
care compared to matched control infants who did not make an insurance 
claim for RSV infection.  A retrospective study of infants born between 32 
and 35 weeks of gestation demonstrated infants hospitalised for RSV 
infection in infancy had higher healthcare utilisation and associated costs in 
the first two years after birth compared to those infants who either did not 
develop a LRTI or were admitted for a non-RSV respiratory cause (Shefali-
Patel et al. 2012).  Most of the differences in cost in that study were related to 
the initial hospital admission due to RSV. 





In this thesis it has been shown that prematurely born infants frequently 
develop LRTIs caused by rhinovirus (HRV).  A study (Miller et al. 2012) of 
very low birth weight (<1500g), prematurely born infants in Argentina 
demonstrated 55% of the cohort of 119 infants developed a HRV acute 
respiratory tract infection.  In addition, HRV LRTI accounted for 33% of the 
36 infants hospitalised due to viral bronchiolitis, compared to 25% for RSV, 
and 11% were hospitalised due to dual infections of HRV and RSV (Miller et 
al. 2012).  Infants developing RSV LRTI, however, had more severe disease 
compared to those with HRV LRTI, as a greater proportion of those 
developing RSV LRTI required hospitalisation, their hospitalisations were 
longer and more infants required intensive care and mechanical ventilation 
(Miller et al. 2012).  This thesis has shown that HRV LRTIs, with or without 
RSV LRTIs, were associated with chronic respiratory morbidity and increased 
healthcare utilisation and cost of care at follow up and, after excluding infants 
with RSV infection, HRV-C LRTIs were associated with increased healthcare 
utilisation and cost of care at follow up.  
 
This thesis demonstrated that in prematurely born infants developing LRTIs 
caused by viruses other than RSV, reduced premorbid lung function 
(increased Rrs) was associated with hospitalisation for the LRTI.  A recent 
study (van der Zalm et al. 2011) of term born infants, using similar lung 
function techniques, showed infants who developed wheeze with HRV 
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infections had higher premorbid Rrs than infants who did not wheeze with 
HRV infections (either upper or lower respiratory tract infections).  
 
HRV LRTI was associated with increased parental reported wheeze at one 
year corrected age in this thesis.  A recent study of term born infants found 
similar results (Midulla et al. 2012).  Multivariate analysis demonstrated 
hospitalisation with HRV bronchiolitis was an independent risk factor for 
parental reported recurrent wheeze (more than two episodes of wheeze) one 
year after initial hospitalisation for HRV bronchiolitis (Midulla et al. 2012).  
Another recent study demonstrated in term born infants that hospitalisation 
for HRV bronchiolitis in infancy was associated with wheeze/asthma in 
adolescence (Ruotsalainen et al. 2012).  In addition, the COAST study 
(Guilbert et al. 2011) showed in high risk (at least one parent with atopy), 
term born infants, that wheezy HRV but not RSV illnesses in the first three 
years after birth were associated with reduced lung function (FEV1, FEV0.5 
and FEF25-75) at eight years of age.  This thesis investigated all viral LRTIs, 
whether wheeze was a component or not.  Infants who had had RSV and 
HRV LRTIs had the most wheeze and use of anti-asthma medication at 
follow up at one year of age, followed by those who had HRV LRTIs without 
RSV LRTIs, suggesting both viruses impact of chronic respiratory morbidity 
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10.2.3 Pandemic Influenza A (H1N1)v 2009 
 
Prematurity was not found to be a risk factor for developing a 2009 pandemic 
influenza A (H1N1) LRTI requiring hospitalisation, with only one of 140 
infants (0.7%) hospitalised.  A prospective study of term born infants carried 
out during the pandemic demonstrated only two infants of 180 (1.1%) 
developed an influenza A (H1N1) LRTI, one of whom required hospitalisation 
(Ede et al. 2012).  Those data suggest influenza A (H1N1) may have acutely 
impacted similarly on term and prematurely born infants. 
 




The infants in this study were all prematurely born and were recruited while 
on the newborn unit or maternity ward, that is prior to exposure to viral LRTIs.  
Despite this, nearly 75% of parents of eligible infants born during the 
recruitment periods consented for them to be included in the study. 
 
10.3.2 Study population 
 
The infants in this study were all born at less than 36 weeks of gestation and 
covered a wide range of gestational ages at birth (23 to 35 weeks), although 
most were of moderate prematurity (median GA of 34 weeks).  Prematurely 
born infants are at high risk of developing RSV and other viral LRTIs and 
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therefore it is important to assess if they suffer long term respiratory morbidity 
and to identify risk factors for their chronic respiratory morbidity. 
 
10.3.3 Prospective follow up 
 
Parents of infants were contacted every two weeks; in addition, parents were 
encouraged to contact the research team whenever their infant was unwell.  
Nasopharyngeal aspirates were taken from infants either in the community or 
in hospital when diagnosed with a viral LRTI.  Thus, it is likely that most 
episodes of LRTIs were captured.  Although infants developing the most 
severe viral LRTIs require hospitalisation, the majority of infants developing 
viral LRTIs are managed in the community.  It is therefore important to 
assess the outcomes of the latter group, which was undertaken in this thesis, 
as potentially they could be a large healthcare burden.  In each results 
chapter the table of demographics include antenatal smoking as one of the 
variables.  In none was there a significant difference in antenatal smoking 
between infants who developed viral LRTIs and those who did not.  No 
comparison of maternal smoking within the viral LRTI groups was made 
between those hospitalised and not hospitalised due to viral LRTIs.  
 
10.3.4 Virus detection 
 
The NPAs were tested for 13 common respiratory viruses by the sensitive 
technique of real time PCR.  There are other viruses, however, including 
corona viruses and the newly identified WU and KI viruses, which are also 
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associated with respiratory LRTIs.  The impact of those viruses on chronic 
respiratory morbidity suffered by prematurely born infants also merits 
investigation.  
 
10.3.5 Lung function assessment at follow up 
 
Lung function assessment at follow up requires sedation.  In a previous study 
(Broughton et al. 2007) 46% of parents gave consent for their infant to 
undergo sedation and lung function testing at one year corrected age.  One 
hundred and seventy seven infants were recruited and lung function was 
successfully measured in 78 infants (44%).  Lung function was measured at 
follow up using total body plethysmography, helium gas dilutional functional 
residual capacity (FRC), compliance and resistance of the respiratory system 
and FRC and lung clearance index measured by the multiple breath wash-
in/out technique.  These techniques allowed assessment of lung volumes, as 
well as small and medium/large airways. 
 
10.3.6 Single nucleotide polymorphism analysis 
 
Infants had their DNA collected at recruitment and then analysed for 11 
single nucleotide polymorphisms (SNP) previously related to RSV infection, 
prematurity or BPD.   
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Infants were assessed both in the community and in hospital, but only ten 
infants who developed RSV LRTIs were hospitalised due to the LRTI (34.5% 
of all infants developing RSV LRTIs and 6.5% of the whole cohort) and only 
two infants who developed other viral LRTIs were hospitalised due to the 
LRTI (6.5% of all infants developing other viral LRTIs and 1.3% of the whole 
cohort).  The results relating to the data at follow up, therefore, are more 
applicable to infants with viral LRTIs managed in the community.  In addition, 
all the infants were symptomatic when assessed and thus the impact of 
asymptomatic viral infections could not be assessed in this thesis. 
 
10.4.2 Gestational age 
 
Although infants in the range 23 to 35 weeks of gestation at birth were 
recruited in this study, their median GA at birth was 34 weeks.  The results of 
this study may not, therefore, be representative of the most prematurely born 
infants. 
 
10.4.3 Sample size 
 
A SNP in the ADAM33 gene was associated with an increased risk of 
developing RSV LRTIs and SNPs in several other genes were associated 
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with increased chronic respiratory morbidity and reduced lung function at one 
year corrected age in infants who had had RSV LRTIs.  The genetic analysis, 
however, was not powered to correct for multiple testing so it is possible 
certain of the results could be due to chance.  In addition, amongst the 
infants with RSV LRTIs, although there were no significant differences in 
ethnic origin for each of the 11 SNPs, the numbers in each group do not 
allow a clinically meaningful conclusion to be drawn. 
 
10.4.4 Viral testing 
 
NPAs were tested for 13 viruses using real-time PCR.  Other viruses causing 
respiratory tract infections in infants (e.g. coronaviruses and newly identified 
polyomaviruses) were not investigated in this thesis and thus infants with 
viral negative LRTIs may have been infected with a virus not investigated in 
this thesis.  In addition, viral shedding from an infant’s respiratory system can 
occur for many weeks after recovery from an acute illness (Peltola et al. 
2013). Thus it is not possible to be certain that any virus detected was 
necessarily the pathogen causing the infant’s clinical symptoms at the time of 
the illness. 
 
Although infants were closely followed, regular NPAs were not undertaken 
when infants were asymptomatic.  It was, therefore, not possible to establish 
the relationship between exactly when an infant was infected with a virus and 
the development of clinical symptoms.  This is a limitation in many previous 
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studies (Lemanske et al. 2005; Broughton et al. 2007; Janssen et al. 2007; 
Guilbert et al. 2011; Ermers et al. 2011). 
 
In Chapter four, 13 (22%) of the 58 infants who developed viral LRTIs with a 
virus detected and 8% of all the 159 infants followed over the first RSV 
season had more than one virus detected from one NPA.  Previous studies 
have demonstrated rates of multiple virus detection between 0-70% 
depending on the population studied and the techniques used to test 
respiratory samples (Lazar et al. 2004, Konig et al. 2004, Semple et al 2005, 
van Woensel et al. 2006, Richard et al. 2008, Harada et al. 2013).  
 
10.4.5 Lung function testing by the multiple breath wash-in/out 
technique 
 
Lung function was undertaken using the multiple breath wash-in/out 
technique at both 36 weeks and one year corrected age.  At 36 weeks 
corrected age the infants had very irregular breathing patterns which meant 
obtaining high quality data was extremely difficult.  The co-efficient of 
variation (CoV) at 36 weeks corrected age was 16% for FRCMBW and 13% for 
LCI.  When undertaken at one year corrected age, in sedated infants with 
regular respiration, the technique produced much more reliable data 
(FRCMBW CoV 8% and LCI CoV 6%). 
 
10.4.6 Comparison with a term born control group 
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This study only recruited prematurely born infants.  Recruitment of term born 
infants would have allowed comparison of risk factors for developing viral 
LRTIs between term and prematurely born infants, but would have required a 
much longer study and would not have addressed the hypotheses of this 
thesis. 
 
10.5 Clinical implication of the results 
 
Palivizumab, a monoclonal antibody used as immunoprophylaxis against 
RSV, is available for use in prematurely born infants.  Due to the high cost, 
however, palivizumab is only available to those prematurely born infants 
deemed to be at the highest risk, currently based on GA and chronological 
age at the start of the RSV season (Joint Committee on Vaccination and 
Immunisation 2010).  These criteria may miss some infants who are at higher 
risk of developing RSV infection based on other risk factors and include 
some infants at lower risk.  Premorbid lung function and genotyping may 
further identify high risk infants. 
 
In a non-randomised trial palivizumab was shown to reduce recurrent 
wheeze in prematurely born infants (Simoes et al. 2007) and in a randomised 
controlled trial to reduce days of wheeze in the first year of life (Blanken et al. 
2013).  Results from this thesis have shown that RSV and HRV LRTIs are 
associated with chronic respiratory morbidity and associated healthcare 
utilisation and associated cost of care in prematurely born infants.  Those 
results highlight that development of therapies directed against HRV infection 
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might further reduce the chronic respiratory morbidity suffered by prematurely 
born infants. 
 
A low uptake of the influenza A H1N1 immunisation in prematurely born 
infants during the pandemic in 2009 was demonstrated highlighting that 
infants need to be better targeted with immunisation campaigns to ensure as 
many infants as possible receive their immunisations. 
 
10.6 Future studies 
 
Studies are required to determine whether an algorithm including more risk 
factors, including results from this thesis might better identify high risk infants 
requiring prophylaxis in either the first or second years after birth.  
 
There is currently no prophylactic agent for rhinovirus infection but more 
studies are required to assess the long term respiratory impact of this and 
other respiratory viruses on term and prematurely born infants. 
 
A larger study, adequately powered for multiple comparisons, is required to 
confirm the findings from the genetics component of this thesis and to assess 
the influence of ethnicity on genetic predisposition to RSV LRTI.  Studies 
investigating genetic markers which may predispose infants to other viral 
LRTIs are also required.  Increased knowledge of genetic markers would 
allow improved targeting of prophlyaxis and education of parents to reduce 
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the risk of developing viral LRTIs.  It may also lead to the development of 




Respiratory viral LRTIs are associated with increased chronic respiratory 
morbidity at follow up.  Certain infants have a functional and genetic 
predisposition to developing severe RSV infections. 
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Notes: 1 2 3 4
For each day please mark if your child: 
Coughed (C)
Wheezed (W)
Took any medicine for a chest problem e.g. inhaler, antibiotic (M)
Visited your GP or A&E because they were unwell (rather than a follow up appointment) (H)
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31
JULY  2009
Sunday Monday Tuesday Wednesday Thursday Friday Saturday
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Diminished lung function, viral infections and chronic respiratory 
morbidity in prematurely born infants 
Study Number: 08/H0808/37 
Thank you for taking the time to fill out this questionnaire. Please circle the most 
appropriate answer for your child or fill in the box.  If there are any questions you do 
not understand or have any queries, please phone Dr Simon Drysdale or Mireia 
Alcazar on 020 3299 8494/07766 759399 or Consultant Paediatrician Anne 
Greenough on 020 7346 3037. 
 
 
Patient Identification Number:……………………………………………………. 
 
Baby’s full name. . . . . . . . . .  . . . . . . . . . . . . . . . . .   . . . . . . . . . . . . . . . . . . . .  
 
 
1.  Chest Symptoms 
1.1   Did your child cough in the first 12 months of life?……………….…………..Yes/No 
If yes indicate how often:   
More than once a week………………………………………Yes/No 
            Once a week or less but more than once a month…….…..Yes/No 
            Once a month or less……………………………………….…Yes/No 
 
 
If yes, was the cough brought on by: 
   Exercise/Activity……….Yes/No/Don’t Know 
   Infection/a cold…………Yes/No/Don’t Know 
 
1.2 Did your child wheeze in the first 12 months of 
life?………………………...……Yes/No 
If yes indicate how often: 
 More than once a week…………………………………….Yes/No 
 Once a week or less, but more than once a month……..Yes/No 
 Once a month or less……………………………………….Yes/No 
 
 
In the first 12 months, was the wheeze brought on by:  
   
   Exercise/Activity……….Yes/No/Don’t Know 
                                       Infection/a cold………...Yes/No/Don’t Know 
 
1.3 Has your child ever required oxygen (via mask or nasal prongs) at 
home?.…...Yes/No 
 
If yes:          
 
Does he/she still require oxygen…………………………….Yes/No 
 
At what age did he/she stop requiring home oxygen?     
 




Treatment for chest symptoms 
 
1.4 Has your child had medicines for chest 
problems?……………………………..…Yes/No 
 
If yes indicate 
 Bronchodilators (relievers) e.g. ventolin/bricanyl/atrovent/serovent…..Yes/No 
 Antibiotics…………………………………………………………………....Yes/No 
 Preventers e.g. Becotide/Pulmicort/Flixotide/steroids by mouth……….Yes/No  
Any other (please name) ………………………………………………..  
 
  
1.5 Has your child received treatment (Synagis/Palivizumab) to try and 
prevent them getting RSV infection (bronchiolitis)?…………………………….Yes/No 
 
 
2.   Hospital Admissions 
 
2.1 Has your child ever been admitted to hospital because of breathing 
difficulties?…………………………………………………………………………..…Yes/N
o 
If yes:  




2.2 Has your child ever been admitted to hospital with 
bronchiolitis?……………….Yes/No 
If yes:  




2.3 Has he/she ever been admitted to hospital for any other reason?……………..Yes/No 
If yes: 




2.4 Has he/she ever been admitted to a children’s intensive care unit?…………...Yes/No 
If yes 
Age of child Diagnosis   Hospital  Approx stay 
 




3.  Other Questions 
3.1 Has your child been diagnosed with:   
Asthma …………………………Yes/No 
  Eczema…………………………Yes/No 
 
 
3.2 Has anyone in the child’s immediate family (e.g. the child’s mother, father, or 
brother/sisters) been diagnosed with: 
 
  Asthma ………………………….Yes/No  
  Eczema………………………….Yes/No      
   Hayfever…………………………Yes/No  
 
 
3.3 Did you breast feed your child?……………………………………..…Yes/No 
 





3.4 Have you smoked since having your baby?  
 
Never ………………………………………………………… 
  Ex - i.e. stopped before/during pregnancy - not resumed.. 
  Current ……………………………….……………………… 
  
 . If current, how many per day: 
 
 Social/occasional (less than one per day) 
 1 – 10 per day 
 11 – 20 per day 
 21 – 30 per day 
 31 or more per day    
  
  









3.6 How many children under the age of five (including the child in this study) are 




3.7 Do you have pets living in the 
house?………………………………………….…..Yes/No 
If yes please specify 
 




3.8 What best describes your type of accommodation? 
Owns it outright…………………………………….Yes/No 
Owns with mortgage or loan………………………Yes/No 
Pays part rent, part mortgage…………………….Yes/No 
Rents from council or housing association………Yes/No 
Rents from Private Landlord………………………Yes/No 
Live there rent free………………………………….Yes/No 
Other (please state)…………………………………. 
 
 








If you are unsure about anything regarding this form, please do not hesitate to contact Dr 
Simon Drysdale or Mireia Alcazar on 020 3299 8494/07766 759399. 
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Patient Information Sheet    Version 2, April 
2008 
 
Diminished lung function, viral infections and chronic  
respiratory morbidity in prematurely born infants 
 
We are inviting you to consider allowing your baby to take part in a research study.  
Before you decide, it is important for you to understand why the research is being 
done and what it will involve.  Please take the time to read the following information 
carefully and discuss it with your friends, relatives and your GP if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish your baby to take part. 
 
Why are we doing it? 
 
Infants who are born prematurely frequently have breathing problems at follow up, 
wheeze and cough requiring treatment.  It is possible that viral infections may make 
those problems worse.  In infants born at the correct time (at term), however, there 
is evidence to suggest that viral infections and subsequent wheezing occur in those 
with prior abnormal lung function and/or a genetic predisposition and thus the viral 
infection itself may have no role in increasing breathing problems at follow up.  
There is no similar information for prematurely born infants.  Yet, in those babies it is 
particularly important to know if viral infections do play a role in the breathing 
problems and whether certain babies are more susceptible, as there is treatment 
available which can reduce the severity of the acute viral infections.  It is, however, 
very expensive and has to be given by five monthly injections so it is important only 
to give the treatment to babies who would really benefit from it.  Hence, the aim of 
our study is to investigate whether abnormal lung function prior to neonatal 
unit/postnatal ward discharge predisposes prematurely born babies to respiratory 
viral infections and if viral infections contribute to the breathing problems at follow up 
suffered by prematurely born infants.  In addition, we will determine if some infants 
have a genetic predisposition to viral infections and wheezing. 
 
How we will do it? 
 
We wish to assess the lung function of prematurely born babies just prior to them 
being discharged from the neonatal unit or postnatal ward.  To assess lung function 
we will use simple breathing tests which are used routinely in clinical practise to 
assess babies with breathing problems.  The baby breathes in and out through a 
facemask which is attached to a device which measures the amount of air the baby 
is breathing in and out and how much effort the baby is putting into breathing.  The 
facemask is then connected to another device which contains a small amount of an 
inert (non harmful) gas.  Each test takes less than five minutes and from the data 
collected we can assess the size of the baby’s lungs and any difficulties of breathing 
in and out.  If the baby is having a blood test for clinical purposes then we would 
wish to collect an extra one millilitre (less than half a teaspoonful of blood).  If not we 
would like to collect a buccal smear from your baby and this requires lightly brushing 
the inside of the cheek with a swab.  The blood and buccal smears will be analysed 
for the variations in genes which have been shown to be associated with viral 
infections and subsequent wheezing in babies born at term.  We also wish to take 
blood samples from you as, because of the size of the samples that can be taken, 
samples from adults are easier to analyse.  It is, however, important to also have 
samples from your baby as sometimes variations in genes occur spontaneously in 
babies and are not inherited from their parents. 




We then wish to follow the babies until they are one year of age corrected for the 
degree of prematurity at birth.  From October to March, we will ask parents to 
contact us every time their baby has symptoms which could be due to a viral 
infection, at home or hospital.  The research doctor or nurse would then arrange to 
visit your baby and a nasopharyngeal aspirate would be taken.  A nasopharyngeal 
aspirate is obtained by using a small “swab” on a stick to collect secretions from just 
inside the baby’s nose.  The secretions are then analysed to determine if the baby 
had a viral infection and which viral infection.  When your baby is 11 months 
corrected age we will ask you to complete a diary card for one month, that is to 
record on a daily basis whether baby coughed, wheezed or required treatment.  For 
babies recruited early in the study we will also ask parents to complete a second 
diary card when their child is nearly two years of age. 
 
When your baby is one year of age, we wish to again assess your baby using the 
same breathing tests as before, but additionally assess the size of the breathing 
tubes (which may be reduced in babies with troublesome wheeze) by assessing the 
baby in a plethysmograph, which is similar to an incubator.  Again the baby breathes 
in and out through a facemask.  All breathing tests at one year of age require the 
baby to be sedated.  The sedation is given orally, is very safe and is used routinely 
in clinical practise to assess babies with actual or suspected breathing problems.  
Throughout the breathing tests, the baby is continuously monitored and looked after 
by a paediatrician. 
 
We would also like to assess how much treatment your baby has required over the 
first year and to do this we wish to examine the medical notes held by the GP and 
hospital.  From those notes we will be able to determine the number of times the 
baby has been to hospital, how long was spent there, plus the type of treatment the 
baby received in hospital and from their GP.   
 
We will compare all of the results between babies who have had viral infections and 
those who have not and hence determine whether viral infections do cause 




Reimbursement for appropriately incurred travel expenses is available on request. 
 
Are there any benefits or disadvantages to take part in this study? 
 
The benefits of taking part are that your baby will be closely followed and any 
breathing problems will be detected early and receive treatment.  The diagnosis of a 
viral infection when the baby is acutely unwell will aid the choice of treatment your 
baby will receive.  There are no risks to your baby taking part in this study, all of the 
tests are those used in routine clinical practise.  There are no disadvantages, but no 
benefits to your baby regarding the assessment of genetic predisposition.  As it is 
not known whether prematurely born infants do have a genetic predisposition to viral 
infections, we will only analyse the samples at the end of the study when all the 
information is available.  The results, however, will provide essential information for 
the care of future babies, that is whether certain babies are genetically predisposed 
to viral infections and wheeze at follow up and thus may benefit from preventative 
treatment. 
 
How will the information be shared? 
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All information that is collected will be kept strictly confidential.  Results form the 
study will be published in scientific journals in which all data are anonymous.  We 




It is important you understand that this study is voluntary and for research purposes.  
You may choose not to allow your baby to participate in this study and you may 
withdraw your child at any time without their medical care or legal rights being 
affected.  If you require any further information please ask.  There are no harmful 
side effects associated with this study.  No indemnity is available, although normal 
NHS procedures apply in the unlikely event of any adverse outcome of the study.  
 
If you decide to allow your baby to take part in the study you will be given a copy of 
the information sheet and consent form to keep.  All information that is collected 
during the course of the research will be kept strictly confidential and if the results 
are published then anonymity will be maintained.  This study was reviewed and 
approved by the Research Ethics Committee of King’s College Hospital NHS 
Foundation Trust. 
 
Thank you very much for considering your baby for enrolment into this project.  If 
you are happy to participate please sign below.  If you have any further questions or 
would like to meet with a member of the research team to discuss this further, 




Dr Simon Drysdale 
Paediatric Clinical Research Fellow 
Tel: 020 3299 8494 
Mob: 07766 759399 
 
 
Professor Anne Greenough 
Professor of Neonatology and 
Clinical Respiratory Physiology 
 
Direct line:  020 3299 3037
Centre Number: KCH 
Study Number: 08/H0808/37 
Patient Identification Number for this trial: 
 
CONSENT FORM 
Title or project:    Diminished lung function, viral infections and chronic  
                            respiratory morbidity in prematurely born infants 
 
Name or researcher:  Professor Anne Greenough 
                                                                                                                       Please initial box 
1. I confirm that I have read and understand the information sheet 
Dated April 2008 (version 2) for the above study.  I have had the  
opportunity to consider the information, ask questions and have had these  
answered satisfactorily. 
                       
2. I understand that my child’s participation is voluntary and that my child is free 
to withdraw at any time, without giving any reason, without his/her medical   
care or legal rights being effected. 
 
3. I understand that relevant sections of any of my child’s medical notes and data  
collected during the study, may be looked at by responsible individuals from   
King’s College London, from regulatory authorities or from the NHS Trust, where 
it is relevant to my child taking part in this research.  I give permission for these 
individuals to have access to my child’s records. 
 
4. I agree to my child’s GP receiving copies of tests results from this study  
 
5.   I agree for my child to take part in the above study. 
 
---------------------------                    ------------------------------                      -------------------------- 
Name or parent/Guardian      Date                                                         Signature 
 
------------------------------------         ------------------------------                       ------------------------- 
Name of person taking consent        Date                                                         Signature 
(if different from researcher) 
 
-------------------------------               ------------------------------                     --------------------------- 
Researcher                                      Date                                                           Signature 
When completed, 1 for patient, 1 for researcher site file; 1 (original) to be kept in medical notes 
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King's College Hospital Research Ethics Committee 
Camberwell Building 
King's College Hospital 




Telephone: 0203 299 3923  
Facsimile: 0203 299 5085 
17 April 2008 
 
Prof Anne Greenough 
Professor of Neonatology and Clinical Respiratory Physiology  
Guy's, King's & St Thomas' School of Medicine 
Frederick Still Ward, 4th Floor Golden Jubilee Wing, 




Dear Prof Greenough 
 
Full title of study: Diminished lung function, viral infections and chronic respiratory 
morbidity in prematurely born infants 
REC reference number: 08/H0808/37 
 
Thank you for your letter of 7
th
 April 2008, responding to the Committee’s request for further information on the 
above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the 
basis described in the application form, protocol and supporting documentation as revised. 
 
Ethical review of research sites 
 
The favourable opinion applies to the sites outlined on the site approval form.  We will write to you again as soon 
as any further Research Ethics Committee has notified the outcome of a SSA.   
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set out in the attached document.  




The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    
Application  26/03/2008  
Investigator CV  Anne Greenough  
Protocol    
GP/Consultant Information Sheets  Dated 18th February 2008  
Participant Information Sheet  Version 2 April 2008  
Participant Consent Form  Version 2 April 2008  
Response to Request for Further Information  Dated 7th April 2008  
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Please note that your Patient Information Sheet and Consent form have been issued with 
Version numbers as none were supplied. Please ensure that this are entered onto the documents 




All researchers and research collaborators who will be participating in the research at NHS sites should apply for 
R&D approval from the relevant care organisation, if they have not yet done so.  R&D approval is required, 
whether or not the study is exempt from SSA.  You should advise researchers and local collaborators accordingly. 
 
Guidance on applying for R&D approval is available from http://www.rdforum.nhs.uk/rdform.htm. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees 
(July 2001) and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research Ethics Website > After 
Review  
 
Here you will find links to the following 
a)   Providing feedback. You are invited to give your view of the service that you have received from the 
National Research Ethics Service on the application procedure. If you wish to make your views known 
please use the feedback form available on the website. 
b)   Progress Reports. Please refer to the attached Standard conditions of approval by Research Ethics 
Committees. 
c)   Safety Reports. Please refer to the attached Standard conditions of approval by Research Ethics 
Committees. 
d)   Amendments. Please refer to the attached Standard conditions of approval by Research Ethics 
Committees. 
e)   End of Study/Project. Please refer to the attached Standard conditions of approval by Research Ethics 
Committees. 
 
We would also like to inform you that we consult regularly with stakeholders to improve our service. If you would 
like to join our Reference Group please email referencegroup@nationalres.org.uk . 
 
 
08/H0808/37 Please quote this number on all correspondence 
 
 









Enclosures: Standard approval conditions 
Site approval form 
 
Copy to: Dr Lorraine Catt 





King's College Hospital Research Ethics Committee 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and following 
subsequent notifications from site assessors.  For issue 2 onwards, all sites with a favourable opinion are listed, adding the new sites approved. 
 









Date of issue: 
 





Prof Anne Greenough 
 
Full title of study: 
 
 
Diminished lung function, viral infections and chronic respiratory morbidity in prematurely born infants 
 
This study was given a favourable ethical opinion by King's College Hospital Research Ethics Committee on 30 April 2008. The favourable opinion is extended to each of the sites 











Date of favourable opinion 






Prof. Anne Greenough Professor of Neonatology King’s College Hospital 
NHS Foundation Trust 
King’s College Hospital 
Research Ethics Committee 
17
th
 April 2008  
 
Approved by the Chair on behalf of the REC: 
 





(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notified by the Chief Investigator or sponsor), 
the suspension of termination of the favourable opinion for an individual site, or any other relevant development.  The date should be recorded
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Appendix 5- Overall flow diagram of 



























  318 
 
 
  319 
 
 
 
